US20230338429A1 - Compounds and use thereof in the expansion of stem cells and/or progenitor cells - Google Patents
Compounds and use thereof in the expansion of stem cells and/or progenitor cells Download PDFInfo
- Publication number
- US20230338429A1 US20230338429A1 US18/320,929 US202318320929A US2023338429A1 US 20230338429 A1 US20230338429 A1 US 20230338429A1 US 202318320929 A US202318320929 A US 202318320929A US 2023338429 A1 US2023338429 A1 US 2023338429A1
- Authority
- US
- United States
- Prior art keywords
- compound
- pyridinyl
- nmr
- mhz
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 346
- 210000000130 stem cell Anatomy 0.000 title abstract description 85
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 198
- -1 2-pyridinyl Chemical group 0.000 claims description 81
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 18
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 14
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 95
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 9
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract description 9
- 208000018706 hematopoietic system disease Diseases 0.000 abstract description 9
- 230000036210 malignancy Effects 0.000 abstract description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 330
- 238000005160 1H NMR spectroscopy Methods 0.000 description 178
- 238000004949 mass spectrometry Methods 0.000 description 172
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 147
- 210000004027 cell Anatomy 0.000 description 125
- 239000000203 mixture Substances 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 44
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 44
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
- 210000004700 fetal blood Anatomy 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 23
- 239000002609 medium Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- 125000005843 halogen group Chemical group 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 102000036693 Thrombopoietin Human genes 0.000 description 9
- 108010041111 Thrombopoietin Proteins 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 229910006074 SO2NH2 Inorganic materials 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- NSGHAKPGHCNTPS-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.C1=CC=C2OC(CN=C([NH3+])N)COC2=C1.C1=CC=C2OC(CN=C([NH3+])N)COC2=C1 NSGHAKPGHCNTPS-UHFFFAOYSA-N 0.000 description 5
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 108700014844 flt3 ligand Proteins 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001263 acyl chlorides Chemical class 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- KSGFJKSNZLTEDI-UHFFFAOYSA-N 1-[benzyl(methyl)amino]-3-[3-(trifluoromethyl)phenoxy]propan-2-ol Chemical compound C=1C=CC=CC=1CN(C)CC(O)COC1=CC=CC(C(F)(F)F)=C1 KSGFJKSNZLTEDI-UHFFFAOYSA-N 0.000 description 3
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 3
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 208000027205 Congenital disease Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- FVTWJXMFYOXOKK-UHFFFAOYSA-N 2-fluoroacetamide Chemical compound NC(=O)CF FVTWJXMFYOXOKK-UHFFFAOYSA-N 0.000 description 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical class NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- GYXHHICIFZSKKZ-UHFFFAOYSA-N 2-sulfanylacetamide Chemical class NC(=O)CS GYXHHICIFZSKKZ-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000011799 Desmoglein Human genes 0.000 description 1
- 108050002238 Desmoglein Proteins 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 101150115210 PTGER2 gene Proteins 0.000 description 1
- 101150053131 PTGER3 gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940118169 Prostaglandin receptor agonist Drugs 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 101150058615 Ptger1 gene Proteins 0.000 description 1
- 101150109738 Ptger4 gene Proteins 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- PIDGGJYETVQYET-UHFFFAOYSA-N chembl173171 Chemical compound C12=CC=C(Br)C=C2N(C)C(O)=C1C1=C(N=O)C2=CC=CC=C2N1 PIDGGJYETVQYET-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- XIHXRRMCNSMUET-UHFFFAOYSA-N guanoclor Chemical compound NC(=N)NNCCOC1=C(Cl)C=CC=C1Cl XIHXRRMCNSMUET-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000005074 megakaryoblast Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- WCONKKYQBKPMNZ-UHFFFAOYSA-N prop-1-en-2-ylboronic acid Chemical compound CC(=C)B(O)O WCONKKYQBKPMNZ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JGFYQVQAXANWJU-UHFFFAOYSA-M sodium fluoroacetate Chemical compound [Na+].[O-]C(=O)CF JGFYQVQAXANWJU-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Definitions
- the invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells (HPCs) and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
- HPCs progenitor cells
- HSCs hematopoietic stem cells
- URB umbilical cord blood
- HSCs are used in the transplantation setting (autologous or allogeneic) which constitutes one of the most effective treatment strategies for achieving cures in patients with hematologic malignancies, bone marrow failure conditions, a variety of congenital diseases of global concern (e.g. sickle cell anemia and thalassemia) and autoimmune diseases such as lupus.
- this opportunity for life-saving or life-improving treatment is not available to many thousands of people worldwide due to an inability to amplify these cells ex vivo sufficiently to make the procedure safe and successful.
- HLA human leucocyte antigen
- HSCs mainly reside in the bone marrow (BM) and must be mobilized to enter the circulation prior to being collected by apheresis, either for autologous or allogeneic hematopoietic stem cell transplantation (HSCT).
- BM bone marrow
- HSCs hematopoietic stem cell transplantation
- Allogeneic HSCT with BM or mobilized pheripheral blood stem cells (mPBSC) is another transplantation alternative.
- mPBSC mobilized pheripheral blood stem cells
- R1, R2, R3, V1, V2, X, and W are as defined herein.
- a further aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a further aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising stem cells and/or progenitor cells expanded by a compound or method as defined herein.
- a further aspect relates to a cell population obtainable/ obtained by a method as defined herein.
- a further aspect relates to a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease, comprising administering a compound or a pharmaceutically acceptable salt thereof as defined herein to a subject in need thereof.
- a further aspect relates to a method of treating a patient receiving an organ transplant, more particularly a solid organ transplant.
- FIG. 1 A depicts the fold expansion of total cells and CD34+ cells in the different culture conditions compared to fresh samples, as well as the proportions of CD34+ cells in the different culture conditions;
- FIG. 1 B depicts the fold expansion of CD34+CD45RA-, CD34+CD45RA+ and CD34+CD201+ cells in the different culture conditions compared to fresh samples;
- FIG. 1 C depicts the proportions of CD34+CD45RA-, CD34+CD45RA+ and CD34+CD201+ cells in the different culture conditions
- FIG. 1 D depicts the cell composition in percentages of different cell types in the different culture conditions
- FIG. 2 A shows the engraftment (as the percentage of human CD45+ cells in bone marrow aspirate) of human cord blood cells from fresh samples or in vitro expanded-samples in the different culture conditions;
- FIG. 2 B show the proportions of myeloid and lymphoid cells in engrafted human cord blood cells in mice.
- said compound is a compound of formula Ia
- R 1 , R 2 and R 3 are as defined herein.
- said compound is a compound of formula Ib
- R 1 , R 2 and R 3 are as defined herein.
- said compound is a compound of formula Ic
- R 1 and R 3 are as defined herein.
- said compound is a compound of formula Id
- R 1 , R 2 and R 3 are as defined herein.
- said compound is a compound of formula Ie
- R 1 , R 2 and R 3 are as defined herein.
- R 1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
- R 1 is halo, C1-3alkyl, C1-3fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-3alkyl.
- R 1 is F, Cl, Br, Me, Et, iPr, n-Pr, CF 3 , cyclopropyl, CCH, CH ⁇ CMe, cyano, or COOEt.
- R 1 is F, Me, Et, iPr, n-Pr, CF 3 , cyclopropyl, CCH, CH ⁇ CMe, cyano, or COOEt.
- R 1 is Me, CF 3 , or joined to R 2 to form (CH 2 ) 3-5 ring.
- R 1 is Me or CF 3 , preferably CF 3 .
- R 2 is H, or C1-6alkyl.
- R 2 is H, or C1-3alkyl.
- R 2 is H or Me, preferably H.
- R 2 is H, methyl, ethyl, i-propyl or n-propyl; or preferably H or methyl.
- R 1 and R 2 are attached together to form (CH 2 ) 3-5 .
- R 3 is an optionally mono or disubstituted phenyl, an optionally monosubstituted 5- or 6-membered heteroaryl, or an optionally monosubstituted fused bicyclic heteroaryl.
- R 3 is an optionally mono or disubstituted phenyl at any of positions 3, 4 and 5 of said phenyl, an optionally monosubstituted 5- or 6-membered heteroaryl, or an optionally monosubstituted fused bicyclic heteroaryl of 9 or 10 members.
- R 3 is an unsubstituted phenyl, a phenyl monosubstituted at position 4, a phenyl monosubstituted at position 3, a phenyl disubstituted at positions 3 and 4, or a phenyl disubstituted at positions 3 and 5.
- R 3 is an unsubstituted or monosubstituted heteroaryl selected from pyridinyl, pyrimidinyl, thiazolyl, benzothiazolyl, isoquinolinyl, quinolinyl, thienyl and indazolyl.
- R 3 is an unsubstituted or monosubstituted heteroaryl selected from 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 6-benzothiazolyl, 5-isoquinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 3-thienyl and 5-indazolyl.
- R 3 is an unsubstituted or monosubstituted heteroaryl selected from 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, and 3-thienyl.
- R 3 when R 3 is substituted phenyl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, sulfonamide, C1-3fluoroalkyl, -COO-C1-3alkyl, carboxamide, amino, phenyl, 5- or 6-membered heteroaryl or two substituents of R 3 form together -O(CH 2 ) 3-5 O- wherein the substituent of said optionally substituted C1-3alkyl is OH, OMe, CN, or COOEt.
- R 3 when R 3 is substituted phenyl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO 2 NH(C1—3alkyl) —SO 2 N(C1—3alkyl) 2 , —SO 2 NH 2 , C1-3fluoroalkyl, -COO-C1-3alkyl, -CONH(C1-3alkyl), —CON(C1-3alkyl) 2 , —CONH 2 , —NH(C1—3alkyl), —N(C1—3alkyl) 2 , —NH 2 , phenyl or 5- or 6-membered heteroaryl; or two substituents of R 3 form together —O(CH 2 )O— or —O(CH 2
- R 3 when R 3 is substituted phenyl, said substituent is F, Cl, Br, Me, Et, CH 2 OH, CH 2 OMe, CH 2 CH 2 OH, CH 2 CH 2 OMe, CH 2 CN, CH 2 COOEt, OCF 3 , OCHF 2 , —OMe, —O—benzyl, —O—phenyl, —SMe, —SO 2 NH 2 , CF 3 , COOMe, —CONHMe, —CONH 2 , —NH 2 , 3-pyridinyl, 4- pyridinyl, or two substituents of R 3 form together form —O(CH 2 )O— or —O(CH 2 CH 2 )O—.
- R 3 when R 3 is substituted phenyl, said substituent is halo, —S—C1—3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl or two substituents of R 3 form together —O(CH 2 ) 3-5 O—.
- R 3 is phenyl substituted at position 4 with H, F, Cl, Br, Me, Et, OMe, OEt, SMe or CF 3 .
- R 3 is phenyl substituted at position 3 with H, F, Cl, Br, Me, or OMe.
- R 3 when R 3 is phenyl substituted at position 3 and 4 together form —CH 2 O—, or —OCH 2 CH 2 O—.
- R 3 when R 3 is substituted heteroaryl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO 2 NH(C1—3alkyl) —SO 2 N(C1—3alkyl) 2 , —SO 2 NH 2 , C1-3fluoroalkyl, -COO-C1-3alkyl, -CONH(C1-3alkyl), -CON(C1-3alkyl) 2 , -CONH 2 , —NH(C1—3alkyl), —N(C1—3alkyl) 2 , —NH 2 , phenyl or 5- or 6-membered heteroaryl; or two substituents of R 3 form together —O(CH 2 )O— or —O(CH 2 CH
- R 3 when R 3 is substituted heteroaryl, said substituent is F, Cl, Br, Me, Et, CH 2 OH, CH 2 OMe, CH 2 CH 2 OH, CH 2 CH 2 OMe, CH 2 CN, CH 2 COOEt, OCF 3 , OCHF 2 , —OMe, —O—benzyl, —O—phenyl, —SMe, —SO 2 NH 2 , CF 3 , COOMe, —CONHMe, —CONH 2 , —NH 2 , 3-pyridinyl, 4- pyridinyl, or two substituents of R 3 form together form —O(CH 2 )O— or —O(CH 2 CH 2 )O—.
- R 3 when R 3 is substituted heteroaryl, such as 2-, 3-, 4-pyridyl or thienyl, said substituent is halo, C1-3alkyl, or —O—C1—3alkyl, preferably R 3 is 4-pyridinyl or 3-thienyl.
- R 1 is C1-6alkyl, C1-6fluoroalkyl
- R 2 is H or R 1 is joined to R 2 to form (CH 2 ) 3-5
- R 3 is an unsubstituted phenyl, a phenyl monosubstituted at position 4, a phenyl monosubstituted at position 3, a phenyl disubstituted at positions 3 and 4, or a phenyl disubstituted at positions 3 and 5 or R 3 is an unsubstituted or monosubstituted heteroaryl selected from pyridinyl, pyrimidinyl, thiazolyl, benzothiazolyl, isoquinolinyl, quinolinyl, thienyl and indazolyl.
- R 1 is halo, C1-3alkyl, C1-3fluoroalkyl, C3cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-3alkyl, preferably R 1 is Me, CF 3 , or joined to R 2 to form (CH 2 ) 3-5 ring; R 2 is H, R 3 is an unsubstituted phenyl, a phenyl monosubstituted at position 4, a phenyl monosubstituted at position 3, a phenyl disubstituted at positions 3 and 4, or a phenyl disubstituted at positions 3 and 5 wherein said phenyl substituent(s) is F, Cl, Br, Me, Et, CH 2 OH, CH 2 OMe, CH 2 CH 2 OH, CH 2 CH 2 OM
- R 1 is C1-3alkyl, or C1-3fluoroalkyl, preferably R 1 is Me;
- R 2 is H,
- R 3 is a phenyl monosubstituted at position 4, or a phenyl disubstituted at positions 3 and 4, wherein said phenyl substituent(s) is F, Cl, Br, Me, Et, CH 2 OH, CH 2 OMe, CH 2 CH 2 OH, CH 2 CH 2 OMe, CH 2 CN, CH 2 COOEt, OCF 3 , OCHF 2 , —OMe, —O—benzyl, —O—phenyl, —SMe, —SO 2 NH 2 , CF 3 , COOMe, —CONHMe, —CONH 2 , —NH 2 , 3-pyridinyl, 4- pyridinyl, or two substituents of R 3 together form —O(CH
- compound of formula I is compounds of Tables 1 or 2.
- compound of formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- compound of formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- Generic proviso 1 when V1 is N, X is S, R 1 and R 2 together form (CH 2 ) 3-5 and R 3 is phenyl, then said phenyl is other than i) unsubstituted phenyl or ii) phenyl substituted at position 4 by F, Cl or OMe, for example when said compound is of formula I or Ia.
- Generic proviso 1a where V1 is N, X is S, R 1 and R 2 together form (CH 2 ) 3-5 , R 3 is optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl, a phenyl monosubstituted at position 3, phenyl disubstituted at positions 3 and 4, a phenyl disubstituted at positions 3 and 5, a phenyl monosubstituted at position 4 by Br, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C2—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO 2 NH(C1—3alkyl) —SO 2 N(C1—3alkyl) 2 , —SO 2 NH 2 , C1-3fluoroalkyl, -COO-C1-3al
- Generic proviso 2 when V1 is N, X is S, R 3 is unsubstituted phenyl and R 2 is H, then R 1 is other than Cl or Br, for example when said compound is of formula I or Ia.
- Generic proviso 3 when V1 and V2 are CH, W is C, X is S, R 2 is H, R 1 is CH 3 and R 3 is phenyl, then said phenyl is other than i) unsubstituted phenyl or ii) phenyl substituted at position 4 by F, Cl, Br or Me, for example when said compound is of formula I or Ie.
- the sulfur atom can be at different oxidation levels, ie. S, SO, or SO 2 . All such oxidation levels are within the scope of the present disclosure.
- the nitrogen atom can be at different oxidation levels, i.e. N or NO. All such oxidation levels are within the scope of the present disclosure.
- alkyl as used herein, unless otherwise defined is understood as referring to a saturated, monovalent unbranched or branched hydrocarbon chain.
- alkyl groups include, but are not limited to, C1-10 alkyl groups, provided that branched alkyls comprise at least 3 carbon atoms, such as C3-10 .
- Straight alkyl may have 1 to 6 or preferably 1 to 3 carbon atoms; whereas branched alkyl comprise C3-6.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl.
- alkenyl is meant to include alkyl residues in which one or more single bond(s) is replaced by a double bond.
- alkynyl is meant to include alkyl residues in which one or more single bond(s) is replaced by a triple bond.
- fluoroalkyl is meant to include alkyls in which one or more hydrogen atom is replaced by a fluoride atom of all alkyls defined above: straight or branched fluoroalkyls and straight or branched lower fluoroalkyls, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl.
- cycloalkyl represents optionally substituted cyclic alkyl moiety having 3 to 10 carbon atoms.
- Examples of “cycloalkyl” groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- carbocyclic ring in the definition of R 1 and R 2 preferably refers to an alkyl chain forming a ring with the aromatic ring atoms to which they are attached, even more preferably the carbocyclic ring refers to a chain (CH 2 ) 3-5 forming a ring with the aromatic ring atoms to which they are attached.
- heteroaryl represents a 5 to 11 membered aromatic cyclic moiety wherein said cyclic moiety is comprising at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N).
- Heteroaryls may be monocyclic or polycyclic rings. Heteroaryls may be 5 to 6 membered monocyclic ring or 5 membered monocyclic ring or 6 membered monocyclic ring. Heteroaryls may be fused 6,6, or 5,6 bicyclic rings.
- the rings comprise at least one ring comprising the heteroatom and the other rings may be cycloalkyl, aryl or heterocycle and the point of attachment may be on any available atom.
- This term includes without limitation, for example, furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzothiazolyl, quinolinyl, isoquinolinyl, indolyl and indazolyl.
- pharmaceutically acceptable salts of the compounds of the present disclosure are derived from pharmaceutically acceptable inorganic and organic acids and bases.
- non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, perchloric and the like, as well as salts prepared from organic acids such as formic, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, benzenesulphonic, naphthalene 2 sulphonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, n
- Salts derived from appropriate bases include alkali metal, alkaline earth metal or ammonium salts.
- the pharmaceutically acceptable salts of the compounds of this disclosure can be synthesized from the compounds of this disclosure which contain a basic or acidic moiety by conventional chemical methods.
- the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
- the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.
- a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- composition comprising stem cells and/or progenitor cells expanded by a compound or method as defined herein.
- the pharmaceutical composition may be further comprising a buffer solution or a an additional pharmaceutically active component, such as an antibiotic.
- the pharmaceutical composition as defined herein is for intravenous administration.
- a method of expanding stem cells and/or progenitor cells comprising contacting a starting cell population and at least one compound or a pharmaceutically acceptable salt thereof as defined herein.
- said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a compound for expanding stem cells and/or progenitor cells and at least one compound or a pharmaceutically acceptable salt thereof as defined herein.
- stem cells and/or progenitor cells such as hematopoietic stem and/or progenitor cells
- said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a first compound for expanding stem cells and/or progenitor cells, expanding the cells for a first period of time, adding at least one compound or a pharmaceutically acceptable salt thereof as defined herein and expanding the cells further for a second period of time.
- stem cells and/or progenitor cells such as hematopoietic stem and/or progenitor cells
- said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a first compound for expanding stem cells and/or progenitor cells, expanding the cells for a first period of time, substantially removing said first compound (e.g. by washing the expanded cells with an appropriate wash medium), contacting said cells expanded from said first period of time with at least one compound or a pharmaceutically acceptable salt thereof as defined herein and expanding the cells further for a second period of time.
- stem cells and/or progenitor cells such as hematopoietic stem and/or progenitor cells
- a (first) compound for expanding stem cells other than a compound of this invention (formula I, or Ia-Ie) may be a compound of formula
- the compound may be one of the following:
- the method of expanding stem cells and/or progenitor cells as defined herein may further be comprising at least one cell expanding agent.
- said cell expanding agent is an agonist antibody against the Thrombopoietin (TPO) receptor (for example, VB22B sc(Fv)2 as detailed in patent publication WO 2007/145227, and the like); a cytokine such as SCF, IL-6, Flt-3 ligand, TPO or a TPO mimetic (for example, such as described in WO/2007/022269; WO/2007/009120; WO/2004/054515; WO/2003/103686; WO/2002/085343; WO/2002/049413; WO/2001/089457; WO/2001/039773; WO/2001/034585; WO/2001/021180; WO/2001/021180; WO/2001/017349; WO/2000/066112; WO/2000/035446; WO
- TPO Thrombopoietin
- the cell expanding agent is selected from Interleukin-3 (IL-3), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Thrombopoietin (TPO), FMS-Like Tyrosine Kinase 3 Ligand (FLT3-L), Stem Cell Factor (SCF), Interleukin-6 (IL-6) and a combination thereof.
- IL-3 Interleukin-3
- GM-CSF Granulocyte Macrophage Colony-Stimulating Factor
- TPO Thrombopoietin
- FLT3-L FMS-Like Tyrosine Kinase 3 Ligand
- SCF Stem Cell Factor
- IL-6 Interleukin-6
- the cell expanding agent may be SCF, FLT3-L, TPO, IL-6 or a combination thereof.
- said cell expanding agent is StemRegenin 1 (SR1).
- a method of modulating (antagonizing) the activityof aryl hydrocarbon receptor comprising contacting stem cells and progenitor cells with a compound as defined herein.
- a method of increasing the number of stem cells and progenitor cells comprising contacting the cells with a compound capable of antagonizing the activity and/or expression of aryl hydrocarbon receptor and/or a downstream effector of aryl hydrocarbon receptor pathway, wherein said compound is a compound as defined herein.
- hematopoietic stem cells such as hematopoietic stem cells
- progenitor cells are human hematopoietic stem and progenitor cells.
- CD34+ stem cells and/or progenitor cells are human hematopoietic stem and progenitor cells.
- the starting cell population is comprising CD34+ cells harvested from mobilized peripheral blood (mPB), bone marrow (BM) or umbilical cord blood (UCB).
- mPB mobilized peripheral blood
- BM bone marrow
- UMB umbilical cord blood
- the starting cell population is human CD34+ stem cells and/or progenitor cells.
- the starting cell population includes CD34+ cells harvested from umbilical cord blood (UCB).
- ULB umbilical cord blood
- the starting cell population consists essentially of CD34+ cells, for example purified from one or two umbilical cord blood units.
- the expanded cells may then be washed to remove the compound or composition of invention and/or any other component of the cell culture and resuspended in an appropriate cell suspension medium for short term use or in a long-term storage medium, for example a medium suitable for cryopreservation.
- a preferred method of administration of expanded cells or a composition comprising said expanded cells is intravenous infusion.
- the number of cells transfused will take into consideration factors such as sex, age, weight, the types of disease or disorder, stage of the disorder, the percentage of the desired cells in the cell population and the amount of cells needed to produce a therapeutic benefit.
- the composition is administered by intravenous infusion and comprises at least ⁇ 0.3 ⁇ 10 5 CD34 + / kg or > 2 ⁇ 10 6 CD34 + for cord blood and 2.5 ⁇ 10 5 CD34 + / kg or more for bone marrow or mobilized peripheral blood cells.
- Expanded stem cells such as hematopoietic stem cells
- hematopoietic progenitor cells may be infused by drip, for example, in the case of treatment of leukemia, into patients pretreated with an anticancer drug, total body irradiation or an immunosuppressive drug for eradication of cancer cells or for facilitation of donor cell engraftment.
- the disease to be treated, the pretreatment and the cell transplantation method are selected appropriately by the person in charge.
- the engraftment of so transplanted hematopoietic stem cells and/or hematopoietic progenitor cells in the recipient, the recovery of hematopoiesis, the presence of side effects of the transplantation and the therapeutic effect of the transplantation can be judged by an ordinary assay used in transplantation therapy.
- said method is in vivo, in vitro or ex vivo, in particular, the method is ex vivo or in vitro.
- a cell population as expanded by a method as defined herein there is provided a cell population as expanded by a method as defined herein.
- a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease comprising administering expanded stem cells (such as hematopoietic stem cells) as defined herein to a subject in need thereof or expanding hematopoietic stem cells by a method as defined herein and administering said expanded stem cells to a subject in need thereof.
- expanded stem cells such as hematopoietic stem cells
- a cell population with expanded HSCs obtainable or obtained by the expansion method described above.
- such cell population is resuspended in a pharmaceutically acceptable medium suitable for administration to a mammalian host, thereby providing a therapeutic composition.
- a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease comprising administering a compound or a pharmaceutically acceptable salt thereof as defined herein to a subject in need thereof.
- the hematopoietic disorder/malignancy, the autoimmune disease and/or the inherited immunodeficient disease comprise bone marrow failure conditions, a congenital diseases (such as sickle cell anemia and thalassemia), lupus, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin’s disease, aplastic anemia, pure red cell aplasia, hemoglobinuria, Fanconi anemia, thalassemia, sickle cell anemia, Wiskott-Aldrich syndrome, inborn errors of metabolism (such as Gaucher disease).
- a congenital diseases such as sickle cell anemia and thalassemia
- lupus such as sickle cell anemia and thalassemia
- a method of treating a patient receiving an organ from a transplantation comprising administering expanded stem cells (such as hematopoietic stem cells) as defined herein to said patient or expanding hematopoietic stem cells by a method as defined herein and administering said expanded hematopoietic stem cells to said patient.
- the expanded cells are bone marrow cells from the organ donnor.
- the subject referred to herein is, for example, a bone marrow donor or an individual with or at risk for depleted or limited blood cell levels.
- the subject is a bone marrow donor prior to bone marrow harvesting or a bone marrow donor after bone marrow harvesting.
- the subject is optionally a recipient of a bone marrow transplant.
- the methods described herein are particularly useful in subjects that have limited bone marrow reserve such as elderly subjects or subjects previously exposed to an immune depleting treatment or myeloablative treatment such as chemotherapy, e.g., for treating leukemia or lymphomas.
- the subject optionally, has a decreased blood cell level or is at risk for developing a decreased blood cell level as compared to a control blood cell level.
- control blood cell level refers to an average level of blood cells in a subject prior to or in the substantial absence of an event that changes blood cell levels in the subject.
- An event that changes blood cell levels in a subject includes, for example, anemia, trauma, chemotherapy, bone marrow transplant and radiation therapy.
- the subject has anemia or blood loss due to, for example, trauma.
- hematopoietic stem cells or “HSCs” is intended to mean cells having both pluripotency which allows them to differentiate into functional mature cells such as granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), and monocytes (e.g., monocytes, macrophages), and the ability to regenerate while maintaining their pluripotency (self-renewal).
- granulocytes e.g., promyelocytes, neutrophils, eosinophils, basophils
- erythrocytes e.g., reticulocytes, erythrocytes
- thrombocytes e.g., megakaryoblasts, platelet producing megakary
- HSCs are part of the starting cell population. These cells are optionally obtained from the body or an organ of the body containing cells of hematopoietic origin. Such sources include un-fractionated bone marrow, umbilical cord, peripheral blood, liver, thymus, lymph and spleen. All of the aforementioned crude or un-fractionated blood products can be enriched for cells having hematopoietic stem cell characteristics in ways known to those of skill in the art.
- starting cell population is meant to identify a cell population comprising stem and/or progenitor cells, such as hematopoietic stem cells (HSCs) and/or hematopoietic progenitor cells, harvested from one of various sources mentioned above, as known in the art.
- stem and/or progenitor cells such as hematopoietic stem cells (HSCs) and/or hematopoietic progenitor cells, harvested from one of various sources mentioned above, as known in the art.
- the starting cell population may first be subjected to enrichment or purification steps, including negative and/or positive selection of cells based on specific cellular markers in order to provide the starting cell population.
- Methods for isolating said starting cell population based on specific cellular markers may use fluorescent activated cell sorting (FACS) technology also called flow cytometry or solid or insoluble substrate to which is bound antibodies or ligands that interact with specific cell surface markers.
- FACS fluorescent activated cell sorting
- cells may be contacted with a solid substrate (e.g., column of beads, flasks, magnetic particles) containing the antibodies and any unbound cells are removed.
- a solid substrate comprising magnetic or paramagnetic beads
- cells bound to the beads can be readily isolated by a magnetic separator.
- the starting cell population can be enriched in CD34+ cells meaning a cell population selected based on the presence of the cell surface marker CD34+.
- CD34+ cells can be detected and counted using for example flow cytometry and fluorescently labeled anti-CD34 antibodies.
- the starting cell population may be used directly for expansion or frozen and stored for use at a later point in time.
- Methods for enriching blood cell population in CD34+ cells include kits commercialized by Miltenyi Biotec (CD34+ direct isolation kit, Miltenyi Biotec, Bergisch, Gladbach, Germany) or by Baxter (Isolex 3000).
- the starting cell population may preferably contain at least 50% CD34+ cells, in some embodiments, more than 90% of CD34+ cells.
- the compounds and further cell expanding agent as used herein may be added to expansion medium immobilized onto a substrate or support used for the culture.
- the expansion of stem cells may be carried out in natural medium, a semi-synthetic medium or a synthetic medium in terms of composition, and may be a solid medium, a semisolid medium or a liquid medium in terms of shape, and any nutrient medium used for hematopoietic stem cell and/or hematopoietic progenitor cell culture, which is supplemented with the mixtures of cell expanding factors described above.
- Such medium typically comprises sodium, potassium, calcium, magnesium, phosphorus, chlorine, amino acids, vitamins, cytokines, hormones, antibiotics, serum, fatty acids, saccharides or the like.
- other chemical components or biological components may be incorporated singly or in combination, as the case requires.
- Such components to be incorporated in the medium may be fetal calf serum, human serum, horse serum, insulin, transfferin, lactoferrin, cholesterol, ethanolamine, sodium selenite, monothioglycerol, 2-mercaptoethanol, bovine serum albumin, sodium pyruvate, polyethylene glycol, various vitamins, various amino acids, agar, agarose, collagen, methylcellulose, various cytokines, various growth factors or the like.
- SFEM StemSpan
- the stem cells and/or progenitor cells can be cultured in a culture vessel generally used for animal cell culture such as a Petri dish, a flask, a plastic bag, a TeflonTM bag, optionally after preliminary coating with an extracellular matrix or a cell adhesion molecule.
- a culture vessel generally used for animal cell culture such as a Petri dish, a flask, a plastic bag, a TeflonTM bag, optionally after preliminary coating with an extracellular matrix or a cell adhesion molecule.
- the material for such a coating may be collagens I to XIX, fibronectin, vitronectin, laminins 1 to 12, nitrogen, tenascin, thrombospondin, von Willebrand factor, osteoponin, fibrinogen, various elastins, various proteoglycans, various cadherins, desmocolin, desmoglein, various integrins, E-selectin, P-selectin, L-selectin, immunoglobulin superfamily, Matrigel, poly-D-lysine, poly-L-lysine, chitin, chitosan, Sepharose, alginic acid gel, hydrogel or a fragment thereof.
- Such a coating material may be a recombinant material having an artificially modified amino acid sequence.
- the hematopoietic stem cells and/or hematopoietic progenitor cells may be cultured by using a bioreactor which can mechanically control the medium composition, pH and the like and obtain high density culture (Schwartz R M, Proc. Natl. Acad. Sci. U.S.A., 88:6760, 1991; Koller M R, Bone Marrow Transplant, 21:653, 1998; Koller, M R, Blood, 82: 378, 1993; Astori G, Bone Marrow Transplant, 35: 1101, 2005). These publications and their content are incorporated herein by reference.
- a starting cell population in particular CD34+ enriched cells, may be grown under conditions for HSC expansion, for example between 2 and 21 days and/or until the indicated fold expansion and the characteristic cell populations are obtained.
- the cells are grown ex vivo under conditions for HSC expansion not more than 21 days, 12 days, 10 days or 7 days.
- compositions may comprise pharmaceutically acceptable carrier(s) and/or excipient(s).
- pharmaceutically acceptable carrier(s) and/or excipient(s) are known in the art. It will be understood by those in the art that a pharmaceutically acceptable carrier and/or excipient must be compatible with the other ingredients of the formulation and tolerated by a subject in need thereof. The proportion of each carrier and/or excipient can be determined by the skilled practitioner in accordance with standard pharmaceutical practice.
- the pharmaceutical composition is in the form of a discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with a liquid carrier or solid carrier or both and then, if necessary, shaping the product into the desired formulation.
- the compounds and expanded cells according to the disclosure may be formulated for parenteral administration, e.g. by injection, for example bolus injection or continuous infusion, and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with/without an added preservative.
- the compositions are formulated in any conventional manner for use in the methods described herein. Administration is via any route known to be effective by one of ordinary skill.
- the compositions is administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, intranasally or topically.
- Abbreviations or symbols used herein include: AcOH: acetic acid; dba: dibenzylidene acetone; DMF: N,N-dimethylformamide; DIPEA: diisopropylamine; DMSO: dimethylsulfoxide; dppf: 1,1′-bis(diphenylphosphino)ferrocene; EtOAc: ethyl acetate; EtOH: ethanol; MeOH: methanol; Hex: hexanes; MS: mass spectrometry; NMR: nuclear magnetic resonance; THF: tetrahydrofuran.
- EtOH (4.16 mL, 71.3 mmol) is added slowly to an ice-cold suspension of NaH (60% w/w; 2.85 g, 71.3 mmol) in ether (51 mL). Additional EtOH (8.5 ml) is added. A mixture of 1.1 (5.0 g, 59.4 mmol) and ethyl formate (5.02 mL, 62.4 mmol) is next added dropwise (55 min). Additional ether (10 mL) is added and the mixture is stirred at room temperature overnight. Ether (50 mL) is added and the mixture is filtered.
- H 2 O 2 (0.90 mL, 7.90 mmol) is added to a cold solution of amide 3.3 (538 mg, 3.95 mmol) in AcOH (4.9 mL). The mixture is stirred at room temperature for 30 min then is heated at 80° C. for 4 h. The mixture is cooled in an ice-bath and 20% Na 2 SO 3 solution is added until there are no trace of peroxide left as determined with a KI-starch paper. 15 N NH 4 OH is next added to basify the mixture. The resulting suspension is warmed to room temperature and is filtered, washing the solid with water.
- DIPEA (0.717 mL, 4.10 mmol) is added dropwise to an ice-cold solution of 10.2 (569 mg, 3.73 mmol) and 10.3 (369 mg, 3.92 mmol) in CH 2 Cl 2 (19 mL). The mixture is stirred at 0° C. for 1 h and at room temperature for 1 h. The mixture is diluted with CH 2 Cl 2 and the solution is washed with water and brine, then dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure.
- PdCl 2 (dppf)-CH 2 Cl 2 adduct (4.91 mg, 6.01 ⁇ mol) is added to a degassed (vacuum to argon 3x) partial solution of compound 1037 (50 mg, 0.120 mmol), boronic acid 17.1 (44.3 mg, 0.360 mmol) and K 2 CO 3 (49.8 mg, 0.360 mmol) in dioxane (1.15 mL) and water (0.287 mL) at room temperature.
- the mixture is degassed again and heated at 85° C. for 21 h.
- the cooled mixture is taken in EtOAc (150 mL) and water (30 mL) is added.
- the separated aqueous layer is extracted with CH 2 Cl 2 (3 x).
- t-BuOK (45.4 mg, 0.405 mmol) is added to a solution of 25.2 (95 mg, 0.324 mmol) in THF (3.2 mL) at room temperature. The mixture is heated at reflux for 2 h. The mixture is taken in CH 2 Cl 2 and the solution is washed with water and brine, dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure.
- CB cells Human CD34+ cord blood (CB) cells were isolated from fresh units using RosetteSepTM CD34 pre-enrichment cocktail followed by CD34 positive selection using EasySep kitTM (StemCell Technologies). The cells were then pre-expanded in bulk, by culturing at 37° C.
- HSC expansion media consisting of StemSpan ACF (StemCell Technologies) supplemented with 100 ng/mL Stem Cell Factor (SCF, Shenandoah), 100 ng/mL FMS-like Tyrosine Kinase 3 Ligand (FLT3L, Shenandoah), 50 ng/mL Thrombopoietin (TPO, Shenandoah), 2 mM GlutaMAXTM (Invitrogen), 10 ⁇ g/mL low density lipoproteins (LDL, StemCell Technologies), 10 ⁇ g/mL Ciprofloxacin and 35 nM UM0128171.
- the culture was monitored daily and supplemented with fresh media as required. Following the pre-expansion, cells were harvested, aliquoted and frozen until use.
- CD34+ pre-expanded cells were cultured in HSC expansion media, in the presence of 35 nM UM0128171.
- Compounds were serially diluted (1 ⁇ 2) in DMSO (10 dilutions per compound) and added to the cells in order to achieve a 1/1000 final dilution.
- StemRegenin1 (SR1) and/or Compound 1001 were included in all experiments as controls to monitor assay performance.
- the plate was incubated at 37° C. for 7 days in static conditions (i.e. no shaking and no addition of media). Flow cytometry analysis was performed at the end of the 7-day expansion.
- HEK cells line was transfected with an AhR-responsive firefly luciferase reporter gene X4-4.27 and the stable transfectants generated were again transfected with phRL-CMV (a Renilla luciferase expression vector; Promega) along with pBAsi-hU6 Pur DNA (a plasmid carrying the puromycin-resistant gene; TaKaRa, Shiga, Japan), and maintained in the presence of both hygromycin B and puromycin (2 mg/mL).
- phRL-CMV Renilla luciferase expression vector
- pBAsi-hU6 Pur DNA a plasmid carrying the puromycin-resistant gene; TaKaRa, Shiga, Japan
- One of the resultant clones was named HEK-XRE 11.1, and used in the reporter gene assays.
- HEK-XRE 11.1 cells were plated in 384-well plates at a density of 25,000 cells in 50 uL volume per well. The induction of ARh pathway was done by addition of MeBIO at 0.1 nM concentration. ARh antagonist compounds were then added to seeded cells in serial dilutions (8 dilutions, 1:3, 10 mM down to 5 nM) in duplicate wells. Renilla expression was not used as internal control. On each plate, Compound 1001 and SR1 were added as dose control (8 dilutions, 1:3, 5 mM down to 2.5 nM for SR1 and 2 mM down to 1 nM for compound 1001). Luminescence activity was evaluated after 24 hours culture using Lumi-384-CellTiterGlo-Corning protocol. Dose-response curves were generated using nonlinear regression in Excel. Results are presented in Tables 1 and 2.
- CB Human CD34+ cord blood (CB) cells from three cord blood units were isolated as previously described and frozen until use.
- CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 35 nM UM0128171 (referred to as UM171), 1 ⁇ M Compound 1001, a combination of both or DMSO. Cultures were monitored daily and supplemented with fresh media as required.
- CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 0.5 ⁇ M Compound 1001 (alone or in combination with 35 nM UM171), 0.5 ⁇ M Compound 1114 (alone or in combination with 35 nM UM171), 0.5 ⁇ M SR1 (alone or in combination with 35 nM UM171), DMSO or_35 nM UM171.
- Phenotype of unexpanded (d0) and expanded (d7) CB cells were analysed using a combination of the following anti-human antibodies: CD34 (BD Biosciences), CD45RA (BD Biosciences or BioLegend), CD201, CD90 and CD117 (from BioLegend), CD86 and Fc ⁇ R1 (both from eBiosciences). Following staining under reduced light at room temperature for 15-30 minutes, cells were washed and analyzed on a FACSCanto II (BD Biosciences) flow cytometer. Fold expansion was calculated by dividing the number of live total cells obtained following expansion by the number of live total cells seeded for each condition. For each subpopulation of interest, the absolute cell numbers were calculated as follows: (cell percentage of subpopulation of interest x live total cell count)/100
- FIG. 1 A left panel
- the use of Compound 1001 in CB cultures increases the number of CD34+ cells (i.e. hematopoietic stem and progenitor cells) compared to other conditions ( FIG. 1 A , middle).
- the combined use of UM171 and Compound 1001 or Compound 1114 increased the overall percentage of CD34+ cells in cultures ( FIG. 1 A , right panel and FIG. 1 D ).
- mice were bred and housed under specific-pathogen-free conditions in sterile ventilated racks at the Institute for Research in Immunology and Cancer. All animal work was in accordance with the Canadian Council on Animal Care guidelines and approved by the Comotti de Déontologie et Ex Southernmentation Animale de l′elle de Quebec.
- CB Human CD34+ cord blood (CB) cells from two cord blood units were isolated as previously described and frozen until use. Upon thawing, both units were pooled and CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 35 nM UM0128171, 1 ⁇ M Compound 1001, a combination of both or DMSO. Cultures were monitored daily and supplemented with fresh media as required.
- NSG bone marrow (BM) was monitored by flow cytometry 3, 12 and 20 weeks post-transplantation.
- NSG BM cells were collected by femoral aspiration (weeks 3 and 12) or by flushing the two femurs when animals were sacrificed at week 20. Flow cytometry analysis was performed on freshly collected BM cells.
- Cells were treated with 1x red blood cell lysis buffer (StemCell Technologies), washed and stained with anti-human CD45 (BioLegend), anti-mouse CD45.1 (eBioscience) and anti-human CD33, anti-human CD19, anti-human CD3 and anti-human CD34 (all from BD Biosciences). Cells then were washed and analyzed using a FACSCanto II (BD Biosciences).
- CB cells expanded in the presence UM171, alone or in combination with Compound 1001 resulted in higher engraftment at 3 weeks post transplantation
- the contribution of lymphoid lineage was greatly increased in the presence of Compound 1001 ( FIG. 2 B ).
- a method for expanding stem cells and/or progenitor cells comprising contacting a starting cell population with a compound of formula I
- R 1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
- R 3 is an optionally mono or disubstituted phenyl at any of positions 3, 4 and 5 of said phenyl.
- any one of embodiments 1 to 10 comprising either i) contacting said starting cell population with a first compound for expanding stem cells and/or progenitor cells and expanding the cells for a first period of time, optionally substantially removing said first compound, adding said compound of formula I or a pharmaceutically acceptable salt thereof and expanding the cells further for a second period of time or ii) contacting said starting cell population with a compound for expanding stem cells and/or progenitor cells and said compound of formula I.
- a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease comprising administering cell population as defined in embodiment 12 or administering a compound as described in any one of embodiments 1 to 10.
- R 1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
- a pharmaceutical composition comprising a compound as defined in any one of embodiments 1 to 24 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising stem cells and/or progenitor cells as defined in embodiment 12 or as expanded by the method as defined in any one of embodiments 1 to 13, and optionally a pharmaceutically acceptable carrier.
Abstract
The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
Description
- This application is a divisional of U.S. Application No. 16/760,780, filed on Apr. 30, 2020, which is a U.S. National Stage of International Application No. PCT/IB2018/058593, filed on Nov. 1, 2018, which claims benefit of US provisional application 62/581,149 filed Nov. 3, 2017. The entire contents of each of U.S. Application No. 16/760,780, International Application No. PCT/IB2018/058593, and US provisional application 62/581,149 are entirely incorporated herein by reference.
- The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells (HPCs) and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
- The three sources of hematopoietic stem cells (HSCs) are the bone marrow, mobilized peripheral blood and the umbilical cord blood (UCB). HSCs are used in the transplantation setting (autologous or allogeneic) which constitutes one of the most effective treatment strategies for achieving cures in patients with hematologic malignancies, bone marrow failure conditions, a variety of congenital diseases of global concern (e.g. sickle cell anemia and thalassemia) and autoimmune diseases such as lupus. However, this opportunity for life-saving or life-improving treatment is not available to many thousands of people worldwide due to an inability to amplify these cells ex vivo sufficiently to make the procedure safe and successful. More particularly, for every 3 patients, one will forego the opportunity for transplant because no human leucocyte antigen (HLA) identical donor can be found. Another proportion of patients will not have access to transplantation simply because too few HSCs are available in the graft (i.e. cord blood or autologous) for successful transplant. The safety and efficacy of marrow transplant is directly dependent on the number of HSCs and HPCs available for engrafting. The more that can be infused, the more rapidly is hematologic function restored, and the shorter is the window of risk for infection due to lack of granulocytes or of bleeding due to lack of platelets. The challenge in providing sufficient HSCs is further escalated where non-myeloablative conditioning is preferred such as in the context of gene therapy for major inherited blood disorders (the major genetic cause of morbidity and mortality worldwide).
- In adults, HSCs mainly reside in the bone marrow (BM) and must be mobilized to enter the circulation prior to being collected by apheresis, either for autologous or allogeneic hematopoietic stem cell transplantation (HSCT). The collection of an adequate number of CD34+ cells, a surrogate marker of (HSCs), is paramount because the dose of CD34+ cells influences the success and rate of hematopoietic recovery. Several reports suggest that a higher infused CD34+ cell dose is independently predictive of improved survival.
- Allogeneic HSCT with BM or mobilized pheripheral blood stem cells (mPBSC) is another transplantation alternative. However, about one third to one fourth of the patients who are eligible for this type of transplant cannot find a suitable donor. For those who get transplanted, there is a high frequency of transplant related mortality due to graft-versus-host disease, relapse or graft rejection; and a risk of immunodeficiency for prolonged periods of time. Alternatively, umbilical cord blood has been shown as a valid option in allogeneic HSCT. However, a single cord blood (CB) unit typically provides insufficient HSCs for an adult patient for a rapid and efficient recovery.
- There is thus a need for novel strategies for increasing the expansion of stem cells, progenitor cells, or both stem cells and progenitor cells.
- An aspect relates to a compound of formula I
- or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, V1, V2, X, and W are as defined herein.
- A further aspect relates to a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- A further aspect relates to a pharmaceutical composition comprising stem cells and/or progenitor cells expanded by a compound or method as defined herein.
- In an aspect, there is provided a method of expanding stem cells and/or progenitor cells, as defined herein.
- A further aspect relates to a cell population obtainable/ obtained by a method as defined herein.
- In an aspect, there is provided a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease as defined herein.
- A further aspect relates to a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease, comprising administering a compound or a pharmaceutically acceptable salt thereof as defined herein to a subject in need thereof.
- A further aspect relates to a method of treating a patient receiving an organ transplant, more particularly a solid organ transplant.
- Reference is now made to the accompanying figures in which:
-
FIG. 1A depicts the fold expansion of total cells and CD34+ cells in the different culture conditions compared to fresh samples, as well as the proportions of CD34+ cells in the different culture conditions; -
FIG. 1B depicts the fold expansion of CD34+CD45RA-, CD34+CD45RA+ and CD34+CD201+ cells in the different culture conditions compared to fresh samples; -
FIG. 1C depicts the proportions of CD34+CD45RA-, CD34+CD45RA+ and CD34+CD201+ cells in the different culture conditions; -
FIG. 1D depicts the cell composition in percentages of different cell types in the different culture conditions; -
FIG. 2A shows the engraftment (as the percentage of human CD45+ cells in bone marrow aspirate) of human cord blood cells from fresh samples or in vitro expanded-samples in the different culture conditions; and -
FIG. 2B show the proportions of myeloid and lymphoid cells in engrafted human cord blood cells in mice. - In one embodiment, there is provided a compound of formula I
- or a pharmaceutically acceptable salt thereof, wherein
- X is O or S;
- V1 is N or CH;
- V2 is N or CH;
- W is N or C;
- wherein not more than one of said V1, V2 and W is N;
- R1 is halo, alkyl, fluoroalkyl, cycloalkyl, alkynyl, alkenyl, cyano, or COORa, wherein Ra is an alkyl;
- R2 is H, alkyl or R2 is absent when W is N;
- or R1 and R2 are attached together with the aromatic ring atoms to form a carbocyclic ring;
- R3 is an optionally substituted phenyl, an optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl.
- In one embodiment, said compound is a compound of formula Ia
- wherein R1, R2 and R3 are as defined herein.
- In one embodiment, said compound is a compound of formula Ib
- wherein R1, R2 and R3 are as defined herein.
- In one embodiment, said compound is a compound of formula Ic
- wherein R1 and R3 are as defined herein.
- In one embodiment, said compound is a compound of formula Id
- wherein R1, R2 and R3 are as defined herein.
- In one embodiment, said compound is a compound of formula Ie
- wherein R1, R2 and R3 are as defined herein.
- In one embodiment, R1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
- In one embodiment, R1 is halo, C1-3alkyl, C1-3fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-3alkyl.
- In one embodiment, R1 is F, Cl, Br, Me, Et, iPr, n-Pr, CF3, cyclopropyl, CCH, CH═CMe, cyano, or COOEt.
- In one embodiment, R1 is F, Me, Et, iPr, n-Pr, CF3, cyclopropyl, CCH, CH═CMe, cyano, or COOEt.
- In one embodiment, R1 is Me, CF3, or joined to R2 to form (CH2)3-5 ring.
- In one embodiment, R1 is Me or CF3, preferably CF3.
- In one embodiment, R2 is H, or C1-6alkyl.
- In one embodiment, R2 is H, or C1-3alkyl.
- In one embodiment, R2 is H or Me, preferably H.
- In one embodiment, R2 is H, methyl, ethyl, i-propyl or n-propyl; or preferably H or methyl.
- In one embodiment, R1 and R2 are attached together to form (CH2)3-5.
- In one embodiment, R3 is an optionally mono or disubstituted phenyl, an optionally monosubstituted 5- or 6-membered heteroaryl, or an optionally monosubstituted fused bicyclic heteroaryl.
- In one embodiment, R3 is an optionally mono or disubstituted phenyl at any of
positions - In one embodiment, R3 is an unsubstituted phenyl, a phenyl monosubstituted at
position 4, a phenyl monosubstituted atposition 3, a phenyl disubstituted atpositions positions - In one embodiment, R3 is an unsubstituted or monosubstituted heteroaryl selected from pyridinyl, pyrimidinyl, thiazolyl, benzothiazolyl, isoquinolinyl, quinolinyl, thienyl and indazolyl.
- In one embodiment, R3 is an unsubstituted or monosubstituted heteroaryl selected from 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 6-benzothiazolyl, 5-isoquinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 3-thienyl and 5-indazolyl.
- In one embodiment, R3 is an unsubstituted or monosubstituted heteroaryl selected from 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, and 3-thienyl.
- In one embodiment, when R3 is substituted phenyl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, sulfonamide, C1-3fluoroalkyl, -COO-C1-3alkyl, carboxamide, amino, phenyl, 5- or 6-membered heteroaryl or two substituents of R3 form together -O(CH2)3-5O- wherein the substituent of said optionally substituted C1-3alkyl is OH, OMe, CN, or COOEt.
- In one embodiment, when R3 is substituted phenyl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO2NH(C1—3alkyl) —SO2N(C1—3alkyl)2, —SO2NH2, C1-3fluoroalkyl, -COO-C1-3alkyl, -CONH(C1-3alkyl), —CON(C1-3alkyl)2, —CONH2, —NH(C1—3alkyl), —N(C1—3alkyl)2, —NH2, phenyl or 5- or 6-membered heteroaryl; or two substituents of R3 form together —O(CH2)O— or —O(CH2CH2)O— ; wherein the substituent of said optionally substituted C1-3alkyl is OH, OMe, CN, or COOEt.
- In one embodiment, when R3 is substituted phenyl, said substituent is F, Cl, Br, Me, Et, CH2OH, CH2OMe, CH2CH2OH, CH2CH2OMe, CH2CN, CH2COOEt, OCF3, OCHF2, —OMe, —O—benzyl, —O—phenyl, —SMe, —SO2NH2, CF3, COOMe, —CONHMe, —CONH2, —NH2, 3-pyridinyl, 4- pyridinyl, or two substituents of R3 form together form —O(CH2)O— or —O(CH2CH2)O—.
- In one embodiment, when R3 is substituted phenyl, said substituent is halo, —S—C1—3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl or two substituents of R3 form together —O(CH2)3-5O—.
- In one embodiment, when R3 is phenyl substituted at
position 4 with H, F, Cl, Br, Me, Et, OMe, OEt, SMe or CF3. - In one embodiment, when R3 is phenyl substituted at
position 3 with H, F, Cl, Br, Me, or OMe. - In one embodiment, when R3 is phenyl substituted at
position - In one embodiment, when R3 is substituted heteroaryl, said substituent is halo, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C1—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO2NH(C1—3alkyl) —SO2N(C1—3alkyl)2, —SO2NH2, C1-3fluoroalkyl, -COO-C1-3alkyl, -CONH(C1-3alkyl), -CON(C1-3alkyl)2, -CONH2, —NH(C1—3alkyl), —N(C1—3alkyl)2, —NH2, phenyl or 5- or 6-membered heteroaryl; or two substituents of R3 form together —O(CH2)O— or —O(CH2CH2)O— ; wherein the substituent of said optionally substituted C1-3alkyl is OH, OMe, CN, or COOEt.
- In one embodiment, when R3 is substituted heteroaryl, said substituent is F, Cl, Br, Me, Et, CH2OH, CH2OMe, CH2CH2OH, CH2CH2OMe, CH2CN, CH2COOEt, OCF3, OCHF2, —OMe, —O—benzyl, —O—phenyl, —SMe, —SO2NH2, CF3, COOMe, —CONHMe, —CONH2, —NH2, 3-pyridinyl, 4- pyridinyl, or two substituents of R3 form together form —O(CH2)O— or —O(CH2CH2)O—.
- In one embodiment, when R3 is substituted heteroaryl, such as 2-, 3-, 4-pyridyl or thienyl, said substituent is halo, C1-3alkyl, or —O—C1—3alkyl, preferably R3 is 4-pyridinyl or 3-thienyl.
- In one embodiment, in formula I, or in any of formula la to Ie, preferably in formula la and Ie, R1 is C1-6alkyl, C1-6fluoroalkyl, R2 is H or R1 is joined to R2 to form (CH2)3-5, R3 is an unsubstituted phenyl, a phenyl monosubstituted at
position 4, a phenyl monosubstituted atposition 3, a phenyl disubstituted atpositions positions - In one embodiment, in formula I, or in any of formula la to Ie, preferably in formula la and Ie, R1 is halo, C1-3alkyl, C1-3fluoroalkyl, C3cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-3alkyl, preferably R1 is Me, CF3, or joined to R2 to form (CH2)3-5 ring; R2 is H, R3 is an unsubstituted phenyl, a phenyl monosubstituted at position 4, a phenyl monosubstituted at position 3, a phenyl disubstituted at positions 3 and 4, or a phenyl disubstituted at positions 3 and 5 wherein said phenyl substituent(s) is F, Cl, Br, Me, Et, CH2OH, CH2OMe, CH2CH2OH, CH2CH2OMe, CH2CN, CH2COOEt, OCF3, OCHF2, —OMe, —O—benzyl, —O—phenyl, —SMe, —SO2NH2, CF3, COOMe, —CONHMe, —CONH2, —NH2, 3-pyridinyl, 4- pyridinyl, or two substituents of R3 together form —O(CH2)O— or —O(CH2CH2)O—or R3 is an unsubstituted or monosubstituted heteroaryl selected from 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, and 3-thienyl, wherein said substituent is halo, C1-3alkyl, or —O—C1—3alkyl.
- In one embodiment, in formula I, or in any of formula la to Ie, preferably in formula la, R1 is C1-3alkyl, or C1-3fluoroalkyl, preferably R1 is Me; R2 is H, R3 is a phenyl monosubstituted at
position 4, or a phenyl disubstituted atpositions - In one embodiment, compound of formula I is compounds of Tables 1 or 2.
- In one embodiment, compound of formula I is
- or a pharmaceutically acceptable salt thereof.
- In one embodiment, compound of formula I is
- or a pharmaceutically acceptable salt thereof.
- The methods as defined herein enjoy the use of the full scope of the compounds as contemplated by the inventors. The compounds that are excluded from the scope of the claimed compounds are those defined by the following provisos or as enumerated below.
- Generic proviso 1: when V1 is N, X is S, R1 and R2 together form (CH2)3-5 and R3 is phenyl, then said phenyl is other than i) unsubstituted phenyl or ii) phenyl substituted at
position 4 by F, Cl or OMe, for example when said compound is of formula I or Ia. - Generic proviso 1a: where V1 is N, X is S, R1 and R2 together form (CH2)3-5, R3 is optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl, a phenyl monosubstituted at
position 3, phenyl disubstituted atpositions positions position 4 by Br, optionally substituted C1-3alkyl, —O—C1—3fluoroalkyl, —O—C2—3alkyl, —O—benzyl, —O—phenyl, —S—C1—3alkyl, —SO2NH(C1—3alkyl) —SO2N(C1—3alkyl)2, —SO2NH2, C1-3fluoroalkyl, -COO-C1-3alkyl, -CONH(C1-3alkyl), -CON(C1-3alkyl)2, -CONH2, —NH(C1—3alkyl), —N(C1—3alkyl)2, or —NH2, for example when said compound is of formula I or Ia. - Generic proviso 2: when V1 is N, X is S, R3 is unsubstituted phenyl and R2 is H, then R1 is other than Cl or Br, for example when said compound is of formula I or Ia.
- Generic proviso 3: when V1 and V2 are CH, W is C, X is S, R2 is H, R1 is CH3 and R3 is phenyl, then said phenyl is other than i) unsubstituted phenyl or ii) phenyl substituted at
position 4 by F, Cl, Br or Me, for example when said compound is of formula I or Ie. - Alternatively, the compounds that are excluded from the scope of the claimed compounds are:
- When there is a sulfur atom present (such as a core ring atom), the sulfur atom can be at different oxidation levels, ie. S, SO, or SO2. All such oxidation levels are within the scope of the present disclosure. When there is a nitrogen atom present, the nitrogen atom can be at different oxidation levels, i.e. N or NO. All such oxidation levels are within the scope of the present disclosure.
- The term “alkyl”, as used herein, unless otherwise defined is understood as referring to a saturated, monovalent unbranched or branched hydrocarbon chain. Examples of alkyl groups include, but are not limited to, C1-10 alkyl groups, provided that branched alkyls comprise at least 3 carbon atoms, such as C3-10 . Straight alkyl may have 1 to 6 or preferably 1 to 3 carbon atoms; whereas branched alkyl comprise C3-6. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl.
- The term “alkenyl” is meant to include alkyl residues in which one or more single bond(s) is replaced by a double bond.
- The term “alkynyl” is meant to include alkyl residues in which one or more single bond(s) is replaced by a triple bond.
- The term “fluoroalkyl” is meant to include alkyls in which one or more hydrogen atom is replaced by a fluoride atom of all alkyls defined above: straight or branched fluoroalkyls and straight or branched lower fluoroalkyls, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl.
- The term “cycloalkyl” represents optionally substituted cyclic alkyl moiety having 3 to 10 carbon atoms. Examples of “cycloalkyl” groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- The term “carbocyclic ring” in the definition of R1 and R2 preferably refers to an alkyl chain forming a ring with the aromatic ring atoms to which they are attached, even more preferably the carbocyclic ring refers to a chain (CH2)3-5 forming a ring with the aromatic ring atoms to which they are attached.
- The term “heteroaryl” represents a 5 to 11 membered aromatic cyclic moiety wherein said cyclic moiety is comprising at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heteroaryls may be monocyclic or polycyclic rings. Heteroaryls may be 5 to 6 membered monocyclic ring or 5 membered monocyclic ring or 6 membered monocyclic ring. Heteroaryls may be fused 6,6, or 5,6 bicyclic rings. When heteroaryl is a polycyclic ring, the rings comprise at least one ring comprising the heteroatom and the other rings may be cycloalkyl, aryl or heterocycle and the point of attachment may be on any available atom. This term includes without limitation, for example, furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzothiazolyl, quinolinyl, isoquinolinyl, indolyl and indazolyl.
- There is also provided pharmaceutically acceptable salts of the compounds of the present disclosure. What is meant by the term pharmaceutically acceptable salts of the compounds is that they are derived from pharmaceutically acceptable inorganic and organic acids and bases.
- For example, conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, perchloric and the like, as well as salts prepared from organic acids such as formic, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, benzenesulphonic,
naphthalene 2 sulphonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like. - Other salts, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the disclosure and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal, alkaline earth metal or ammonium salts.
- The pharmaceutically acceptable salts of the compounds of this disclosure can be synthesized from the compounds of this disclosure which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents. Similarly, the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.
- In one embodiment there is provided a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- In one embodiment there is provided a pharmaceutical composition comprising stem cells and/or progenitor cells expanded by a compound or method as defined herein.
- The pharmaceutical composition may be further comprising a buffer solution or a an additional pharmaceutically active component, such as an antibiotic.
- In one embodiment the pharmaceutical composition as defined herein, is for intravenous administration.
- In one embodiment there is provided a method of expanding stem cells and/or progenitor cells, (such as hematopoietic stem and/or progenitor cells) the method comprising contacting a starting cell population and at least one compound or a pharmaceutically acceptable salt thereof as defined herein.
- In one embodiment of the methods herein, said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a compound for expanding stem cells and/or progenitor cells and at least one compound or a pharmaceutically acceptable salt thereof as defined herein.
- In one embodiment of the methods herein, said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a first compound for expanding stem cells and/or progenitor cells, expanding the cells for a first period of time, adding at least one compound or a pharmaceutically acceptable salt thereof as defined herein and expanding the cells further for a second period of time.
- In one embodiment of the methods herein, said methods are comprising the steps of contacting stem cells and/or progenitor cells (such as hematopoietic stem and/or progenitor cells) with a first compound for expanding stem cells and/or progenitor cells, expanding the cells for a first period of time, substantially removing said first compound (e.g. by washing the expanded cells with an appropriate wash medium), contacting said cells expanded from said first period of time with at least one compound or a pharmaceutically acceptable salt thereof as defined herein and expanding the cells further for a second period of time.
- A (first) compound for expanding stem cells, other than a compound of this invention (formula I, or Ia-Ie) may be a compound of formula
- such as those described in WO 2013/110198 (PCT/CA2013/050052), the content of which is incorporated herein by reference in it’s entirety. In particular, the compound may be one of the following:
- The method of expanding stem cells and/or progenitor cells as defined herein, may further be comprising at least one cell expanding agent.
- In one embodiment of the method of expanding hematopoietic stem cells and/or progenitor cells as defined herein, said cell expanding agent is an agonist antibody against the Thrombopoietin (TPO) receptor (for example, VB22B sc(Fv)2 as detailed in patent publication WO 2007/145227, and the like); a cytokine such as SCF, IL-6, Flt-3 ligand, TPO or a TPO mimetic (for example, such as described in WO/2007/022269; WO/2007/009120; WO/2004/054515; WO/2003/103686; WO/2002/085343; WO/2002/049413; WO/2001/089457; WO/2001/039773; WO/2001/034585; WO/2001/021180; WO/2001/021180; WO/2001/017349; WO/2000/066112; WO/2000/035446; WO/2000/028987; WO/2008/028645; and the like, which are incorporated herein by reference); granulocyte colony stimulating factor (G-CSF); granulocyte macrophage colony stimulating factor (GM-CSF); a prostaglandin or a prostaglandin receptor agonist (for example, prostaglandin E2 receptor-1 (EP-I) agonist, prostaglandin E2 receptor-2 (EP-2) agonist, prostaglandin E2 receptor-3 (EP-3) agonist and prostaglandin E2 receptor-4 (EP-4) agonists, as detailed in patent publication WO/2008/073748 which is incorporated herein by reference); tetraethylenepentamine (TEPA); Notch-ligands (Delta-1); and/or a WNT agonist. These publications and their content are incorporated herein by reference.
- Preferably the cell expanding agent is selected from Interleukin-3 (IL-3), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Thrombopoietin (TPO), FMS-
Like Tyrosine Kinase 3 Ligand (FLT3-L), Stem Cell Factor (SCF), Interleukin-6 (IL-6) and a combination thereof. - The cell expanding agent may be SCF, FLT3-L, TPO, IL-6 or a combination thereof. In one embodiment of the method of expanding stem cells (such as hematopoietic stem cells) and/or progenitor cells as defined herein, said cell expanding agent, is StemRegenin 1 (SR1).
- In one embodiment there is provided a method of modulating (antagonizing) the activityof aryl hydrocarbon receptor, comprising contacting stem cells and progenitor cells with a compound as defined herein.
- In one embodiment there is further provided a method of increasing the number of stem cells and progenitor cells; said method comprising contacting the cells with a compound capable of antagonizing the activity and/or expression of aryl hydrocarbon receptor and/or a downstream effector of aryl hydrocarbon receptor pathway, wherein said compound is a compound as defined herein.
- In one embodiment there is provided a method of expanding stem cells (such as hematopoietic stem cells) and/or progenitor cells as defined herein, wherein hematopoietic stem cells and/or progenitor cells are human hematopoietic stem and progenitor cells.
- In one embodiment there is provided a method of expanding CD34+ stem cells and/or progenitor cells as defined herein, wherein CD34+ stem cells and/or progenitor cells are human hematopoietic stem and progenitor cells.
- In one embodiment the starting cell population is comprising CD34+ cells harvested from mobilized peripheral blood (mPB), bone marrow (BM) or umbilical cord blood (UCB). In one embodiment, the starting cell population is human CD34+ stem cells and/or progenitor cells.
- In one embodiment the starting cell population includes CD34+ cells harvested from umbilical cord blood (UCB).
- In one embodiment the starting cell population consists essentially of CD34+ cells, for example purified from one or two umbilical cord blood units.
- The expanded cells may then be washed to remove the compound or composition of invention and/or any other component of the cell culture and resuspended in an appropriate cell suspension medium for short term use or in a long-term storage medium, for example a medium suitable for cryopreservation.
- A preferred method of administration of expanded cells or a composition comprising said expanded cells is intravenous infusion. The number of cells transfused will take into consideration factors such as sex, age, weight, the types of disease or disorder, stage of the disorder, the percentage of the desired cells in the cell population and the amount of cells needed to produce a therapeutic benefit. In one particular embodiment, the composition is administered by intravenous infusion and comprises at least ≥ 0.3 × 105 CD34+/ kg or > 2 × 106 CD34+ for cord blood and 2.5 × 105 CD34+/ kg or more for bone marrow or mobilized peripheral blood cells.
- Expanded stem cells (such as hematopoietic stem cells) and/or hematopoietic progenitor cells may be infused by drip, for example, in the case of treatment of leukemia, into patients pretreated with an anticancer drug, total body irradiation or an immunosuppressive drug for eradication of cancer cells or for facilitation of donor cell engraftment. The disease to be treated, the pretreatment and the cell transplantation method are selected appropriately by the person in charge. The engraftment of so transplanted hematopoietic stem cells and/or hematopoietic progenitor cells in the recipient, the recovery of hematopoiesis, the presence of side effects of the transplantation and the therapeutic effect of the transplantation can be judged by an ordinary assay used in transplantation therapy.
- In one embodiment of the method of expanding stem cells and/or progenitor cells as defined herein, said method is in vivo, in vitro or ex vivo, in particular, the method is ex vivo or in vitro.
- In one embodiment, there is provided a cell population as expanded by a method as defined herein.
- In one embodiment, there is provided a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease, comprising administering expanded stem cells (such as hematopoietic stem cells) as defined herein to a subject in need thereof or expanding hematopoietic stem cells by a method as defined herein and administering said expanded stem cells to a subject in need thereof.
- There is further provided a cell population with expanded HSCs, obtainable or obtained by the expansion method described above. In one specific embodiment, such cell population is resuspended in a pharmaceutically acceptable medium suitable for administration to a mammalian host, thereby providing a therapeutic composition.
- There is further provided a method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease, comprising administering a compound or a pharmaceutically acceptable salt thereof as defined herein to a subject in need thereof.
- In one embodiment, of the methods as defined herein, the hematopoietic disorder/malignancy, the autoimmune disease and/or the inherited immunodeficient disease comprise bone marrow failure conditions, a congenital diseases (such as sickle cell anemia and thalassemia), lupus, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin’s disease, aplastic anemia, pure red cell aplasia, hemoglobinuria, Fanconi anemia, thalassemia, sickle cell anemia, Wiskott-Aldrich syndrome, inborn errors of metabolism (such as Gaucher disease).
- In one embodiment, there is provided a method of treating a patient receiving an organ from a transplantation (ex. solid organ transplantation), comprising administering expanded stem cells (such as hematopoietic stem cells) as defined herein to said patient or expanding hematopoietic stem cells by a method as defined herein and administering said expanded hematopoietic stem cells to said patient. In a further embodiment, the expanded cells are bone marrow cells from the organ donnor.
- Regarding the method of treating a patient receiving an organ from a transplantation (ex. solid organ transplantation), reference can be made to Basak GW et al., Am J Transplant 2015 PMID:25648262; Elahimehr R et al., Transplant Rev (Orlando) 2016, PMID:27553809 and Marino Granados JM et al., Curr Opin Organ Transplant 2015, PMC4391059. Good review of preclinical and clinical studies.
- The subject referred to herein is, for example, a bone marrow donor or an individual with or at risk for depleted or limited blood cell levels. Optionally, the subject is a bone marrow donor prior to bone marrow harvesting or a bone marrow donor after bone marrow harvesting. The subject is optionally a recipient of a bone marrow transplant. The methods described herein are particularly useful in subjects that have limited bone marrow reserve such as elderly subjects or subjects previously exposed to an immune depleting treatment or myeloablative treatment such as chemotherapy, e.g., for treating leukemia or lymphomas. The subject, optionally, has a decreased blood cell level or is at risk for developing a decreased blood cell level as compared to a control blood cell level. As used herein the term control blood cell level refers to an average level of blood cells in a subject prior to or in the substantial absence of an event that changes blood cell levels in the subject. An event that changes blood cell levels in a subject includes, for example, anemia, trauma, chemotherapy, bone marrow transplant and radiation therapy. For example, the subject has anemia or blood loss due to, for example, trauma.
- As used herein, the term “hematopoietic stem cells” or “HSCs” is intended to mean cells having both pluripotency which allows them to differentiate into functional mature cells such as granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), and monocytes (e.g., monocytes, macrophages), and the ability to regenerate while maintaining their pluripotency (self-renewal).
- HSCs are part of the starting cell population. These cells are optionally obtained from the body or an organ of the body containing cells of hematopoietic origin. Such sources include un-fractionated bone marrow, umbilical cord, peripheral blood, liver, thymus, lymph and spleen. All of the aforementioned crude or un-fractionated blood products can be enriched for cells having hematopoietic stem cell characteristics in ways known to those of skill in the art.
- As used herein, the term “starting cell population” is meant to identify a cell population comprising stem and/or progenitor cells, such as hematopoietic stem cells (HSCs) and/or hematopoietic progenitor cells, harvested from one of various sources mentioned above, as known in the art.
- The starting cell population may first be subjected to enrichment or purification steps, including negative and/or positive selection of cells based on specific cellular markers in order to provide the starting cell population. Methods for isolating said starting cell population based on specific cellular markers may use fluorescent activated cell sorting (FACS) technology also called flow cytometry or solid or insoluble substrate to which is bound antibodies or ligands that interact with specific cell surface markers. For example, cells may be contacted with a solid substrate (e.g., column of beads, flasks, magnetic particles) containing the antibodies and any unbound cells are removed. When a solid substrate comprising magnetic or paramagnetic beads is used, cells bound to the beads can be readily isolated by a magnetic separator.
- The starting cell population can be enriched in CD34+ cells meaning a cell population selected based on the presence of the cell surface marker CD34+. CD34+ cells can be detected and counted using for example flow cytometry and fluorescently labeled anti-CD34 antibodies. Moreover, the starting cell population may be used directly for expansion or frozen and stored for use at a later point in time. Methods for enriching blood cell population in CD34+ cells include kits commercialized by Miltenyi Biotec (CD34+ direct isolation kit, Miltenyi Biotec, Bergisch, Gladbach, Germany) or by Baxter (Isolex 3000). The starting cell population may preferably contain at least 50% CD34+ cells, in some embodiments, more than 90% of CD34+ cells.
- The compounds and further cell expanding agent as used herein may be added to expansion medium immobilized onto a substrate or support used for the culture.
- The expansion of stem cells may be carried out in natural medium, a semi-synthetic medium or a synthetic medium in terms of composition, and may be a solid medium, a semisolid medium or a liquid medium in terms of shape, and any nutrient medium used for hematopoietic stem cell and/or hematopoietic progenitor cell culture, which is supplemented with the mixtures of cell expanding factors described above. Such medium typically comprises sodium, potassium, calcium, magnesium, phosphorus, chlorine, amino acids, vitamins, cytokines, hormones, antibiotics, serum, fatty acids, saccharides or the like. In the culture, other chemical components or biological components may be incorporated singly or in combination, as the case requires. Such components to be incorporated in the medium may be fetal calf serum, human serum, horse serum, insulin, transfferin, lactoferrin, cholesterol, ethanolamine, sodium selenite, monothioglycerol, 2-mercaptoethanol, bovine serum albumin, sodium pyruvate, polyethylene glycol, various vitamins, various amino acids, agar, agarose, collagen, methylcellulose, various cytokines, various growth factors or the like. Examples of such basal medium appropriate for a method of expanding HSCs include, without limitation, StemSpan™ Serum-Free Expansion Medium (SFEM) (StemCell Technologies, Vancouver, Canada), StemSpan™ H3000-Defined Medium (StemCell Technologies, Vancouver, Canada), CellGro™, SCGM (CellGenix, Freiburg Germany), StemPro™-34 SFM (Invitrogen), Dulbecco’s Modified Eagles’s Medium (DMEM), Ham’s Nutrient Mixture H12 Mixture F12, McCoy’s 5A medium, Eagles’s Minimum Essential Medium (EMEM), αMEM medium (alpha Modified Eagles’s Minimum Essential Medium), RPMI1640 medium, Isocove’s Modified Dulbecco’s Medium (IMDM), StemPro34 (Invitrogen), X-VIVO 10 (Cambrex), X-VIVO 15 (Cambrex) and Stemline II (Sigma-Aldrich).
- The stem cells and/or progenitor cells can be cultured in a culture vessel generally used for animal cell culture such as a Petri dish, a flask, a plastic bag, a Teflon™ bag, optionally after preliminary coating with an extracellular matrix or a cell adhesion molecule. The material for such a coating may be collagens I to XIX, fibronectin, vitronectin,
laminins 1 to 12, nitrogen, tenascin, thrombospondin, von Willebrand factor, osteoponin, fibrinogen, various elastins, various proteoglycans, various cadherins, desmocolin, desmoglein, various integrins, E-selectin, P-selectin, L-selectin, immunoglobulin superfamily, Matrigel, poly-D-lysine, poly-L-lysine, chitin, chitosan, Sepharose, alginic acid gel, hydrogel or a fragment thereof. Such a coating material may be a recombinant material having an artificially modified amino acid sequence. The hematopoietic stem cells and/or hematopoietic progenitor cells may be cultured by using a bioreactor which can mechanically control the medium composition, pH and the like and obtain high density culture (Schwartz R M, Proc. Natl. Acad. Sci. U.S.A., 88:6760, 1991; Koller M R, Bone Marrow Transplant, 21:653, 1998; Koller, M R, Blood, 82: 378, 1993; Astori G, Bone Marrow Transplant, 35: 1101, 2005). These publications and their content are incorporated herein by reference. - A starting cell population, in particular CD34+ enriched cells, may be grown under conditions for HSC expansion, for example between 2 and 21 days and/or until the indicated fold expansion and the characteristic cell populations are obtained. In one specific embodiment, the cells are grown ex vivo under conditions for HSC expansion not more than 21 days, 12 days, 10 days or 7 days.
- Pharmaceutical compositions may comprise pharmaceutically acceptable carrier(s) and/or excipient(s). Many pharmaceutically acceptable carrier(s) and/or excipient(s) are known in the art. It will be understood by those in the art that a pharmaceutically acceptable carrier and/or excipient must be compatible with the other ingredients of the formulation and tolerated by a subject in need thereof. The proportion of each carrier and/or excipient can be determined by the skilled practitioner in accordance with standard pharmaceutical practice.
- In order to ensure consistency of administration, in an embodiment of the present disclosure, the pharmaceutical composition is in the form of a discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with a liquid carrier or solid carrier or both and then, if necessary, shaping the product into the desired formulation.
- The compounds and expanded cells according to the disclosure may be formulated for parenteral administration, e.g. by injection, for example bolus injection or continuous infusion, and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with/without an added preservative. The compositions are formulated in any conventional manner for use in the methods described herein. Administration is via any route known to be effective by one of ordinary skill. For example, the compositions is administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, intranasally or topically.
- The following examples are provided to further illustrate details for the preparation and use of the compounds of the present disclosure. They are not intended to be limitations on the scope of the instant disclosure in any way, and they should not be so construed. Furthermore, the compounds described in the following examples are not to be construed as forming the only genus that is considered as the disclosure, and any combination of the compounds or their moieties may itself form a genus.
-
- The compounds of the general formula V can be prepared by the condensation of compounds II, an ortho halo-pyridinecarbonitrile (V1 or V2 or W = N) or a 2-halobenzonitrile (V1, V2, W = C, R2 = H), with 2-mercaptoacetamide derivatives III or IV in the presence of a base in a solvent such as ethanol or DMF.
-
- The compounds of the general formula IX can be prepared by the condensation of compounds VI, an ortho halo-pyridinecarbonitrile (R2 = H, CH3 or linked to R1 via (CH2)3-5 linkers), with 2-hydroxyacetamide derivatives VII in the presence of a base in a solvent such as ethanol followed by the cyclization of intermediate VIII in the presence of a stronger base.
- Abbreviations or symbols used herein include: AcOH: acetic acid; dba: dibenzylidene acetone; DMF: N,N-dimethylformamide; DIPEA: diisopropylamine; DMSO: dimethylsulfoxide; dppf: 1,1′-bis(diphenylphosphino)ferrocene; EtOAc: ethyl acetate; EtOH: ethanol; MeOH: methanol; Hex: hexanes; MS: mass spectrometry; NMR: nuclear magnetic resonance; THF: tetrahydrofuran.
- Other features of the present invention will become apparent from the following non-limiting examples which illustrate, by way of examples, the principle of the invention. As it is well known to a person skilled in the art, reactions are performed in an inert atmosphere (nitrogen or argon) where necessary to protect reaction components from air and moisture. Temperature are given in degrees Celsius (°C). The reactants used in the examples below may be obtained either as described herein, or if not described herein, are themselves either commercially available (described as A0 in table) or may be prepared from commercially available materials by methods known in the art. Flash chromatography is carried out on silica (SiO2) using a Teledyne Isco Rf instrument. Mass spectra analyses are recorded using electrospray mass spectrometry. NMR are recorded on a 500 MHz Bruker or 400 MHz Varian instruments. Preparative HPLC is performed using an Agilent instrument with one the following conditions:
- Column: Phenomenex-Kinetex C18, 21×100 mm, 5 µm
- Mobile Phase: Solvent A: 5% MeOH, 95% Water + 0.1% Formic acid, Solvent B: 95% MeOH, 5% Water + 0.1% Formic acid
- Flow: 20 mL / min, room temperature.
- Collection wavelength = 220 and 254 nm
- Mobile Phase: From 0 to 3 min: isocratic 30% solvent B, followed by a 12 minutes gradient to 100% solvent B. Last 5
minutes 100% solvent B. - Mobile Phase: From 0 to 2 min: isocratic 30% solvent B, followed by an 8 minutes gradient to 100% solvent B. Last 2
minutes 100% solvent B. -
- EtOH (4.16 mL, 71.3 mmol) is added slowly to an ice-cold suspension of NaH (60% w/w; 2.85 g, 71.3 mmol) in ether (51 mL). Additional EtOH (8.5 ml) is added. A mixture of 1.1 (5.0 g, 59.4 mmol) and ethyl formate (5.02 mL, 62.4 mmol) is next added dropwise (55 min). Additional ether (10 mL) is added and the mixture is stirred at room temperature overnight. Ether (50 mL) is added and the mixture is filtered. The solid is washed with ether (25 mL) then dried under reduced pressure to give sodium salt 1.2;1H NMR (500 MHz, DMSO-d6) δ ppm 1.56 (quin, J=7.90 Hz, 2 H), 1.87 (t, J=7.72 Hz, 2 H), 2.24 (td, J=7.30, 0.95 Hz, 2 H), 8.50, 8.87 (2 s, 1 H).
- A solution of 2-cyanoacetamide (4.58 g, 54.4 mmol) in water (27.5 mL) is added to 1.2 (7.30 g, 54.4 mmol) followed by a solution of piperidin-1-ium acetate (1.38 g, 9.53 mmol) (prepared by adding piperidine (0.81 g; 0.94 mL) to AcOH (0.57 g; 0.54 mL) in water (1.4 mL)) in water (1.4 mL). The mixture is heated at reflux for 2 h and let warm to room temperature (overnight). The pH is adjusted to 5 by addition of AcOH. The resulting suspension is cooled in an ice-bath and is filtered. The solid is washed with water and dried in the air to give pyridone 1.3; m/z = 161.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.03 (quin, J=7.57 Hz, 2 H), 2.64 (t, J=7.41 Hz, 2 H), 2.80 (t, J=7.72 Hz, 2 H), 8.00 (s, 1 H), 12.62 (br. s., 1 H).
- Pyridone 1.3 (1.0 g, 6.24 mmol) is added to a suspension of PCl5 (0.390 g, 1.87 mmol) in POCl3 (1.75 mL, 18.7 mmol) at room temperature. The mixture is heated at reflux for 2.5 h. The cooled mixture is poured into a mixture of ice and water (75 mL). The mixture is basified by addition of solid Na2CO3 (pH 7-8). The mixture is extracted with EtOAc (2x). The combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-40% EtOAc:Hex) to afford 2-chloropyridine 1.4; MS: m/z = 179.3/181.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.11 (quin, J=7.65 Hz, 2 H), 2.93 (t, J=7.57 Hz, 2 H), 3.00 (t, J=7.72 Hz, 2 H), 8.26 (s, 1 H).
-
- DMF (10.30 µl, 0.133 mmol) is added to a suspension of acid 2.1 (0.6 g, 2.66 mmol), (COCl)2 (0.466 mL, 5.32 mmol) in CH2Cl2 (10.6 mL) at room temperature. The mixture is stirred at room temperature for 6 h then is concentrated under reduced pressure to give acyl chloride 2.2.
- A solution of acyl chloride 2.2 (649 mg, 2.66 mmol) in dioxane (1.5 mL) is added to an ice-cold NH4OH solution (1.60 mL, 23.9 mmol). The mixture is stirred at 0° C. for 45 min. The mixture is diluted with water (50 mL) and EtOAc is added (100 mL). The phases are separated. The organic layer is washed with water (2 x), brine (25 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to give amide 2.3; MS: m/z = 225.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.95 (br. s., 1 H), 8.17 (br. s., 1 H), 8.39 (dd, J=2.52, 0.63 Hz, 1 H), 8.91 (dd, J=2.52, 0.63 Hz, 1 H).
- (CF3CO)2O (0.308 mL, 2.18 mmol) is added quickly to an ice-cold solution/suspension of amide 2.3 (445 mg, 1.98 mmol) in CH2Cl2 (14 mL). The mixture is stirred at 0° C. for 2 h. Saturated NaHCO3 solution (15 mL) and CH2Cl2 are added and the mixture is stirred at room temperature for 5 min. The phases are separated. The organic layer is washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-20%EtOAc:Hex) to yield chloropyridine 2.4; 1H NMR (500 MHz, DMSO-d6) δ ppm 9.09 (dd, J=2.52, 0.63 Hz, 1 H), 9.16 (dd, J=2.52, 0.63 Hz, 1 H).
-
- (COCl)2 (1.28 mL, 14.6 mmol) is added to a suspension of acid 3.1 (1.00 g, 7.29 mmol) in CH2Cl2 (29 mL) at room temperature. The mixture is stirred at room temperature for 2 h. The reaction mixture is concentrated under reduced pressure to give acyl chloride 3.2. The compound is used directly in the next reaction.
- Cold NH4OH solution (4.86 mL, 72.9 mmol) is added quickly to an ice-cold suspension acyl chloride 3.2 (1.13 g, 7.29 mmol) in a mixture of dioxane (10 mL) and THF (10 mL). The mixture is stirred at 0° C. for 45 min. The crude mixture is diluted with water and extracted with EtOAc (3 x). The aqueous layer is saturated with solid NaCl and re-extracted with EtOAc (2 x). The combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give amide 3.3; MS: m/z = 137.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.34 (d, J=0.63 Hz, 3 H), 7.53 (br. s., 1 H), 7.98 - 8.04 (m, 1H), 8.08 (br. s., 1H), 8.54 (dd, J=2.21, 0.63 Hz, 1 H), 8.82 (d, J=1.58 Hz, 1 H).
- H2O2 (0.90 mL, 7.90 mmol) is added to a cold solution of amide 3.3 (538 mg, 3.95 mmol) in AcOH (4.9 mL). The mixture is stirred at room temperature for 30 min then is heated at 80° C. for 4 h. The mixture is cooled in an ice-bath and 20% Na2SO3 solution is added until there are no trace of peroxide left as determined with a KI-starch paper. 15 N NH4OH is next added to basify the mixture. The resulting suspension is warmed to room temperature and is filtered, washing the solid with water. The solid is dried in the air to yield 3.4; MS: m/z = 153.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.29 (d, J=0.63 Hz, 2 H), 7.54 - 7.62 (m, 1 H), 7.72 (br. s., 1H), 8.15 (br. s., 1 H), 8.24 - 8.29 (m, 1 H), 8.43 (s, 1 H).
- Pyridine 1-oxide 3.4 (306 mg, 2.01 mmol) is added to cold (about 5° C.) POCl3 (1.87 mL, 20.11 mmol). The resulting suspension is heated at 60° C. for 4 h and at 100° C. for 2.5 h. The cooled reaction mixture is poured into a mixture of ice and water (50 mL) and stirred vigorously. Solid Na2CO3 is added to obtain a pH of about 7. The mixture is extracted with EtOAc. The organic layer is washed with water and brine, then dried (Na2SO4) and concentrated under reduced pressure. The residue is purified by flash chromatography (10-30%EtOAc:Hex) to give first 6-chloro isomer 3.6 and, in second, 2-chloro isomer 3.5; 3.6: MS: m/z = 153.1 (MH+); 1H NMR (500 MHz, CDCl3) δ ppm 2.46 (d, J=0.63 Hz, 3 H), 7.82 (dq, J=2.21, 0.90 Hz, 1 H), 8.54 (dd, J=2.21, 0.63 Hz, 1 H); 3.5: MS: m/z = 153.3/155.2 (MH+); 1H NMR (500 MHz, CDCl3) □ ppm 2.40 (t, J=0.60 Hz, 3 H), 7.82 (dq, J=2.20, 0.60 Hz, 1 H), 8.43 (dq, J=2.52, 0.90 Hz, 1 H).
-
- A solution of 4.1 (1.0 g, 5.60 mmol; M. Graffner-Nordberg, J. Med. Chem. 2001, 44, 2391) in DMF (11.2 mL) is added over 10 min to a solution of isoamyl nitrite (1.13 mL, 8.40 mmol) in DMF (4.7 mL) maintained at 70° C. After 1.5 h, the temperature is raised to 85° C. and maintained for 18 h. An additional amount of isoamyl nitrite (3.5 mL, 25.99 mmol) is added and the mixture is stirred at 85° C. for 4 h. The mixture is cooled to room temperature and is poured into water (200 mL). The mixture is extracted with EtOAc (3x). The combined organic layers are washed with water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (0-50%EtOAc:Hex) to give 4.2; 1H NMR (500 MHz, CDCl3) δ ppm 8.28 (d, J=2.21 Hz, 1 H), 8.87 (d, J=2.21 Hz, 1 H).
-
- (COCl)2 (0.49 mL, 5.61 mmol) and DMF (8.7 µl, 0.112 mmol) are added to a suspension of 5.1 (506 mg, 2.24 mmol; Schlosser et al.
Tetrahedron 2004, 60, 11869) in CH2Cl2 (11.2 mL) at room temperature. The mixture is stirred at room temperature for 3.5 h then is concentrated under reduced pressure to give 5.2; 1H NMR (500 MHz, CDCl3) δ ppm 8.15 (s, 1H), 8.90 (s, 1 H). - A solution of 5.2 (547 mg, 2.24 mmol) in dioxane (1.5 mL) is added dropwise to an ice-cold solution of NH4OH (15 M) (1.49 mL, 22.43 mmol) in dioxane (1.0 mL). The mixture is stirred at 0° C. for 1 h. The reaction mixture is poured into water (125 mL) and the mixture is extracted with EtOAc (2x). The combined organic layers are washed with water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure to give 5.3; MS: m/z: no molecular peak observed; 1H NMR (500 MHz, CDCl3) δ ppm 6.11 (br. s., 1 H), 6.42 (br. s., 1H), 8.09 (s, 1 H), 8.80 (s, 1 H).
- (CF3CO)2O (0.33 mL, 2.34 mmol) is added dropwise to an ice cold suspension/solution of 5.3 (405 mg, 1.80 mmol) in Et3N (0.654 mL, 4.69 mmol) and CH2Cl2 (12 mL). The reaction mixture is stirred at 0° C. for 1.75 h. Saturated NaHCO3 solution (5 mL) is added and the mixture is stirred vigorously for 5 min. The mixture is diluted with CH2Cl2 (60 mL) and saturated NaHCO3 solution (20 mL). The phases are separated. The organic layer is washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (0-50%EtOAc:Hex) to give 5.4; MS: m/z = no molecular peak observed; 1H NMR (500 MHz, CDCl3) δ ppm 7.94 (s, 1 H), 8.93 (s, 1 H).
-
- (COCl)2 (1.91 mL, 21.8 mmol) and DMF (0.012 mL, 0.156 mmol) are added to solution of 6.1 (1.35 g, 3.11 mmol; Schlosser et al.
Tetrahedron 2004, 60, 11869) in CH2Cl2 (18 mL) at room temperature. The mixture is stirred at room temperature for 3 h then is concentrated under reduced pressure. The residue is kept on the high vacuum pump until stable weight to give 6.2; (500 MHz, CDCl3) δ ppm 7.85 (d, J=8.2 Hz, 1 H), 8.08 (dq, J=8.2, 0.06 Hz, 1 H). - A solution of 6.2 (759 mg, 3.11 mmol) in dioxane (3.1 mL) is added dropwise to an ice-cold solution of NH4OH (15 M) (2.1 mL, 31.1 mmol). The mixture is stirred at 0° C. for 1 h. The mixture is poured into water (125 mL) and extracted with EtOAc (2x). The combined organic layers are washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-50%EtOAc:Hex) to give 6.3; MS: m/z = 225.1/227.3 (MH+); 1H NMR (500 MHz, CDCl3) δ ppm 5.68 (br. s., 1 H), 7.55 (br. s., 1 H), 7.77 (d, J=8.51 Hz, 1 H), 8.05 (dd, J=8.51, 0.63 Hz, 1 H).
- (CF3CO)2O (0.23 mL, 1.63 mmol) is added dropwise to an ice-cold solution/suspension of 6.3 (281 mg, 1.251 mmol) and Et3N (0.45 mL, 3.25 mmol) in CH2Cl2 (8.3 mL). The mixture is stirred at 0° C. for 2 h. Saturated NaHCO3 solution and CH2Cl2 are added and the mixture is stirred at room temperature for 5 min. The phases are separated. The organic layer is washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-20%EtOAc:Hex) to give 6.4; 1H NMR (400 MHz, CDCl3) δ ppm 7.87 (d, J=8.61 Hz, 1 H), 8.10 (d, J=8.61 Hz, 1 H).
-
- A mixture of 7.1 (302 mg, 1.57 mmol; V.J. Colandrea, WO2005/058848), SOCl2 (6.9 mL, 94 mmol) and DMF (0.68 mL, 8.79 mmol) is heated at reflux overnight (14 h). The cooled mixture is concentrated under reduced pressure. The residue is taken in EtOAc (70 mL) and the solution is washed with a 1:1 mixture of saturated NaHCO3 solution and brine (3x), then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (0-20%EtOAc:Hex) to give 7.2; 1H NMR (400 MHz, CDCl3) δ ppm 1.44 (t, J=7.04 Hz, 3 H), 4.47 (q, J=7.04 Hz, 2 H), 8.58 (d, J=2.35 Hz, 1 H), 9.16 (d, J=2.35 Hz, 1 H).
-
- A mixture of 8.1 (1.70 g, 10.51 mmol), Zn(CN)2 (0.74 g, 6.30 mmol) and Zn (0.031 g, 0.47 mmol) in DMF (10.5 mL) is degassed (B. Van Wagenen, US2003/55085). PdCl2(dppf)-CH2Cl2 adduct (0.189 g, 0.231 mmol) is added and the solution is again degassed then is heated at 125° C. for 5 h. The crude mixture is diluted with EtOAc (150 mL) and the mixture is filtered through diatomaceous earth (washing the cake with EtOAc (25 mL)). The filtrate is washed twice with a mixture of water and saturated NaHCO3 solution (3/1) and with brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-100%EtOAc:Hex) to give 8.2; MS: m/z = 153.1/155.1 (MH+); 1H NMR (400 MHz, CDCl3) δ ppm 2.60 (s, 3 H), 7.34 (d, J=8.22 Hz, 1 H), 7.73 (d, J=8.61 Hz, 1 H).
-
- A mixture of 2-mercaptoacetic acid 9.1 (0.679 mL, 9.77 mmol) and 4-fluoroaniline 9.2 (0.926 mL, 9.77 mmol) is heated at 130° C. for 5 h. The cooled mixture is taken in EtOAc and the solution is washed with 0.5N HCl solution, water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (15-40%EtOAc:Hex) to give thiol 9.3; MS: m/z = 186.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.95 (t, J=5.90 Hz, 1 H), 3.28 (d, J=5.87 Hz, 2 H), 7.15 (t, J=9.00 Hz, 2 H), 7.59 (dd, J=9.39, 5.48 Hz, 2 H), 10.13 (s, 1 H).
-
- DMF (0.042 mL, 0.54 mmol) is added to an ice-cold solution of acid 10.1 (1.45 g, 10.81 mmol) and (COCl)2 (1.892 mL, 21.62 mmol) in CH2Cl2 (21.6 mL). The mixture is stirred overnight (16 h) at room temperature. The reaction mixture is concentrated under reduced pressure to give intermediate 10.2; 1H NMR (500 MHz, CDCl3) δ ppm 2.44 (s, 3 H), 4.18 (s, 2 H).
- DIPEA (0.717 mL, 4.10 mmol) is added dropwise to an ice-cold solution of 10.2 (569 mg, 3.73 mmol) and 10.3 (369 mg, 3.92 mmol) in CH2Cl2 (19 mL). The mixture is stirred at 0° C. for 1 h and at room temperature for 1 h. The mixture is diluted with CH2Cl2 and the solution is washed with water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (20-50%EtOAc:Hex) to give intermediate 10.4; MS: m/z = 211.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.37 (s, 3H), 3.90 (s, 2H), 7.11 (dd, J=7.43, 5.09 Hz, 1 H), 7.78 (ddd, J=8.20, 7.40, 1.96 Hz, 1 H), 8.00 (d, J=8.22 Hz, 1 H), 8.32 (ddd, J=4.70, 2.00, 1.00 Hz, 1 H), 10.71 (s, 1 H).
-
- A solution of 10.2 (0.848 g, 5.56 mmol) in CH2Cl2 (2.8 mL) is added dropwise to an ice-cold suspension of 11.1 (0.381 g, 2.78 mmol) in CH2Cl2 (8.4 mL) and pyridine (0.450 mL, 5.56 mmol). The mixture is stirred at 0° C. for 1.5 h. Water (5 mL) is added and the mixture is diluted with CH2Cl2. The mixture is washed with 1 N HCl solution, water, saturated NaHCO3 solution, brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (20-50%EtOAc:Hex) to afford 11.2; 1H NMR (500 MHz, CDCl3) δ ppm 2.39 (s, 3 H), 2.46 (s, 3 H), 2.92 (t, J=7.09 Hz, 2 H), 3.66 (s, 2 H), 3.68 (s, 2 H), 4.32 (t, J=6.94 Hz, 2 H), 7.18 (d, J=8.51 Hz, 2 H), 7.44 (d, J=8.51 Hz, 2 H), 8.08 (br. s., 1 H).
- K2CO3 (400 mg, 2.89 mmol) is added to a degassed solution of 11.2 (356 mg, 0.964 mmol) in MeOH (9.6 mL) at room temperature. The mixture is stirred at room temperature overnight (20 h). The mixture is concentrated under reduced pressure. Water (10 mL) is added and the mixture is acidified with 1N HCl solution (pH < 2). The mixture is extracted with EtOAc (2x). The combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (40-100%EtOAc:Hex) to give 11.3; MS: m/z 212.1 (MH+); 1H NMR (500 MHz, CDCl3) δ ppm 1.39 (br. s., 1 H), 2.03 (t, J=9.30 Hz, 1 H), 2.86 (t, J=6.46 Hz, 2 H), 3.41 (d, J=9.14 Hz, 2 H), 3.82 - 3.90 (m, 2 H), 7.23 (d, J=8.20 Hz, 2 H), 7.50 (d, J=8.51 Hz, 2 H), 8.46 (br. s., 1 H).
-
- A mixture of chloropyridine 1.4 (30 mg, 0.168 mmol), thiol 9.3 (34.2 mg, 0.185 mmol) and K2CO3 (58.0 mg, 0.420 mmol) in EtOH (1.7 mL) is heated at reflux for 4.5 h. The cooled mixture is diluted with EtOAc and the resulting solution is washed with water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is recrystallized in a mixture of MeOH and CHCl3 to give compound 1002; MS: m/z = 328.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.53 Hz, 2 H), 3.00 (t, J=7.43 Hz, 2 H), 3.02 (t, J=7.60 Hz, 2 H), 7.15 (t, J=9.00 Hz, 2 H), 7.29 (br. s, 2 H), 7.69 (dd, J=9.00, 5.09 Hz, 2 H), 8.28 (s, 1 H), 9.42 (s, 1 H).
-
- A mixture of chloropyridine 13.1 (50 mg, 0.23 mmol), thiol 13.2 (42 mg, 0.25 mmol) and K2CO3 (79.5 mg, 0.575 mmol) in EtOH (2.3 mL) is heated at reflux for 5 h. The cooled mixture is diluted with water (15 mL). The resulting suspension is stirred for 15 min then is filtered and the solid is washed with a few drops of MeOH and hexanes to yield compound 1003; MS: m/z = 347.9/349.7 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.09 (t, J=7.41 Hz, 1 H), 7.33 (t, J=7.88 Hz, 2 H), 7.37 (s, 1 H), 7.69 (d, J=7.57 Hz, 1 H), 8.78 (d, J=2.21 Hz, 1 H), 8.84 (d, J=2.21 Hz, 1 H), 9.54 (s, 1 H).
-
- A suspension of 3.5 (40 mg, 0.262 mmol), thiol 13.2 (48.2 mg, 0.288 mmol) and K2CO3 (91 mg, 0.655 mmol) in EtOH (2.6 mL) is heated at reflux for 5.5 h. The cooled mixture is diluted with EtOAc and is washed with water and brine (15 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (30-50% EtOAc:Hex) to give compound 1009; MS: m/z = 284.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.07 (tt, J=7.37, 1.14 Hz, 1 H), 7.24 - 7.37 (m, 4 H), 7.69 (dd, J=8.67, 1.10 Hz, 2 H), 8.32 (dd, J=2.05, 0.79 Hz, 1 H), 8.54 (dd, J=2.21, 0.63 Hz, 1 H), 9.40 (s, 1 H).
-
- A mixture of 5.4 (30 mg, 0.145 mmol), thiol 15.1 (41.1 mg, 0.167 mmol) and K2CO3 (50.2 mg, 0.363 mmol) in EtOH (1.4 mL) is stirred at room temperature for 10 min then heated at reflux for 3 h. The cooled mixture is diluted with EtOAc (60 mL) and the solution is washed with water and brine, then is dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-50%EtOAc:Hex) then further purified by preparative HPLC (method A) to give compound 1049; MS: m/z = 415.9/417.9 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.48 (br. s., 2 H), 7.53 (d, J=8.61 Hz, 2 H), 7.70 (d, J=8.61 Hz, 2 H), 8.73 (s, 1 H), 9.39 (s, 1 H), 9.92 (s, 1 H).
-
- A mixture of 16.1 (22 mg, 0.163 mmol), thiol 13.2 (28.6 mg, 0.171 mmol) and K2CO3 (56.2 mg, 0.407 mmol) in DMF (0.65 mL) is stirred at room temperature for 7 h. The mixture is diluted with EtOAc (50 mL) and the solution is washed with water and brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-20%EtOAc:Hex) to give compound 1118; MS: m/z = 283.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.44 (s, 3 H), 7.06 (tt, J=7.40, 1.17 Hz, 1 H), 7.19 (s, 2 H), 7.31 (dd, J=8.61, 7.43 Hz, 1 H), 7.35 (dd, J=8.22, 1.17 Hz, 1 H), 7.69 (dd, J=8.80, 0.98 Hz, 2 H), 7.76 (d, J=8.22 Hz, 1 H), 7.91 (s, 1 H), 9.29 (s, 1 H).
-
- PdCl2(dppf)-CH2Cl2 adduct (4.91 mg, 6.01 µmol) is added to a degassed (vacuum to argon 3x) partial solution of compound 1037 (50 mg, 0.120 mmol), boronic acid 17.1 (44.3 mg, 0.360 mmol) and K2CO3 (49.8 mg, 0.360 mmol) in dioxane (1.15 mL) and water (0.287 mL) at room temperature. The mixture is degassed again and heated at 85° C. for 21 h. The cooled mixture is taken in EtOAc (150 mL) and water (30 mL) is added. The separated aqueous layer is extracted with CH2Cl2 (3 x). The combined organic layers are washed with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The solid is recrystallized in a 1:1 mixture of CHCl3 and MeOH to give compound 1055; MS: m/z = 415.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.39 - 7.47 (m, 2 H), 7.50 (dd, J=8.02, 5.28 Hz, 1 H), 7.57 (s, 2 H), 7.78 (dt, J=7.04, 2.15 Hz, 1 H), 7.99 - 8.12 (m, 2 H), 8.58 (dd, J=4.70, 1.57 Hz, 1 H), 8.87 (d, J=1.96 Hz, 1 H), 9.04 (d, J=5.87 Hz, 1 H), 9.72 (s, 1 H).
-
- To a mixture of compound 1012 (50 mg, 0.143 mmol), Pd(Ph3P)4 (16.5 mg, 0.014 mmol) and Cul (2.73 mg, 0.014 mmol) in THF (0.72 mL) and DMF (0.72 mL) are added sequentially DIPEA (0.41 mL, 2.86 mmol) and ethynyltrimethylsilane (101 µL, 0.716 mmol). The mixture is flushed with N2 and heated at 110° C. for 2.5 h. The cooled mixture is diluted with water (15 mL) and extracted with EtOAc (3 x). The aqueous layer is filtered and extracted with EtOAc. The combined organic layers are dried (Na2SO4), filtered and concentrated. The residue is purified by flash chromatography (0-100%EtOAc:Hex) to give 18.1; MS: m/z = 367.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 0.22 - 0.32 (m, 9 H), 7.55 (s, 2 H), 7.77 (br. s., 2H), 8.71 - 8.77 (m, 2H), 9.84 (s, 1 H).
- To a solution of 18.1 (50 mg, 0.136 mmol) in MeOH (2 mL) is added K2CO3 (37.7 mg, 0.273 mmol). The mixture is stirred at room temperature for 1 h then is concentrated under reduced pressure. The residue dissolved in 10% MeOH in CH2Cl2 (50 mL) is diluted with water. The resulting suspension is filtered and the solid dried in the air to give compound 1020; MS: m/z = 295.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 4.50 (s, 1 H), 7.57 (s, 2 H), 7.76 (br. s., 1 H), 8.44 (br. s., 1H), 8.69 - 8.80 (m, 1 H), 9.84 (br. s., 1 H).
-
- A suspension of 1020 (20 mg, 0.068 mmol) and Pd-
C 10% Degussa Type, 50% wet (7.2 mg) in MeOH (5 mL) is stirred under a hydrogen atmosphere for 45 min. The mixture is filtered through a 0.45 µm filter unit, washed with MeOH (1 mL) and concentrated to afford compound 1021; MS: m/z = 299.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 1.28 (t, J=7.57 Hz, 3 H), 2.76 (q, J=7.57 Hz, 2 H), 7.52 (s, 2 H), 7.75 - 7.77 (m, 2 H), 8.41 - 8.44 (m, 3H), 8.59 (d, J=1.89 Hz, 1 H), 9.74 (s, 1 H). -
- A mixture of 1003 (25.7 mg, 0.074 mmol), prop-1-en-2-ylboronic acid (7.8 µL, 0.081 mmol) and K3PO4 (47.0 mg, 0.221 mmol) in DME-Water (2:1, 3 mL) is purged with a stream of N2 for 5 min in a sealable vial. To this mixture is added Pd(Ph3P)4 (8.53 mg, 7.38 µmol), the vial is sealed and the mixture is heated at 90° C. under microwave radiations for 4 h. The cooled mixture is diluted with EtOAc and water. The aqueous phase is extracted with EtOAc (3x) and the combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by preparative HPLC (method B) to afford 1090; MS: m/z = 310.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.22 (s, 3 H), 5.27 (s, 1 H), 5.65 (s, 1 H), 7.03 - 7.12 (m, 1 H), 7.33 (t, J=7.83 Hz, 2 H), 7.42 (s, 1 H), 7.70 (d, J=7.43 Hz, 2 H), 8.66 (d, J=2.35 Hz, 1 H), 8.87 (d, J=2.35 Hz, 1 H), 9.44 (s, 1 H).
-
- A suspension of compound 1090 (57.3 mg, 0.185 mmol) and Pd-
C 10% Degussa Type, 50% wet (20 mg) in MeOH (25 mL) is stirred under a hydrogen atmosphere for 18 h. The mixture is filtered on a pad of diatomaceous earth, washed with MeOH and concentrated under reduced pressure. The residue is purified by preparative HPLC (method B) to afford compound 1103; MS: m/z = 312.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.31 (d, J=6.65 Hz, 6 H), 3.09 (dt, J=13.89, 6.75 Hz, 1 H), 7.03 - 7.11 (m, 1 H), 7.28 - 7.40 (m, 4 H), 7.70 (d, J=7.83 Hz, 2 H), 8.44 (d, J=1.96 Hz, 1 H), 8.60 (d, J=1.96 Hz, 1 H), 9.40 (s, 1 H). -
- A suspension of compound 1003 (56.9 mg, 0.163 mmol), allyltributylstannane (60.2 µL, 0.196 mmol) and K2CO3 (45.2 mg, 0.327 mmol) in toluene/water (5/1) (3.3 mL) is purged with a stream of N2 for 10 min in a sealable vial. To this mixture is added Pd(Ph3)4 (4.72 mg, 4.09 µmol) and the vial is sealed and the mixture is heated at 105° C. for 23 h. The mixture is diluted with EtOAc and water, extracted twice with EtOAc. The combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. Since the reaction is not complete, the residue is resubmitted to the same reaction conditions (15 h heating). The crude material is purified by preparative HPLC (method B) then is filtered through a pad of silica gel (Hex/EtOAc (50/50) with 3% Et3N). The filtrate is concentrated under reduced pressure to give compound 1111; MS: m/z = 310.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.53 (d, J=6.65 Hz, 2 H), 5.10 - 5.19 (m, 2 H), 5.97 - 6.11 (m, 1 H), 7.04 - 7.11 (m, 1H), 7.35 (d, J=6.65 Hz, 2 H), 7.31 (d, J=8.22 Hz, 2 H), 7.65 - 7.73 (m, 2 H), 8.34 (d, J=1.96 Hz, 1 H), 8.54 (d, J=1.96 Hz, 1 H), 9.42 (s, 1 H).
-
- A suspension of compound 1003 (29.8 mg, 0.086 mmol), triethylborane (34.2 µl, 0.034 mmol), K3PO4 (36.3 mg, 0.171 mmol) and di((3S,5S,7S)-adamantan-1-yl)(butyl)phosphine (1.53 mg, 4.28 µmol) in toluene/water (10/1) (1.57 mL) is purged with a stream of N2 for 5 min in a sealable vial. To this mixture is added Pd2(dba)3 (0.980 mg, 1.070 µmol) and the vial is sealed and the mixture is heated at 105° C. for 17 h. The cooled mixture is diluted with EtOAc and water and extracted twice with EtOAc. The combined organic layers are washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by preparative HPLC (method B) to get compound 1112; MS: m/z = 298.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.28 (t, J=7.43 Hz, 3 H), 2.76 (q, J=7.70 Hz, 2 H), 7.07 (t, J=7.24 Hz, 1 H), 7.29 - 7.36 (m, 4 H), 7.69 (d, J=8.22 Hz, 2 H), 8.38 (s, 1 H), 8.57 (s, 1 H), 9.40 (s, 1 H).
-
- A suspension of compound 1111 (30 mg, 0.097 mmol) and Pd-
C 10% Degussa Type, 50% wet (10.3 mg) in MeOH (6 mL) is stirred under a hydrogen atmosphere for 18 h. The mixture is filtered (0.45 µm filter unit) and concentrated under reduced pressure. The residue is purified by preparative HPLC (method B) to give compound 1134; MS: m/z = 312.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 0.94 (t, J=7.43 Hz, 3 H), 1.69 (dq, J=15.06, 7.24 Hz, 2 H), 2.67 - 2.74 (m, 2 H), 7.05 - 7.10 (m, 1 H), 7.28 - 7.37 (m, 4 H), 7.67 -7.73(m, 2 H) 8.36 (d, J=1.96 Hz, 1 H), 8.54 (d, J=1.96 Hz, 1 H), 9.40 (s, 1 H). -
- A mixture of 1.4 (75 mg, 0.420 mmol), 25.1 (66.6 mg, 0.441 mmol; J.M. Hung et al., Eur. J. Med. Chem. 2014, 86, 420) and Na2CO3 (46.7 mg, 0.441 mmol) in EtOH (1.7 mL) is heated at reflux for 18 h. The cooled mixture is partitioned between EtOAc and water. The organic layer is washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (10-30% EtOAc:Hex) to give 25.2; MS: m/z = 294.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.06 (quin, J=7.65 Hz, 2 H), 2.85 (td, J=7.49, 3.63 Hz, 4 H), 5.06 (s, 2 H), 7.06 (t, J=7.41 Hz, 1 H), 7.31 (t, J=8.20 Hz, 2 H), 7.56 (dd, J=8.67, 1.10 Hz, 2 H), 8.09 (s, 1 H), 10.16 (s, 1 H).
- t-BuOK (45.4 mg, 0.405 mmol) is added to a solution of 25.2 (95 mg, 0.324 mmol) in THF (3.2 mL) at room temperature. The mixture is heated at reflux for 2 h. The mixture is taken in CH2Cl2 and the solution is washed with water and brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (2-15% EtOAc:CH2Cl2) to yield compound 1153; MS: m/z = 294.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.57 Hz, 2 H), 2.98 (t, J=7.25 Hz, 2 H), 2.99 (t, J=7.57 Hz, 2 H), 6.33 (s, 2 H), 7.04 (tt, J=7.57, 0.95 Hz, 1 H), 7.30 (dd, J=8.51, 7.57 Hz, 2 H), 7.82 (dd, J=7.57, 1.26 Hz, 2 H), 8.12 (s, 1 H), 9.84 (s, 1 H).
-
Compound 1001; MS: m/z = 310.3; 1H NMR (500 MHz, DMSO-d6) □ ppm 2.14 (quin, J=7.49 Hz, 2 H), 2.90 - 3.06 (m, 4 H), 7.06 (tt, J=7.57, 0.95 Hz, 1 H), 7.29 (s, 1 H), 7.31 (dd, J=8.51, 7.57 Hz, 2 H), 7.69 (dd, J=8.51, 1.30 Hz, 2 H), 8.28 (s, 1 H), 9.35 (s, 1 H). - Compound 1002; Described in example 12
- Compound 1003; MS: Described in example 13
- Compound 1004; MS: m/z = 304.1/306.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.09 (tt, J=7.25, 1.26 Hz, 1 H), 7.33 (dd, J=8.51, 7.57 Hz, 1 H), 7.37 (s, 2 H), 7.69 (dd, J=8.83, 1.26 Hz, 1 H), 8.65 - 8.76 (m, 1 H), 9.54 (s, 1 H).
- Compound 1005; MS: m/z = 298.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.36 (s, 3 H) 2.55 (s, 3 H) 7.06 (tt, J=7.33, 1.18 Hz, 1 H) 7.27 (s, 2 H) 7.31 (dd, J=8.51, 7.57 Hz, 2 H) 7.68 (dd, J=8.83, 1.26 Hz, 2 H) 8.22 (s, 1 H) 9.34 (s, 1 H)
- Compound 1006; MS: m/z = 311.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.49 Hz, 2 H), 3.00 (t, J=7.25 Hz, 2 H), 3.02 (t, J=7.25 Hz, 2 H), 7.35 (dd, J=8.51, 4.73 Hz, 1 H), 7.37 (s, 2 H), 8.09 (ddd, J=8.35, 2.52, 1.42 Hz, 1 H), 8.27 (dd, J=4.73, 1.58 Hz, 1 H), 8.30 (s, 1 H), 8.87 (d, J=2.52 Hz, 1 H), 9.57 (s, 1 H).
- Compound 1007; MS: m/z = 311.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.53 Hz, 2 H), 3.00 (t, J=7.00 Hz, 2 H), 3.01 (t, J=6.90 Hz, 2 H), 7.12 (dd, J=7.04, 5.09 Hz, 1 H), 7.36 (s, 2 H), 7.80 (ddd, J=8.00, 6.70, 1.56 Hz, 1 H), 8.05 (d, J=8.61 Hz, 1 H), 8.31 (s, 1H), 8.35 (d, J=3.91 Hz, 1 H), 9.49 (s, 1 H).
- Compound 1008; MS: m/z = 338.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.10 (tt, J=7.41, 1.26 Hz, 1 H), 7.34 (dd, J=8.51, 7.25 Hz, 2 H), 7.52 (s, 2 H), 7.70 (dd, J=8.67, 1.10 Hz, 2 H), 8.97 - 9.10 (m, 2 H), 9.61 (s, 1 H).
- Compound 1009; Described in example 14
- Compound 1010; MS: m/z = 288.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.09 (tt, J=7.41, 0.90 Hz, 1 H), 7.33 (s, 2 H), 7.33 (t, J=7.88 Hz, 2 H), 7.69 (dd, J=8.67, 1.10 Hz, 2 H), 8.46 (dd, J=9.62, 2.68 Hz, 1 H), 8.74 (dd, J=2.84, 0.95 Hz, 1 H), 9.51 (s, 1 H).
- Compound 1011; MS: m/z = 305.2/307.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.54 (s, 2 H), 7.75 (d, J=6.31 Hz, 1 H), 8.44 (d, J=6.31 Hz, 1 H), 8.74 (d, J=2.21 Hz, 1 H), 8.75 (d, J=2.52 Hz, 1 H) 9.86 (s, 1 H).
- Compound 1012; MS: m/z = 349.1/351.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.54 (s, 2 H), 7.75 (d, J=6.31 Hz, 2 H), 8.43 (d, J=6.31 Hz, 2 H), 8.80 (d, J=2.21 Hz, 1 H), 8.88 (d, J=2.21 Hz, 1 H), 9.86 (s, 1 H).
- Compound 1013; MS: m/z = 339.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.69 (s, 2 H), 7.76 (d, J=6.31 Hz, 2 H), 8.45 (d, J=6.31 Hz, 2 H), 9.06 (dd, J=2.21, 0.63 Hz, 1 H), 9.09 (dd, J=2.21, 0.63 Hz, 1 H), 9.93 (s, 1 H).
- Compound 1014; MS: m/z = 311.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.57 Hz, 2 H), 3.00 (t, J=6.90 Hz, 2 H), 3.02 (t, J=7.60 Hz, 2 H), 7.47 (s, 2 H), 7.75 (d, J=6.31 Hz, 2 H), 8.32 (s, 1 H), 8.41 (d, J=6.31 Hz, 2 H), 9.69 (s, 1 H).
- Compound 1015; MS: m/z = 339.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.38 (dd, J=8.04, 4.89 Hz, 1 H), 7.60 (br. s., 2 H), 8.09 (d, J=8.20 Hz, 1 H), 8.30 (d, J=4.10 Hz, 1 H), 8.89 (br. s., 1 H), 9.05 (s, 1 H), 9.07 (s, 1 H), 9.82 (s, 1 H).
- Compound 1016; MS: m/z = 295.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.10 (tt, J=7.60, 0.90 Hz, 1 H), 7.34 (dd, J=8.51, 7.25 Hz, 2 H), 7.47 (s, 2 H), 7.69 (dd, J=8.51, 1.26 Hz, 2 H), 8.99 - 9.08 (m, 2 H), 9.63 (s, 1 H).
- Compound 1017; MS: m/z = 382.1 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 2.70 (t, J=7.09 Hz, 2 H), 3.59 (td, J=7.17, 5.20 Hz, 2 H), 4.62 (t, J=5.20 Hz, 1 H), 7.17 (d, J=8.51 Hz, 2 H), 7.50 (s, 2 H), 7.58 (d, J=8.51 Hz, 2 H), 9.04 (d, J=0.95 Hz, 2 H), 9.55 (s, 1 H).
- Compound 1018; MS: m/z = 382.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 3.28 (s, 3 H), 4.37 (s, 2 H), 7.28 (d, J=8.83 Hz, 2 H), 7.53 (s, 2 H), 7.68 (d, J=8.51 Hz, 2 H), 8.94 -9.08 (m, 2 H), 9.63 (s, 1 H).
- Compound 1019; MS: m/z = 368.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 4.47 (d, J=5.67 Hz, 2 H), 5.11 (t, J=5.83 Hz, 1 H), 7.28 (d, J=8.51 Hz, 2 H), 7.51 (s, 2 H), 7.64 (d, J=8.51 Hz, 2 H), 8.97 - 9.08 (m, 2 H), 9.58 (s, 1 H).
- Compound 1020 ; Described in example 18
- Compound 1021; Described in example 19
- Compound 1022 MS: m/z = 339.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.15 (td, J=5.99, 0.95 Hz, 1 H) 7.59 (s, 2 H) 7.78 - 7.87 (m, 1 H) 8.06 (d, J=8.20 Hz, 1 H) 8.38 (dd, J=4.89, 1.10 Hz, 1 H) 9.00 - 9.10 (m, 2 H) 9.97 (s, 1 H).
- Compound 1023 MS: m/z = 359.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.25 (d, J=1.17 Hz, 3 H) 6.87 (s, 1 H) 7.21 (br. s., 2 H) 8.72 (s, 1 H) 8.83 (d, J=1.57 Hz, 1 H).
- Compound 1024 MS: m/z = 366.3 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 1.19 (t, J=7.57 Hz, 3 H) 2.59 (q, J=7.57 Hz, 2 H) 7.18 (m, J=8.83 Hz, 2 H) 7.50 (s, 2 H) 7.56 - 7.63 (m, 2 H) 9.04 (s, 2 H) 9.55 (s, 1 H).
- Compound 1025; MS: m/z = 338.2 (MH+); 1H NMR (500 MHz, DMSO-d6) δ ppm 7.11 (tt, J=7.30, 1.30 Hz, 1 H), 7.35 (dd, J=8.51, 7.25 Hz, 2 H), 7.43 (s, 2 H), 7.69 (dd, J=8.67, 1.10 Hz, 2 H), 8.72 (br. d, J=0.60 Hz, 1 H), 9.39 (s, 1 H), 9.80 (s, 1 H).
- Compound 1026; MS: m/z = 339.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.60 (s, 2 H), 7.76 (d, J=6.26 Hz, 2 H), 8.46 (d, J=6.26 Hz, 2 H), 8.76 (s, 1 H), 9.41 (s, 1 H), 10.13 (br. s., 1 H).
- Compound 1027; MS: m/z = 338 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.97 (s, 2 H), 7.11 (tt, J=7.40, 1.20 Hz, 1 H), 7.35 (dd, J=8.22, 7.43 Hz, 2 H), 7.70 (dd, J=8.41, 0.98 Hz, 2 H), 8.01 (d, J=8.61 Hz, 1 H), 8.78 (d, J=8.61 Hz, 1 H), 9.73 (s, 1 H).
- Compound 1028; MS: m/z = 339.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.14 (s, 2 H), 7.77 (d, J=6.26 Hz, 1 H), 8.03 (d, J=8.22 Hz, 1 H), 8.46 (d, J=6.26 Hz, 1 H), 8.80 (d, J=8.22 Hz, 1 H), 10.07 (br. s., 1 H).
- Compound 1029; MS: 394.9 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.59 (s, 2 H) 7.80 (dd, J=8.80, 2.15 Hz, 1 H) 8.05 (d, J=8.61 Hz, 1 H) 8.56 (d, J=1.96 Hz, 1 H) 9.06 (d, J=3.13 Hz, 2 H) 9.30 (s, 1 H) 9.89 (s, 1 H).
- Compound 1030; MS: 414.0 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.28 - 7.36 (m, 1 H) 7.39 - 7.48 (m, 2 H) 7.55 (br. s., 2 H) 7.61 - 7.70 (m, 4 H) 7.77 - 7.85 (m, 2 H) 8.99 - 9.09 (m, 2 H) 9.70 (s, 1 H).
- Compound 1031; MS: 444.0 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 5.10 (s, 2 H) 6.75 (dt, J=8.22, 1.17 Hz, 1 H) 7.19 - 7.28 (m, 1 H) 7.29 - 7.37 (m, 2 H) 7.37 - 7.44 (m, 2 H) 7.44 - 7.51 (m, 3 H) 7.54 (s, 2 H) 9.05 (d, J=3.52 Hz, 2 H) 9.58 (s, 1 H).
- Compound 1032; MS: 424.0 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.19 (t, J=7.04 Hz, 2 H) 3.63 (s, 2 H) 4.08 (q, J=7.04 Hz, 2 H) 7.22 (m, J=8.61 Hz, 2 H) 7.52 (s, 2 H) 7.60 - 7.68 (m, 2 H) 9.04 (s, 2 H) 9.61 (s, 1 H).
- Compound 1033; MS: 444.0 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.76 (s, 3 H) 7.10 (d, J=8.61 Hz, 1 H) 7.31 - 7.36 (m, 1 H) 7.40 - 7.45 (m, 2 H) 7.50 (dd, J=8.41, 1.37 Hz, 4 H) 7.64 - 7.70 (m, 2 H) 9.03 (s, 2 H) 9.57 (s, 1 H).
- Compound 1034; MS: m/z = 337.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.08 (tt, J=7.40, 1.20 Hz, 1 H), 7.33 (t, J=7.83 Hz, 2 H), 7.42 (s, 2 H), 7.69 (dd, J=8.61, 1.17 Hz, 2 H), 7.79 (dd, J=8.61, 1.57 Hz, 1 H), 8.15 (d, J=8.61 Hz, 1 H), 8.62 (s, 1 H), 9.52 (s, 1 H).
- Compound 1035; MS: m/z = 338.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.61 (s, 2 H), 7.78 (d, J=6.65 Hz, 2 H), 7.82 (dd, J=8.61, 1.57 Hz, 1 H), 8.17 (d, J=8.61 Hz, 1 H), 8.45 (d, J=5.09 Hz, 2 H), 8.67 (s, 1 H), 9.91 (br. s., 1 H).
- Compound 1036; MS: m/z = 415.9/417.9 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.26 - 7.34 (m, 2 H) 7.60 (s, 2 H) 7.70 (dt, J=7.43, 1.96 Hz, 1 H) 8.06 (t, J=1.76 Hz, 1 H) 9.02 -9.09 (m, 2 H) 9.75 (s, 1 H).
- Compound 1037; MS: m/z = 415.9/417.9 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.50 (d, J=8.61 Hz, 2 H) 7.55 (br. s., 2 H) 7.63 - 7.75 (m, 2 H) 9.03 (d, J=4.70 Hz, 2 H) 9.71 (s, 1 H).
- Compound 1038; MS: m/z = 377.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.98 (s, 2 H) 7.30 (d, J=8.61 Hz, 2 H) 7.53 (s, 2 H) 7.67 - 7.74 (m, 2 H) 8.98 - 9.06 (m, 2 H) 9.67 (s, 1 H).
- Compound 1039; MS: m/z = 391.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.51 (s, 2 H) 7.67 - 7.80 (m, 2 H) 7.82 (d, J=6.65 Hz, 1 H) 8.07 (d, J=8.22 Hz, 1 H) 8.53 (d, J=5.87 Hz, 1 H) 9.04 - 9.10 (m, 2 H) 9.36 (d, J=0.78 Hz, 1 H) 10.00 (s, 1 H).
- Compound 1040; MS: m/z = 389.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.48 (s, 2 H) 7.55 (dd, J=8.41, 4.11 Hz, 1 H) 7.62 (dd, J=7.43, 1.17 Hz, 1 H) 7.78 (dd, J=8.22, 7.43 Hz, 1 H) 7.95 (d, J=8.61 Hz, 1 H) 8.24 - 8.35 (m, 1 H) 8.92 (dd, J=4.11, 1.76 Hz, 1 H) 9.05 (s, 2 H) 10.00 (s, 1 H).
- Compound 1041; MS: m/z = 389.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.49 (dd, J=8.22, 4.30 Hz, 1 H) 7.62 (s, 2 H) 7.97 (d, J=9.00 Hz, 1 H) 8.04 (dd, J=9.00, 2.35 Hz, 1 H) 8.24 - 8.32 (m, 1 H) 8.40 (d, J=2.35 Hz, 1 H) 8.79 (dd, J=4.11, 1.76 Hz, 1 H) 9.01 - 9.11 (m, 2 H) 9.94 (s, 1 H).
- Compound 1042; MS: m/z = 389.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.58 (td, J=7.53, 1.37 Hz, 1 H) 7.66 (td, J=7.53, 1.37 Hz, 3 H) 7.89 - 8.01 (m, 2 H) 8.70 (d, J=2.35 Hz, 1 H) 9.01 - 9.11 (m, 2 H) 9.14 (d, J=2.74 Hz, 1 H) 10.07 (s, 1 H).
- Compound 1043; MS: m/z = 389.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.40 - 7.69 (m, 3 H) 7.72 - 7.88 (m, 2 H) 7.98 (br. s., 1 H) 8.13 (s, 1 H) 8.82 (br. s., 1 H) 9.04 (br. s., 2 H) 10.14 (br. s., 1 H).
- Compound 1044; MS: m/z = 342.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.39 (t, J=7.04 Hz, 3 H), 4.41 (q, J=7.04 Hz, 2 H), 7.09 (tt, J=7.40, 1.20 Hz, 1 H), 7.33 (dd, J=8.61, 7.43 Hz, 2 H), 7.59 (s, 2 H), 7.69 (dd, J=8.80, 0.98 Hz, 2 H), 9.14 (d, J=1.96 Hz, 1 H), 9.16 (d, J=1.96 Hz, 1 H), 9.56 (s, 1 H).
- Compound 1045; MS: m/z = 372.0/374.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.39 (d, J=9.00 Hz, 2 H), 7.56 (s, 1 H), 7.75 (d, J=9.00 Hz, 2 H), 9.00 - 9.08 (m, 2 H), 9.74 (s, 1 H).
- Compound 1046; MS: m/z = 396.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.78 (t, J=6.85 Hz, 2 H), 3.25 (s, 3 H), 3.53 (t, J=6.85 Hz, 2 H), 7.19 (d, J=8.22 Hz, 2 H), 7.50 (s, 2 H), 7.59 (d, J=8.22 Hz, 2 H), 9.04 (s, 2 H), 9.56 (s, 1 H).
- Compound 1047; MS: m/z = 352.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3 H), 7.14 (d, J=8.61 Hz, 2 H), 7.50 (s, 2 H), 7.57 (d, J=8.22 Hz, 2 H), 9.03 (s, 2 H), 9.54 (s, 1 H).
- Compound 1048; MS: m/z = 368.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.75 (s, 3 H), 6.91 (d, J=9.00 Hz, 2 H), 7.47 (s, 2 H), 7.58 (d, J=9.00 Hz, 2 H), 9.03 (s, 2 H), 9.51 (s, 1 H).
- Compound 1049; Described in example 15
- Compound 1050; MS: m/z = 413.9/415.9 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.02 (br. s., 2 H), 7.53 (d, J=9.00 Hz, 2 H), 7.71 (d, J=8.61 Hz, 2 H), 8.01 (d, J=8.61 Hz, 1 H), 8.78 (d, J=8.61 Hz, 1 H), 9.85 (s, 1 H).
- Compound 1051; MS: m/z = 372.0/374.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.41 (d, J=9.00 Hz, 2 H), 7.47 (s, 2 H), 7.75 (d, J=9.00 Hz, 2 H), 8.73 (s, 1 H), 9.39 (s, 1 H), 9.93 (s, 1 H).
- Compound 1052; MS: m/z = 350.0 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3 H), 7.15 (d, J=8.22 Hz, 2 H), 7.41 (s, 2 H), 7.57 (d, J=8.61 Hz, 2 H), 8.71 (s, 1 H), 9.38 (s, 1 H), 9.73 (s, 1 H).
- Compound 1053; MS: m/z = 369.9/371.9 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.01 (s, 2 H), 7.41 (d, J=9.00 Hz, 2 H), 7.76 (d, J=9.00 Hz, 2 H), 8.01 (d, J=8.61 Hz, 1 H), 8.78 (d, J=8.61 Hz, 1 H), 9.86 (s, 1 H).
- Compound 1054; MS: m/z = 350.0 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.29 (s, 3 H), 6.94 (s, 2 H), 7.15 (d, J=8.61 Hz, 2 H), 7.58 (d, J=8.61 Hz, 2 H), 8.00 (d, J=8.22 Hz, 1 H), 8.77 (d, J=8.61 Hz, 1 H), 9.66 (s, 1 H).
- Compound 1055; Described in example 17
- Compound 1056; MS: m/z = 415.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.40 - 7.54 (m, 2 H) 7.58 (s, 2 H) 7.63 - 7.71 (m, 2 H) 7.82 (dt, J=7.83, 1.76 Hz, 1 H) 8.16 (t, J=1.76 Hz, 1 H) 8.61 - 8.70 (m, 2 H) 9.00 - 9.09 (m, 2 H) 9.75 (s, 1 H).
- Compound 1057; MS: m/z = 415.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.46 (dd, J=7.83, 4.70 Hz, 1 H) 7.56 (br. s., 2 H) 7.72 (m, J=9.00 Hz, 2 H) 7.85 (m, J=8.61 Hz, 2 H) 8.07 (d, J=7.83 Hz, 1 H) 8.53 (d, J=3.52 Hz, 1 H) 8.90 (d, J=1.96 Hz, 1 H) 9.04 (d, J=5.09 Hz, 2 H) 9.74 (s, 1 H).
- Compound 1058; MS: m/z = 415.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.58 (s, 2 H) 7.66 - 7.74 (m, 2 H) 7.77 - 7.85 (m, 2 H) 7.85 - 7.93 (m, 2 H) 8.56 - 8.62 (m, 2 H) 9.00 -9.09 (m, 2 H) 9.79 (s, 1 H).
- Compound 1059; MS: m/z = 414.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.34 - 7.39 (m, 2 H) 7.39 - 7.45 (m, 1 H) 7.45 - 7.50 (m, 2 H) 7.56 (s, 2 H) 7.62 - 7.66 (m, 2 H) 7.72 (dt, J=7.53, 1.71 Hz, 1 H) 8.04 (t, J=1.96 Hz, 1 H) 9.02 - 9.06 (m, 2 H) 9.68 (s, 1 H).
- Compound 1060; MS: m/z = 356.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.10 - 7.21 (m, 2 H) 7.50 (br. s., 2 H) 7.63 - 7.73 (m, 2 H) 9.02 (s, 2 H) 9.66 (br. s., 1 H).
- Compound 1061; MS: m/z = 406.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.62 (s, 2 H) 7.68 (d, J=8.61 Hz, 2 H) 7.94 (d, J=8.61 Hz, 2 H) 9.00 - 9.11 (m, 2 H) 9.92 (s, 1 H).
- Compound 1062; MS: m/z = 362.0/364.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.36 (s, 2 H), 7.50 (d, J=8.61 Hz, 2 H), 7.69 (d, J=9.00 Hz, 2 H), 8.33 (dd, J=1.96, 0.78 Hz, 1 H), 8.54 (d, J=1.56 Hz, 1 H), 9.53 (s, 1 H).
- Compound 1063; MS: m/z = 285.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.50 (s, 2 H), 7.75 (d, J=6.65 Hz, 2 H), 8.37 (dd, J=1.96, 0.78 Hz, 1 H), 8.42 (d, J=6.26 Hz, 2 H), 8.56 (d, J=1.96 Hz, 1 H), 9.74 (s, 1 H).
- Compound 1064; MS: m/z = 412.9/414.9 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.46 (s, 2 H), 7.51 (d, J=9.00 Hz, 2 H), 7.69 (d, J=9.00 Hz, 2 H), 7.80 (dd, J=8.61, 1.57 Hz, 1 H), 8.16 (d, J=8.61 Hz, 1 H), 8.63 (s, 1 H), 9.65 (s, 1 H).
- Compound 1065; MS: m/z = 351.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3 H), 7.13 (d, J=8.22 Hz, 2 H), 7.39 (s, 2 H), 7.56 (d, J=8.61 Hz, 2 H), 7.79 (dd, J=8.61, 1.57 Hz, 1 H), 8.15 (d, J=8.61 Hz, 1 H), 8.61 (s, 1 H), 9.44 (s, 1 H).
- Compound 1066; MS: m/z = 371.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.38 (d, J=8.61 Hz, 2 H), 7.46 (s, 2 H), 7.74 (d, J=8.61 Hz, 2 H), 7.80 (dd, J=8.61, 1.57 Hz, 1 H), 8.16 (d, J=8.22 Hz, 1 H), 8.63 (s, 1 H), 9.65 (s, 1 H).
- Compound 1067; MS: m/z = 338.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.37 (dd, J=8.22, 4.70 Hz, 1 H), 7.50 (s, 2 H), 7.81 (dd, J=8.41, 1.37 Hz, 1 H), 8.09 (ddd, J=8.31, 2.45, 1.37 Hz, 1 H), 8.17 (d, J=8.61 Hz, 1 H), 8.29 (br. d, J=3.90 Hz, 1 H), 8.65 (s, 1 H), 8.88 (d, J=1.96 Hz, 1 H), 9.73 (s, 1 H).
- Compound 1068; MS: m/z = 318.1/320.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.36 (s, 2 H), 7.37 (d, J=9.00 Hz, 2 H), 7.74 (d, J=8.61 Hz, 2 H), 8.33 (dd, J=2.15, 0.98 Hz, 1 H), 8.54 (dd, J=2.35, 0.78 Hz, 1 H), 9.53 (s, 1 H).
- Compound 1069; MS: m/z = 298.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.27 (s, 3 H), 2.43 (s, 3 H), 7.12 (d, J=8.22 Hz, 2 H), 7.28 (s, 2 H), 7.56 (d, J=8.22 Hz, 1 H), 8.31 (dd, J=1.96, 0.78 Hz, 1 H), 8.53 (d, J=1.57 Hz, 1 H), 9.33 (s, 1 H).
- Compound 1070; MS: m/z = 353.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.44 (s, 3 H), 7.23 (d, J=8.22 Hz, 1 H), 7.57 (s, 2 H), 7.96 (dd, J=8.41, 2.54 Hz, 1 H), 8.74 (d, J=2.35 Hz, 1 H), 9.02 - 9.09 (m, 2 H), 9.74 (s, 1 H).
- Compound 1071; MS: m/z = 369.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H), 6.83 (dd, J=8.61, 0.78 Hz, 1 H), 7.53 (s, 2 H), 7.96 (dd, J=8.61, 2.74 Hz, 1 H), 8.39 -8.45 (m, 1 H), 9.00 - 9.08 (m, 2 H), 9.68 (s, 1 H).
- Compound 1072; MS: m/z = 284.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.63 (s, 3 H), 6.80 (s, 2 H), 7.08 (tt, J=7.40, 1.20 Hz, 1 H), 7.33 (dd, J=8.61, 7.43 Hz, 2 H), 7.42 (d, J=8.61 Hz, 1 H), 7.70 (dd, J=8.61, 1.17 Hz, 2 H), 8.30 (d, J=8.22 Hz, 1 H), 9.50 (s, 1 H).
- Compound 1073; MS: m/z = 318.1/320.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.63 (s, 3 H), 6.85 (s, 2 H), 7.38 (d, J=9.00 Hz, 2 H), 7.43 (d, J=8.61 Hz, 1 H), 7.75 (d, J=8.61 Hz, 2 H), 8.30 (d, J=8.22 Hz, 1 H), 9.64 (s, 1 H).
- Compound 1074; MS: m/z = 390.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.38 (t, J=9.00 Hz, 1 H) 7.58 (s, 2 H) 7.65 (ddd, J=9.10, 4.40, 2.54 Hz, 1 H) 7.98 - 8.03 (m, 1 H) 9.01 - 9.06 (m, 2 H) 9.78 (s, 1 H).
- Compound 1075; MS: m/z = 374.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.39 (dt, J=10.56, 9.19 Hz, 1 H) 7.44 - 7.53 (m, 1 H) 7.57 (br. s., 2 H) 7.85 (ddd, J=13.40, 7.53, 2.54 Hz, 1 H) 9.03 (d, J=4.70 Hz, 2 H) 9.79 (br. s., 1 H).
- Compound 1076; MS: 370.0 m/z = (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.22 (d, J=1.96 Hz, 3 H) 7.09 (t, J=9.19 Hz, 1 H) 7.45 - 7.54 (m, 3 H) 7.60 (dd, J=7.04, 2.35 Hz, 1 H) 9.02 (s, 2 H) 9.58 (s, 1 H).
- Compound 1077; MS: m/z = 356.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.85 - 6.93 (m, 1 H) 7.35 (td, J=8.12, 6.85 Hz, 1 H) 7.48 - 7.54 (m, 1 H) 7.58 (s, 2 H) 7.67 (dt, J=12.03, 2.20 Hz, 1 H) 9.00 - 9.07 (m, 2 H) 9.76 (s, 1 H).
- Compound 1078; MS: m/z = 370.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.18 (s, 3 H) 7.20 (t, J=8.61 Hz, 1 H) 7.40 (dd, J=8.22, 1.96 Hz, 1 H) 7.54 (br. s., 2 H) 7.60 (dd, J=12.52, 1.96 Hz, 1 H) 9.03 (d, J=4.70 Hz, 2 H) 9.68 (br. s., 1 H).
- Compound 1079; MS: m/z = 374.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.91 (tt, J=9.39, 2.35 Hz, 1 H) 7.47 - 7.56 (m, 2 H) 7.64 (s, 2 H) 9.05 (dd, J=11.15, 1.76 Hz, 2 H) 9.89 (s, 1 H).
- Compound 1080; MS: m/z = 368.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.75 (s, 3 H), 6.92 (d, J=9.00 Hz, 2 H), 7.39 (s, 2 H), 7.58 (d, J=9.00 Hz, 2 H), 8.70 (s, 1 H), 9.37 (s, 1 H), 9.70 (s, 1 H).
- Compound 1081; MS: m/z = 340.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.53 Hz, 2 H), 3.00 (q, J=7.56 Hz, 2 H), 3.74 (s, 3 H), 6.89 (d, J=9.39 Hz, 2 H), 7.23 (s, 2 H), 7.56 (d, J=9.00 Hz, 1 H), 8.26 (s, 1 H), 9.25 (s, 1 H).
- Compound 1082; MS: m/z = 344.0/346.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.14 (quin, J=7.53 Hz, 2 H), 3.01 (q, J=7.56 Hz, 4 H), 7.33 (s, 2 H), 7.36 (d, J=8.61 Hz, 2 H), 7.74 (d, J=9.00 Hz, 2 H), 8.29 (s, 1 H), 9.48 (s, 1 H).
- Compound 1083; MS: m/z = 367.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.75 (s, 3 H), 6.91 (d, J=9.00 Hz, 2 H), 7.37 (s, 2 H), 7.57 (d, J=9.00 Hz, 2 H), 7.78 (d, J=8.61 Hz, 1 H), 8.14 (d, J=8.61 Hz, 1 H), 8.60 (s, 1 H), 9.42 (s, 1 H).
- Compound 1084; MS: m/z = 422.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.35 (d, J=8.61 Hz, 2 H), 7.57 (br. s, 2 H), 7.82 (d, J=9.00 Hz, 2 H), 9.02 - 9.09 (m, 2 H), 9.80 (s, 1 H).
- Compound 1085; MS: m/z = 368.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.75 (s, 3 H), 6.67 (dd, J=8.22, 2.35 Hz, 1 H), 7.23 (t, J=8.22 Hz, 1 H), 7.32 (dd, J=9.00, 1.56 Hz, 1 H), 7.39 (t, J=2.15 Hz, 1 H), 7.54 (br. s, 2 H), 9.01 - 9.08 (m, 2 H), 9.57 (s, 1 H).
- Compound 1086; MS: m/z = 404.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.16 (d, J=9.00 Hz, 2 H), 7.18 (t, J=73.95 Hz, 1 H), 7.54 (s, 2 H), 7.73 (d, J=9.39 Hz, 2 H), 8.97 -9.11 (m, 2H), 9.71 (s, 1 H).
- Compound 1087; MS: m/z = 402.0/404.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H), 7.14 (d, J=9.00 Hz, 1 H), 7.54 (s, 2 H), 7.60 (dd, J=9.00, 2.74 Hz, 1 H), 7.87 (d, J=2.35 Hz, 1 H), 8.99 - 9.09 (m, 2 H), 9.62 (s, 1 H).
- Compound 1088; MS: m/z = 356.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.19 (t, J=9.00 Hz, 2 H), 7.44 (s, 2 H), 7.70 (dd, J=9.00, 5.09 Hz, 2 H,) 8.72 (s, 1 H), 9.39 (s, 1 H), 9.86 (s, 1 H).
- Compound 1089; MS: m/z = 355.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.17 (t, J=8.80 Hz, 2 H), 7.42 (s, 2 H), 7.70 (dd, J=9.39, 5.09 Hz, 2 H), 7.79 (dd, J=8.61, 1.57 Hz, 1 H), 8.15 (d, J=8.22 Hz, 1 H), 8.62 (s, 1 H), 9.58 (s, 1 H).
- Compound 1090; Described in example 20
- Compound 1091; MS: m/z = 310.1 (MH+);1H NMR (400 MHz, DMSO-d6) δ ppm 0.80 (d, J=5.09 Hz, 2 H), 1.07 (d, J=7.83 Hz, 2 H), 2.06 - 2.13 (m, 1 H), 7.07 (t, J=7.24 Hz, 1 H), 7.27 - 7.35 (m, 4 H), 7.69 (d, J=8.22 Hz, 2 H), 8.15 (s, 1 H), 8.57 (s, 1 H), 9.39 (s, 1 H).
- Compound 1092; MS: m/z = 430.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.95 - 7.03 (m, 4 H) 7.07 - 7.14 (m, 1 H) 7.33 - 7.41 (m, 2 H) 7.50 (s, 2 H) 7.65 - 7.72 (m, 2 H) 9.02 (s, 2 H) 9.64 (s, 1 H).
- Compound 1093; MS: m/z = 372.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.12 (dt, J=9.10, 0.93 Hz, 1 H) 7.34 (t, J=8.22 Hz, 1 H) 7.52 - 7.69 (m, 3 H) 7.90 (t, J=1.96 Hz, 1 H) 8.98 - 9.09 (m, 2 H) 9.75 (br. s., 1 H).
- Compound 1094; MS: m/z = 352.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.29 (s, 3 H) 6.90 (d, J=7.83 Hz, 1 H) 7.20 (t, J=7.83 Hz, 1 H) 7.43 - 7.57 (m, 4 H) 9.02 (d, J=0.78 Hz, 2 H) 9.52 (s, 1 H).
- Compound 1095; MS: m/z = 407.9 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.57 (d, J=9.00 Hz, 1 H) 7.61 (br. s., 2 H) 7.69 (dd, J=8.80, 2.54 Hz, 1 H) 8.10 (d, J=2.35 Hz, 1 H) 9.00 - 9.08 (m, 2 H) 9.83 (br. s., 1 H).
- Compound 1096; MS: m/z = 386.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.31 (s, 3 H) 7.34 (d, J=8.61 Hz, 1 H) 7.51 - 7.58 (m, 3 H) 7.71 (d, J=2.35 Hz, 1 H) 9.03 (d, J=3.52 Hz, 2 H) 9.64 (s, 1 H).
- Compound 1097; MS: m/z = 388.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.12 (dd, J=8.61, 2.35 Hz, 1 H) 7.23 (d, J=8.61 Hz, 1 H) 7.50 (d, J=2.35 Hz, 3 H) 9.02 (d, J=1.96 Hz, 2 H) 9.60 (s, 1 H) 10.15 (s, 1 H).
- Compound 1098; MS: m/z = 382.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 5.99 (s, 2 H) 6.86 (d, J=8.22 Hz, 1 H) 7.09 (dd, J=8.41, 2.15 Hz, 1 H) 7.31 (d, J=1.96 Hz, 1 H) 7.47 (s, 2 H) 9.01 (s, 2 H) 9.51 (s, 1 H).
- Compound 1099; MS: m/z = 396.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 4.15 - 4.26 (m, 4 H) 6.79 (d, J=9.00 Hz, 1 H) 7.11 (dd, J=8.80, 2.54 Hz, 1 H) 7.27 (d, J=2.35 Hz, 1 H) 7.46 (br. s., 2 H) 9.01 (s, 2 H) 9.44 (s, 1 H).
- Compound 1100; MS: m/z = 344.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.34 (dd, J=5.28, 1.37 Hz, 1 H) 7.45 (dd, J=5.28, 3.33 Hz, 1 H) 7.53 (s, 2 H) 7.66 (dd, J=3.13, 1.57 Hz, 1 H) 9.02 (d, J=3.13 Hz, 2 H) 10.08 (s, 1 H).
- Compound 1101; MS: m/z = 409.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.78 (s, 3 H) 7.55 (s, 2 H) 7.70 (dd, J=9.00, 1.96 Hz, 1 H) 7.94 (d, J=8.61 Hz, 1 H) 8.31 (d, J=1.96 Hz, 1 H) 9.04 (d, J=5.87 Hz, 2 H) 9.78 (s, 1 H).
- Compound 1102; MS: m/z = 340.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.76 (s, 2 H) 8.08 (d, J=5.87 Hz, 1 H) 8.66 (d, J=5.48 Hz, 1 H) 8.91 (s, 1 H) 9.05 (d, J=1.56 Hz, 1 H) 9.09 (s, 1 H) 10.54 (s, 1 H).
- Compound 1103; Described in example 21
- Compound 1104; MS: m/z = 324.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.76 - 1.92 (m, 4 H) 2.88 (t, J=6.06 Hz, 2 H) 2.95 (t, J=6.46 Hz, 2 H) 7.03 - 7.09 (m, 1 H) 7.25 - 7.35 (m, 4 H) 7.68 (d, J=7.43 Hz, 2 H) 8.18 (s, 1 H) 9.34 (s, 1 H).
- Compound 1105; MS: m/z = 354.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.74 - 1.93 (m, 4 H), 2.87 (t, J=6.06 Hz, 2 H), 2.95 (t, J=6.46 Hz, 2 H), 3.73 (s, 3 H), 6.85 - 6.92 (m, 2 H), 7.24 (s, 2 H), 7.53 - 7.59 (m, 2 H), 8.16 (s, 1 H), 9.24 (s, 1 H).
- Compound 1106; MS: m/z = 342.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.76 - 1.92 (m, 4 H), 2.87 (t, J=6.06 Hz, 2 H), 2.95 (t, J=6.46 Hz, 2 H), 7.11 - 7.18 (m, 2 H), 7.29 (br. s., 2 H), 7.65 - 7.72 (m, 2 H), 8.18 (s, 1 H), 9.41 (br. s., 1 H).
- Compound 1107; MS: m/z = 340.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.21 (t, J=4.70 Hz, 1 H) 7.61 (s, 2 H) 8.68 (d, J=4.70 Hz, 2 H) 9.04 (d, J=5.87 Hz, 2 H) 10.42 (s, 1 H).
- Compound 1108; MS: m/z = 340.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.70 (s, 2 H) 8.37 (d, J=2.74 Hz, 1 H) 8.45 (dd, J=2.74, 1.57 Hz, 1 H) 9.01 - 9.06 (m, 1 H) 9.08 (d, J=1.56 Hz, 1 H) 9.27 (d, J=1.57 Hz, 1 H) 10.44 (s, 1 H).
- Compound 1109; MS: m/z = 340.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.67 (s, 2 H) 8.89 (s, 1 H) 9.05 (d, J=1.56 Hz, 1 H) 9.08 (d, J=1.57 Hz, 1 H) 9.10 (s, 2 H) 10.00 (s, 1 H).
- Compound 1110; MS: m/z = 378.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.44 - 7.52 (m, 3 H) 7.53 - 7.59 (m, 1 H) 8.03 (s, 1 H) 8.06 (s, 1 H) 9.02 (s, 2 H) 9.64 (s, 1 H) 12.99 (s, 1 H).
- Compound 1111; Described in example 22
- Compound 1112; Described in example 23
- Compound 1113; MS: m/z = 338.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.66 (br. s., 4 H), 1.85 (d, J=4.70 Hz, 2 H), 2.85 - 2.91 (m, 2 H), 3.08 (d, J=10.96 Hz, 2 H), 6.99 - 7.13 (m, 1 H), 7.21 - 7.37 (m, 4 H), 7.63 - 7.75 (m, 2 H), 8.19 (s, 1 H), 9.35 (s, 1 H).
-
Compound 1114; MS: m/z = 314.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 3.74 (br. s, 2 H), 6.90 (d, J=9.00 Hz, 2 H), 7.26 (s, 2 H), 7.57 (d, J=9.00 Hz, 2 H), 8.30 (dd, J=2.15, 0.98 Hz, 1 H), 8.53 (d, J=1.57 Hz, 1 H), 9.30 (s, 1 H). - Compound 1115; MS: m/z = 302.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.16 (t, J=8.80 Hz, 2 H), 7.32 (s, 2 H), 7.70 (dd, J=9.39, 5.09 Hz, 2 H), 8.32 (dd, J=1.96, 0.78 Hz, 1 H), 8.54 (d, J=1.57 Hz, 1 H), 9.47 (s, 1 H).
- Compound 1116; MS: m/z = 368.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.75 (s, 3 H), 6.92 (br. s, 2 H), 6.93 (d, J=9.00 Hz, 2 H), 7.58 (d, J=9.00 Hz, 2 H), 7.99 (d, J=8.61 Hz, 1 H), 8.77 (d, J=8.22 Hz, 1 H), 9.63 (s, 1 H).
- Compound 1117; MS: m/z = 356.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.98 (s, 2 H), 7.19 (t, J=8.80 Hz, 2 H), 7.71 (dd, J=9.39, 5.09 Hz, 2 H), 8.01 (d, J=8.22 Hz, 1 H), 8.78 (d, J=8.61 Hz, 1 H), 9.79 (s, 1 H).
- Compound 1118; Described in example 16
- Compound 1119; MS: m/z = 313.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 3.74 (s, 3 H), 6.89 (d, J=9.00 Hz, 2 H), 7.13 (s, 2 H), 7.33 (dd, J=8.41, 1.37 Hz, 1 H), 7.56 (d, J=9.00 Hz, 2 H), 7.74 (d, J=8.22 Hz, 1 H), 7.89 (s, 1 H), 9.19 (s, 1 H).
- Compound 1120; MS: m/z = 301.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.15 (t, J=9.00 Hz, 2 H), 7.19 (s, 2 H), 7.35 (dd, J=8.41, 1.37 Hz, 1 H), 7.69 (dd, J=9.00, 5.48 Hz, 2 H), 7.75 (d, J=8.22 Hz, 1 H), 7.91 (s, 1 H), 9.37 (s, 1 H).
- Compound 1121; MS: m/z = 386.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.82 (s, 3 H) 7.14 (dd, J=11.35, 8.61 Hz, 1 H) 7.25 - 7.33 (m, 1 H) 7.46 - 7.62 (m, 3 H) 9.03 (d, J=5.09 Hz, 2 H) 9.61 (s, 1 H).
- Compound 1122; MS: m/z = 382.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 (t, J=7.04 Hz, 3 H) 3.99 (q, J=6.91 Hz, 2 H) 6.83 - 6.92 (m, 2 H) 7.45 (s, 2 H) 7.50 - 7.58 (m, 2 H) 9.01 (s, 2 H) 9.48 (s, 1 H).
- Compound 1123; MS: m/z = 381.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.23 (br. s., 1 H) 7.58 (s, 2 H) 7.78 (d, J=9.00 Hz, 2 H) 7.84 (d, J=9.00 Hz, 3 H) 9.04 (d, J=6.26 Hz, 2 H) 9.78 (s, 1 H).
- Compound 1124; MS: m/z = 395.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.76 (d, J=4.30 Hz, 3 H) 7.58 (s, 2 H) 7.79 (s, 4 H) 8.32 (d, J=4.70 Hz, 1 H) 9.04 (d, J=5.87 Hz, 2 H) 9.77 (s, 1 H).
- Compound 1125; MS: m/z = 396.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.82 (s, 3 H) 7.62 (s, 2 H) 7.85 - 7.96 (m, 4 H) 8.99 - 9.09 (m, 2 H) 9.90 (s, 1 H).
- Compound 1126; MS: m/z = 381.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.86 (s, 6 H) 6.69 (d, J=9.39 Hz, 2 H) 7.35 - 7.50 (m, 4 H) 8.99 (s, 2 H) 9.36 (s, 1 H).
- Compound 1127; MS: m/z = 417.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.25 (s, 2 H) 7.62 (s, 2 H) 7.72 - 7.80 (m, 2 H) 7.85 - 7.93 (m, 2 H) 8.99 - 9.10 (m, 2 H) 9.90 (s, 1 H).
- Compound 1128; MS: m/z = 357.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.58 (s, 2 H) 7.77 (td, J=8.71, 2.93 Hz, 1 H) 8.05 (dd, J=9.19, 4.11 Hz, 1 H) 8.37 (d, J=3.13 Hz, 1 H) 8.99 - 9.08 (m, 2 H) 10.16 (s, 1 H).
- Compound 1129; MS: m/z = 314.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.63 (s, 3 H), 3.75 (s, 3 H), 6.75 (br. s, 2 H), 6.91 (d, J=9.00 Hz, 2 H), 7.41 (d, J=8.61 Hz, 1 H), 7.57 (d, J=9.00 Hz, 2 H), 8.29 (d, J=8.22 Hz, 1 H), 9.40 (s, 1 H).
- Compound 1130; MS: m/z = 315.0/317.0 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.23 (s, 2 H), 7.35 (dd, J=7.83, 1.57 Hz, 1 H), 7.36 (d, J=9.00 Hz, 3 H), 7.76 (d, J=8.22 Hz, 1 H), 7.74 (d, J=9.00 Hz, 3 H), 7.92 (s, 1 H), 9.43 (s, 1 H).
- Compound 1131; LCMS: m/z = 297.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.27 (s, 3 H), 2.43 (s, 3 H), 7.12 (d, J=8.22 Hz, 2 H), 7.16 (s, 2 H), 7.34 (dd, J=8.22, 0.78 Hz, 1 H), 7.56 (d, J=8.22 Hz, 2 H), 7.75 (d, J=8.22 Hz, 1 H), 7.90 (s, 1 H), 9.22 (s, 1 H).
- Compound 1132; MS: m/z = 361.0/363.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.24 (s, 2 H), 7.35 (dd, J=8.22, 1.17 Hz, 1 H), 7.49 (d, J=9.00 Hz, 2 H), 7.69 (d, J=9.00 Hz, 2 H), 7.76 (d, J=8.22 Hz, 1 H), 7.92 (s, 1 H), 9.43 (s, 1 H).
- Compound 1133; MS: m/z = 384.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.45 (s, 3 H), 7.24 (m, J=8.61 Hz, 2 H), 7.51 (s, 2 H), 7.65 (m, J=8.61 Hz, 2 H), 9.02 (d, J=1.17 Hz, 2 H), 9.61 (s, 1 H).
- Compound 1134; Described in example 24
- Compound 1135; MS: m/z = 348.2,/350.2 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 3.83 (s, 3 H), 7.11 (d, J=9.00 Hz, 1 H), 7.32 (br. s., 2 H), 7.58 (dd, J=9.00, 2.35 Hz, 1 H), 7.87 (d, J=2.74 Hz, 1 H), 8.31 (s, 1 H), 8.52 (s, 1 H), 9.42 (br. s., 1 H).
- Compound 1136; MS: m/z = 401.0/403.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H), 7.13 (d, J=9.00 Hz, 1 H), 7.43 (s, 2 H), 7.60 (dd, J=9.00, 2.74 Hz, 1 H), 7.79 (d, J=8.61 Hz, 1 H), 7.86 (d, J=2.74 Hz, 1 H), 8.15 (d, J=8.22 Hz, 1 H), 8.62 (s, 1 H), 9.53 (s, 1 H).
- Compound 1137; MS: m/z = 352.2 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (s, 3 H), 7.42 (br. s., 2 H), 7.67 (m, J=8.61 Hz, 2 H), 7.94 (m, J=8.61 Hz, 2 H), 8.34 (s, 1 H), 8.53 - 8.56 (m, 1 H), 9.74 (br. s., 1 H).
- Compound 1138; MS: m/z = 405.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.54 (s, 2 H), 7.69 (d, J=9.00 Hz, 2 H), 7.81 (dd, J=8.61, 1.57 Hz, 1 H), 7.96 (d, J=8.61 Hz, 2 H), 8.17 (d, J=8.22 Hz, 1 H), 8.65 (s, 1 H), 9.86 (s, 1 H).
- Compound 1139; MS: m/z = 318.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.41 (s, 3 H) 7.07 - 7.13 (m, 1 H) 7.33 (t, J=8.02 Hz, 1 H) 7.38 (s, 2 H) 7.61 - 7.66 (m, 1 H) 7.90 (t, J=2.15 Hz, 1 H) 8.33 (d, J=1.17 Hz, 1 H) 8.53 (d, J=1.96 Hz, 1 H) 9.54 (s, 1 H).
- Compound 1140; MS: m/z = 298.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3 H) 2.41 (s, 3 H) 6.87 (d, J=7.43 Hz, 1 H) 7.18 (t, J=7.63 Hz, 1 H) 7.29 (s, 2 H) 7.46 (d, J=7.43 Hz, 1 H) 7.53 (s, 1 H) 8.28 - 8.32 (m, 1 H) 8.52 (d, J=1.57 Hz, 1 H) 9.30 (s, 1 H).
- Compound 1141; MS: m/z = 342.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.41 (s, 3 H) 4.16 - 4.24 (m, 4 H) 6.77 (d, J=9.00 Hz, 1 H) 7.10 (dd, J=8.80, 2.54 Hz, 1 H) 7.20 - 7.31 (m, 3 H) 8.29 (d, J=1.17 Hz, 1 H) 8.51 (d, J=1.96 Hz, 1 H) 9.23 (s, 1 H).
- Compound 1142; MS: m/z = 328.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 (t, J=7.04 Hz, 3 H) 2.41 (s, 3 H) 3.98 (q, J=6.78 Hz, 2 H) 6.82 - 6.90 (m, 2 H) 7.23 (s, 2 H) 7.48 - 7.57 (m, 2 H) 8.25 - 8.31 (m, 1 H) 8.51 (d, J=1.96 Hz, 1 H) 9.27 (s, 1 H).
- Compound 1143; MS: m/z = 330.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.41 (s, 3 H) 2.44 (s, 3 H) 7.18 - 7.26 (m, 2 H) 7.30 (s, 2 H) 7.61 - 7.68 (m, 2 H) 8.30 (d, J=1.17 Hz, 1 H) 8.52 (d, J=1.56 Hz, 1 H) 9.40 (s, 1 H).
- Compound 1144; MS: m/z = 371.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.11 (dt, J=6.85, 1.08 Hz, 1 H) 7.34 (t, J=8.02 Hz, 1 H) 7.48 (s, 2 H) 7.60 - 7.67 (m, 1 H) 7.79 (dd, J=8.61, 1.57 Hz, 1 H) 7.89 (t, J=2.15 Hz, 1 H) 8.14 (d, J=8.61 Hz, 1 H) 8.62 (s, 1 H) 9.66 (s, 1 H).
- Compound 1145; MS: m/z = 351.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3 H) 6.89 (d, J=7.43 Hz, 1 H) 7.19 (t, J=7.63 Hz, 1 H) 7.40 (s, 2 H) 7.46 (d, J=8.61 Hz, 1 H) 7.53 (s, 1 H) 7.77 (dd, J=8.61, 1.57 Hz, 1 H) 8.13 (d, J=8.61 Hz, 1 H) 8.60 (s, 1 H) 9.42 (s, 1 H).
- Compound 1146; MS: m/z = 395.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 4.15 -4.26 (m, 4 H) 6.78 (d, J=8.61 Hz, 1 H) 7.10 (dd, J=8.80, 2.54 Hz, 1 H) 7.26 (d, J=2.74 Hz, 1 H) 7.35 (s, 2 H) 7.76 (dd, J=8.61, 1.57 Hz, 1 H) 8.12 (d, J=8.61 Hz, 1 H) 8.58 (s, 1 H) 9.34 (s, 1 H).
- Compound 1147; MS: m/z = 381.1 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 (t, J=6.85 Hz, 3 H) 3.99 (q, J=6.78 Hz, 2 H) 6.84 - 6.91 (m, 2 H) 7.34 (s, 2 H) 7.50 - 7.56 (m, 2 H) 7.76 (dd, J=8.61, 1.57 Hz, 1 H) 8.12 (d, J=8.61 Hz, 1 H) 8.58 (s, 1 H) 9.38 (s, 1 H).
- Compound 1148; MS: m/z = 383.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.45 (s, 3 H) 7.19 - 7.26 (m, 2 H) 7.41 (s, 2 H) 7.60 - 7.69 (m, 2 H) 7.77 (dd, J=8.61, 1.57 Hz, 1 H) 8.13 (d, J=8.22 Hz, 1 H) 8.60 (s, 1 H) 9.52 (s, 1 H).
- Compound 1149; MS: m/z = 368.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.42 (s, 3 H) 7.31 (d, J=8.22 Hz, 2 H) 7.35 (s, 2 H) 7.77 - 7.83 (m, 2 H) 8.32 (d, J=1.17 Hz, 1 H) 8.53 (d, J=1.96 Hz, 1 H) 9.58 (s, 1 H).
- Compound 1150; MS: m/z = 290.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.41 (s, 3 H) 7.28 - 7.39 (m, 3 H) 7.43 (dd, J=5.09, 3.52 Hz, 1 H) 7.64 (dd, J=3.33, 1.37 Hz, 1 H) 8.30 (d, J=1.17 Hz, 1 H) 8.52 (d, J=1.96 Hz, 1 H) 9.88 (s, 1 H).
- Compound 1151; MS: m/z = 421.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.32 (d, J=8.61 Hz, 2 H) 7.45 (s, 2 H) 7.75 - 7.84 (m, 3 H) 8.15 (d, J=8.22 Hz, 1 H) 8.62 (s, 1 H) 9.70 (s, 1 H).
- Compound 1152; MS: m/z = 343.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 7.34 (dd, J=5.09, 1.17 Hz, 1 H) 7.39 - 7.47 (m, 3 H) 7.65 (dd, J=3.13, 1.17 Hz, 1 H) 7.77 (dd, J=8.41, 1.37 Hz, 1 H) 8.13 (d, J=8.22 Hz, 1 H) 8.60 (s, 1 H) 9.99 (s, 1 H).
- Compound 1153; Described in example 25
- Compound 1154; MS: m/z = 340.0 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 6.56 (s, 2 H), 7.17 (t, J=8.61 Hz, 2 H), 7.85 (dd, J=9.39, 5.09 Hz, 2 H), 8.88 (d, J=2.35 Hz, 1 H), 8.90 (d, J=1.96 Hz, 1 H), 10.21 (s, 1 H).
- Human CD34+ cord blood (CB) cells were isolated from fresh units using RosetteSep™ CD34 pre-enrichment cocktail followed by CD34 positive selection using EasySep kit™ (StemCell Technologies). The cells were then pre-expanded in bulk, by culturing at 37° C. for 6 days in HSC expansion media consisting of StemSpan ACF (StemCell Technologies) supplemented with 100 ng/mL Stem Cell Factor (SCF, Shenandoah), 100 ng/mL FMS-
like Tyrosine Kinase 3 Ligand (FLT3L, Shenandoah), 50 ng/mL Thrombopoietin (TPO, Shenandoah), 2 mM GlutaMAX™ (Invitrogen), 10 µg/mL low density lipoproteins (LDL, StemCell Technologies), 10 µg/mL Ciprofloxacin and 35 nM UM0128171. The culture was monitored daily and supplemented with fresh media as required. Following the pre-expansion, cells were harvested, aliquoted and frozen until use. - For each activity assessment, CD34+ pre-expanded cells (approximately 2000 per well in a 384-well plate) were cultured in HSC expansion media, in the presence of 35 nM UM0128171. Compounds were serially diluted (½) in DMSO (10 dilutions per compound) and added to the cells in order to achieve a 1/1000 final dilution. StemRegenin1 (SR1) and/or
Compound 1001 were included in all experiments as controls to monitor assay performance. The plate was incubated at 37° C. for 7 days in static conditions (i.e. no shaking and no addition of media). Flow cytometry analysis was performed at the end of the 7-day expansion. Cells were stained with PE-labeled anti-human CD45RA (BD Biosciences) and APC-labeled anti-human CD34 (BD Biosciences) and analyzed using Intellicyt IQue cytometer equipped with ForeCyt software. Gates were drawn around the populations of interest to obtain cell numbers and relative proportions. The EC1.5 value, which is the concentration at which the compound/vehicle ratio is greater or equal to 1.5, was calculated by plotting the CD34+ cell number against concentrations (log-scale) in a 4-PL curve and fitting the curve using IDBS XLfit (set model 251) in Microsoft Excel. Results are presented in Tables 1 and 2. - HEK cells line was transfected with an AhR-responsive firefly luciferase reporter gene X4-4.27 and the stable transfectants generated were again transfected with phRL-CMV (a Renilla luciferase expression vector; Promega) along with pBAsi-hU6 Pur DNA (a plasmid carrying the puromycin-resistant gene; TaKaRa, Shiga, Japan), and maintained in the presence of both hygromycin B and puromycin (2 mg/mL). One of the resultant clones was named HEK-XRE 11.1, and used in the reporter gene assays.
- HEK-XRE 11.1 cells were plated in 384-well plates at a density of 25,000 cells in 50 uL volume per well. The induction of ARh pathway was done by addition of MeBIO at 0.1 nM concentration. ARh antagonist compounds were then added to seeded cells in serial dilutions (8 dilutions, 1:3, 10 mM down to 5 nM) in duplicate wells. Renilla expression was not used as internal control. On each plate,
Compound 1001 and SR1 were added as dose control (8 dilutions, 1:3, 5 mM down to 2.5 nM for SR1 and 2 mM down to 1 nM for compound 1001). Luminescence activity was evaluated after 24 hours culture using Lumi-384-CellTiterGlo-Corning protocol. Dose-response curves were generated using nonlinear regression in Excel. Results are presented in Tables 1 and 2. - Human CD34+ cord blood (CB) cells from three cord blood units were isolated as previously described and frozen until use. In a first experiment, two units were pooled upon thawing and CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 35 nM UM0128171 (referred to as UM171), 1
µM Compound 1001, a combination of both or DMSO. Cultures were monitored daily and supplemented with fresh media as required. In a second experiment, one unit was thawed and CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 0.5 µM Compound 1001 (alone or in combination with 35 nM UM171), 0.5 µM Compound 1114 (alone or in combination with 35 nM UM171), 0.5 µM SR1 (alone or in combination with 35 nM UM171), DMSO or_35 nM UM171. - Phenotype of unexpanded (d0) and expanded (d7) CB cells were analysed using a combination of the following anti-human antibodies: CD34 (BD Biosciences), CD45RA (BD Biosciences or BioLegend), CD201, CD90 and CD117 (from BioLegend), CD86 and FcεR1 (both from eBiosciences). Following staining under reduced light at room temperature for 15-30 minutes, cells were washed and analyzed on a FACSCanto II (BD Biosciences) flow cytometer. Fold expansion was calculated by dividing the number of live total cells obtained following expansion by the number of live total cells seeded for each condition. For each subpopulation of interest, the absolute cell numbers were calculated as follows: (cell percentage of subpopulation of interest x live total cell count)/100
- Whereas the total number of cells in culture was increased in all conditions (
FIG. 1A , left panel), the use ofCompound 1001 in CB cultures increases the number of CD34+ cells (i.e. hematopoietic stem and progenitor cells) compared to other conditions (FIG. 1A , middle). The combined use of UM171 andCompound 1001 orCompound 1114 increased the overall percentage of CD34+ cells in cultures (FIG. 1A , right panel andFIG. 1D ). The presence ofCompound 1001 orCompound 1114, alone or in combination with UM171, favors the expansion of CD34+CD45RA+ cells (FIGS. 1B, 1C and 1D ), enriched in short term progenitors (Doulatov, Sergei, et al., Nature immunology 11.7 (2010): 585.). On the other hand, the presence of UM171 in culture, alone or in combination withCompound 1001 orCompound 1114, increases the expansion (FIG. 1B ) and proportions (FIGS. 1C and 1D ) of CD34+CD45RA- and CD34+CD201+ cells, enriched in long-term progenitors (Majeti, Ravindra, Christopher Y. Park, and Irving L. Weissman. Cell stem cell 1.6 (2007): 635-645; Notta, Faiyaz, et al. Science 333.6039 (2011): 218-221 and Fares, Iman, et al. Blood (2017): blood-2016.). The combined use of UM171 andCompound 1001 orCompound 1114 also increased the percentage of Dendritic Cells and Mast Cells compared to Compounds used alone (FIG. 1D ). Therefore, we can induce different proportions of the different types of hematopoietic progenitors or other cellular types depending on the presence of UM171 andCompound 1001 orCompound 1114. - Assessment of engraftment and myeloid vs lymphoid lineage contribution in vivo NSG (NOD.Cg-Prkdcscid I12rgtmIWjI/SzJ, The Jackson Laboratory, ME, USA) mice were bred and housed under specific-pathogen-free conditions in sterile ventilated racks at the Institute for Research in Immunology and Cancer. All animal work was in accordance with the Canadian Council on Animal Care guidelines and approved by the Comité de Déontologie et Expérimentation Animale de l′Université de Montréal.
- Human CD34+ cord blood (CB) cells from two cord blood units were isolated as previously described and frozen until use. Upon thawing, both units were pooled and CB CD34+ cells were cultured for 7 days in HSC expansion media supplemented with 35 nM UM0128171, 1
µM Compound 1001, a combination of both or DMSO. Cultures were monitored daily and supplemented with fresh media as required. - Two thousand unexpanded CD34+ CB cells or their progeny present in 7-day cultures were transplanted by tail vein injection into sub-lethally irradiated (250 cGy, <24 hr before transplantation) 8 to 12 week-old female NSG (NODScid IL2Rynull, Jackson Laboratory). Human cells in NSG bone marrow (BM) was monitored by
flow cytometry weeks 3 and 12) or by flushing the two femurs when animals were sacrificed atweek 20. Flow cytometry analysis was performed on freshly collected BM cells. Cells were treated with 1x red blood cell lysis buffer (StemCell Technologies), washed and stained with anti-human CD45 (BioLegend), anti-mouse CD45.1 (eBioscience) and anti-human CD33, anti-human CD19, anti-human CD3 and anti-human CD34 (all from BD Biosciences). Cells then were washed and analyzed using a FACSCanto II (BD Biosciences). - While CB cells expanded in the presence UM171, alone or in combination with
Compound 1001, resulted in higher engraftment at 3 weeks post transplantation, CB cells expanded in the presence ofCompound 1001, alone or in combination with UM171, engrafted with higher efficiency in the long term (12 and 20 weeks post transplantation,FIG. 2A ). Furthermore, the contribution of lymphoid lineage was greatly increased in the presence of Compound 1001 (FIG. 2B ). -
TABLE 1 Cpd# V1 V2 W R1 R2 R3 procedures EC1.5 (nM) AHR (nM) 1001 N CH C (CH2)3 Ph A1,B1,C1 <100 <50 1002 N CH C (CH2)3 4-F-Ph A1,B1,C1 100 - 1000 <50 1003 N CH C Br H Ph A0,B1,C2 100 - 1000 <50 1004 N CH C Cl H Ph A0,B1,C1 100 - 1000 <50 1005 N CH C CH3 CH3 Ph A0,B1,C1 100 - 1000 50 - 500 1006 N CH C (CH2)3 3-pyridinyl A1,B1,C1 1000 - 5000 50 - 500 1007 N CH C (CH2)3 2-pyridinyl A1,B2,C1 100 - 1000 <50 1008 N CH C CF3 H Ph A2,B1,C1 100 - 1000 >500 1009 N CH C CH3 H Ph A3,B1,C3 100 - 1000 <50 1010 N CH C F H Ph A0,B1,C3 >5000 50 - 500 1011 N CH C Cl H 4-pyridinyl A0,B2,C3 1000 - 5000 <50 1012 N CH C Br H 4-pyridinyl A0,B2,C1 100 - 1000 50 - 500 1013 N CH C CF3 H 4-pyridinyl A2,B2,C3 100 - 1000 >500 1014 N CH C (CH2)3 4-pyridinyl A1,B2,C1 1000 - 5000 50 - 500 1015 N CH C CF3 H 3-pyridinyl A2,B1,C3 100 - 1000 >500 1016 N CH C CN H Ph A4,B1,C1 100 - 1000 >500 1017 N CH C CF3 H 4-(CH2CH2OH)-Ph A2,B3,C1 100 - 1000 50 - 500 1018 N CH C CF3 H 4-(CH2OCH3)-Ph A2,B2,C1 1000 - 5000 <50 1019 N CH C CF3 H 4-(CH2OH)-Ph A2,B3,C1 >5000 >500 1020 N CH C CCH H 4-pyridinyl Example 18 >5000 50 - 500 1021 N CH C Et H 4-pyridinyl Example 19 100 - 1000 50 - 500 1022 N CH C CF3 H 2-pyridinyl A2,B2,C1 100 - 1000 <50 1023 N CH C CF3 H 5-CH3-2-thiazolyl A2,B2,C1 >5000 50 - 500 1024 N CH C CF3 H 4-Et-Ph A2,B2,C1 100 - 1000 <50 1025 CH CH N CF3 Ph A5,B1,C3 100 - 1000 <50 1026 CH CH N CF3 4-pyridinyl A5,B2,C3 1000 - 5000 50 - 500 1027 CH N C CF3 H Ph A6,B1,C3 >5000 <50 1028 CH N C CF3 H 4-pyridinyl A6,B2,C3 >5000 50 - 500 1029 N CH C CF3 H 6-benzothiazolyl A2,B2,C2 100 - 1000 50 - 500 1030 N CH C CF3 H 4-Ph-Ph A2,B2,C2 >5000 50 - 500 1031 N CH C CF3 H 4-BnO-Ph A2,B2,C2 100 - 1000 50 - 500 1032 N CH C CF3 H 4-(CH2CO2Et)-Ph A2,B2,C1 1000 - 5000 50 - 500 1033 N CH C CF3 H (4-OCH3-3-Ph)-Ph A2,B2,C4 100 - 1000 50 - 500 1034 CH CH C CF3 H Ph A0,B1,C3 100 - 1000 <50 1035 CH CH C CF3 H 4-pyridinyl A0,B2,C3 100 - 1000 <50 1036 N CH C CF3 H 3-Br-Ph A2,B2,C2 100 - 1000 <50 1037 N CH C CF3 H 4-Br-Ph A2,B2,C2 100 - 1000 <50 1038 N CH C CF3 H 4-(CH2CN)-Ph A2, B2, C4 >5000 <50 1039 N CH C CF3 H 5-isoquinolinyl A2,B2,C2 >5000 50 - 500 1040 N CH C CF3 H 5-quinolinyl A2,B2,C2 >5000 50 - 500 1041 N CH C CF3 H 6-quinolinyl A2,B2,C2 1000 - 5000 50 - 500 1042 N CH C CF3 H 3-quinolinyl A2,B2,C2 1000 - 5000 >500 1043 N CH C CF3 H 4-quinolinyl A2,B2,C2 >5000 >500 1044 N CH C CO2Et H Ph A7,B1,C3 >5000 50 - 500 1045 N CH C CF3 H 4-Cl-Ph A2,B1,C1 <100 <50 1046 N CH C CF3 H 4-(CH2CH2OMe)-Ph A2,B1,C3 >5000 50 - 500 1047 N CH C CF3 H 4-CH3-Ph A2,B1,C1 100 - 1000 <50 1048 N CH C CF3 H 4-OCH3-Ph A2,B1,C1 <100 <50 1049 CH CH N CF3 4-Br-Ph A5,B1,C4 100 - 1000 50 - 500 1050 CH N C CF3 H 4-Br-Ph A6,B1,C4 >5000 50 - 500 1051 CH CH N CF3 4-Cl-Ph A5,B1,C3 1000 - 5000 50 - 500 1052 CH CH N CF3 4-CH3-Ph A5,B1,C3 1000 - 5000 50 - 500 1053 CH N C CF3 H 4-Cl-Ph A6,B1,C3 1000 - 5000 50 - 500 1054 CH N C CF3 H 4-CH3-Ph A6,B1,C3 >5000 50 - 500 1055 N CH C CF3 H 4-(3-pyridinyl)-Ph Example 17 >5000 50 - 500 1056 N CH C CF3 H 4-(4-pyridinyl)-Ph D >5000 50 - 500 1057 N CH C CF3 H 3-(3-pyridinyl)-Ph D 1000 - 5000 <50 1058 N CH C CF3 H 3-(4-pyridinyl)-Ph D 100 - 1000 <50 1059 N CH C CF3 H 3-Ph-Ph D 1000 - 5000 50 - 500 1060 N CH C CF3 H 4-F-Ph A2,B1,C2 <100 <50 1061 N CH C CF3 H 4-CF3-Ph A2,B2,C2 <100 <50 1062 N CH C CH3 H 4-Br-Ph A3,B1,C4 <100 <50 1063 N CH C CH3 H 4-pyridinyl A3,B2,C3 >5000 50 - 500 1064 CH CH C CF3 H 4-Br-Ph A0,B1,C4 100 - 1000 50 - 500 1065 CH CH C CF3 H 4-CH3-Ph A0,B1,C3 100 - 1000 50 - 500 1066 CH CH C CF3 H 4-CI-Ph A0,B1,C3 100 - 1000 <50 1067 CH CH C CF3 H 3-pyridinyl A0,B1,C3 1000 - 5000 <50 1068 N CH C CH3 H 4-Cl-Ph A3,B1,C1 <100 <50 1069 N CH C CH3 H 4-CH3-Ph A3,B1,C3 100 - 1000 <50 1070 N CH C CF3 H 6-CH3-3-pyridinyl A2,B1,C3 >5000 50 - 500 1071 N CH C CF3 H 6-OCH3-3-pyridinyl A2,B1,C1 100 - 1000 <50 1072 CH N C CH3 H Ph A8,B1,C3 >5000 50 - 500 1073 CH N C CH3 H 4-Cl-Ph A8,B1,C3 >5000 50 - 500 1074 N CH C CF3 H 3-Cl-4-F-Ph A2,B1,C4 100 - 1000 <50 1075 N CH C CF3 H 3,4-diF-Ph A2,B1,C2 100 - 1000 <50 1076 N CH C CF3 H 3-CH3-4-F-Ph A2,B1,C2 100 - 1000 50 - 500 1077 N CH C CF3 H 3-F-Ph A2,B1,C2 100 - 1000 <50 1078 N CH C CF3 H 3-F-4-CH3-Ph A2,B1,C2 1000 - 5000 50 - 500 1079 N CH C CF3 H 3,5-diF-Ph A2,B1,C4 1000 - 5000 50 - 500 1080 CH CH N CF3 3-OCH3-Ph A5,B1,C3 100 - 1000 <50 1081 N CH C (CH2)3 3-OCH3-Ph A1,B1,C1 <100 <50 1082 N CH C (CH2)3 4-Cl-Ph A1.B1,C1 <100 <50 1083 CH CH C CF3 H 4-OCH3-Ph A0,B1,C3 <100 50 - 500 1084 N CH C CF3 H 4-CF3O-Ph A2,B1,C1 <100 <50 1085 N CH C CF3 H 3-OCH3-Ph A2,B1,C1 100 - 1000 50 - 500 1086 N CH C CF3 H 4-OCHF2-Ph A2,B1,C1 100 - 1000 <50 1087 N CH C CF3 H 3-Cl-4-OCH3-Ph A2,B1,C1 <100 <50 1088 CH CH N CF3 4-F-Ph A5,B1,C3 >5000 <50 1089 CH CH C CF3 H 4-F-Ph A0,B1,C3 100 - 1000 <50 1090 N CH C CH2=CMe H Ph Example 20 >5000 <50 1091 N CH C c-Pr H Ph D 100 - 1000 50 - 500 1092 N CH C CF3 H 4-OPh-Ph A2,B1,C2 100 - 1000 50 - 500 1093 N CH C CF3 H 3-Cl-Ph A2,B1,C2 <100 <50 1094 N CH C CF3 H 3-CH3-Ph A2,B1,C2 <100 <50 1095 N CH C CF3 H 3,4-diCl-Ph A2,B1,C2 100 - 1000 50 - 500 1096 N CH C CF3 H 3-CH3-4-Cl-Ph A2,B1,C2 1000 - 5000 50 - 500 1097 N CH C CF3 H 3-OH-4-Cl-Ph A2,B1,C1 1000 - 5000 >500 1098 N CH C CF3 H 3,4-(OCH2O)-Ph A2,B1,C2 <100 50 - 500 1099 N CH C CF3 H 3,4-(OCH2CH2O)-Ph A2,B1,C2 <100 50 - 500 1100 N CH C CF3 H 3-thienyl A2,B2,C2 <100 <50 1101 N CH C CF3 H 2-CH3-5-benzothiazolyl A2,B2,C2 100 - 1000 <50 1102 N CH C CF3 H 4-pyrimidinyl A2,B2,C2 >5000 50 - 500 1103 N CH C i-Pr H Ph Example 21 100 - 1000 <50 1104 N CH C (CH2)4 Ph A1,B1,C1 100 - 1000 50 - 500 1105 N CH C (CH2)4 4-OCH3-Ph A1,B1,C1 >5000 50 - 500 1106 N CH C (CH2)4 4-F-Ph A1,B1,C2 1000 - 5000 50 - 500 1107 N CH C CF3 H 2-pyrimidinyl A2,B2,C4 1000 - 5000 <50 1108 N CH C CF3 H 2-pyridazinyl A2, B2, C4 >5000 <50 1109 N CH C CF3 H 5-pyrimidinyl A2,B2,C4 >5000 >500 1110 N CH C CF3 H 5-indazolyl A2,B2,C4 >5000 50 - 500 1111 N CH C Allyl H Ph Example 22 1000 - 5000 50 - 500 1112 N CH C Et H Ph Example 23 100 - 1000 50 - 500 1113 N CH C (CH2)5 Ph A1,B1,C2 1000 - 5000 50 - 500 1114 N CH C CH3 H 4-OCH3-Ph A3,B1,C1 <100 <50 1115 N CH C CH3 H 4-F-Ph A3,B1,C1 <100 <50 1116 CH N C CF3 H 4-OCH3-Ph A6,B1,C3 100 - 1000 50 - 500 1117 CH N C CF3 H 4-F-Ph A6,B1,C3 100 - 1000 <50 1118 CH CH C CH3 H Ph A0,B1,C5 >5000 <50 1119 CH CH C CH3 H 4-OCH3-Ph A0,B1,C5 100 - 1000 50 - 500 1120 CH CH C CH3 H 4-F-Ph A0,B1,C5 <100 <50 1121 N CH C CF3 H 3-OCH3-4-F-Ph A2,B1,C2 100 - 1000 50 - 500 1122 N CH C CF3 H 4-OEt-Ph A2,B1,C4 <100 <50 1123 N CH C CF3 H 4-CONH2-Ph A2,B1,C2 >5000 50 - 500 1124 N CH C CF3 H 4-(CONHCH3)-Ph A2,B1,C2 100 - 1000 50 - 500 1125 N CH C CF3 H 4-(CO2CH3)-Ph A2,B1,C2 100 - 1000 50 - 500 1126 N CH C CF3 H 4-(NMe2)-Ph A2,B1,C2 1000 - 5000 50 - 500 1127 N CH C CF3 H 4-(SO2NH2)-Ph A2,B1,C2 >5000 50 - 500 1128 N CH C CF3 H 5-F-2-pyridinyl A2,B1,C2 100 - 1000 - 1129 CH N C CH3 H 4-OCH3-Ph A8,B1,C5 100 - 1000 50 - 500 1130 CH CH C CH3 H 4-Cl-Ph A0,B1,C5 >5000 50 - 500 1131 CH CH C CH3 H 4-CH3-Ph A0,B1,C5 >5000 50 - 500 1132 CH CH C CH3 H 4-Br-Ph A0,B1,C5 >5000 50 - 500 1133 N CH C CF3 H 4-SCH3-Ph A2,B1,C4 <100 <50 1134 N CH C n-Pr H Ph Example 24 >5000 <50 1135 N CH C CH3 H 3-Cl-4-OCH3-Ph A3,B2,C2 <100 <50 1136 CH CH C CF3 H 3-Cl-4-OCH3-Ph A0,B2,C1 >5000 <50 1137 N CH C CH3 H 4-CF3-Ph A3,B2,C3 <100 <50 1138 CH CH C CF3 H 4-CF3-Ph A0,B2,C4 >5000 50 - 500 1139 N CH C CH3 H 3-Cl-Ph A3,B1,C2 100 - 1000 <50 1140 N CH C CH3 H 3-CH3-Ph A3,B1,C2 100 - 1000 50 - 500 1141 N CH C CH3 H 3,4-(OCH2CH2O)-Ph A3,B1,C2 100 - 1000 50 - 500 1142 N CH C CH3 H 4-OEt-Ph A3,B1,C2 100 - 1000 <50 1143 N CH C CH3 H 4-SCH3-Ph A3,B1,C2 <100 <50 1144 CH CH C CF3 H 3-Cl-Ph A0,B1,C2 >5000 <50 1145 CH CH C CF3 H 3-CH3-Ph A0,B1,C2 >5000 50 - 500 1146 CH CH C CF3 H 3,4-(OCH2CH2O)-Ph A0,B1,C2 >5000 50 - 500 1147 CH CH C CF3 H 4-OEt-Ph A0,B1,C2 >5000 50 - 500 1148 CH CH C CF3 H 4-SCH3-Ph A0,B1,C2 100 - 1000 50 - 500 1149 N CH C CH3 H 4-OCF3-Ph A3,B1,C2 100 - 1000 <50 1150 N CH C CH3 H 3-thienyl A0,B2, C2 100 - 1000 <50 1151 CH CH C CH3 H 4-OCF3-Ph A3,B1,C2 >5000 50 - 500 1152 CH CH C CF3 H 3-thienyl A0,B2,C3 >5000 <50 -
TABLE 2 Cpd# V1 V2 W R1 R2 R3 Procedures EC1.5 nM AHR 1153 N CH C (CH2)3 Ph Example 25 >5000 50 - 500 1154 N CH C CF3 H 4-F-Ph A2, E 100 - 1000 <50 - While the present description has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations, including such departures from the present disclosure as come within known or customary practice within the art to and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
- All references cited herein are incorporated by reference in their entirety.
- 1. A method for expanding stem cells and/or progenitor cells, said method comprising contacting a starting cell population with a compound of formula I
- or a pharmaceutically acceptable salt thereof, wherein
- X is O or S;
- V1 is N or CH;
- V2 is N or CH;
- W is N or C;
- wherein not more than one of said V1, V2 and W is N;
- R1 is halo, alkyl, fluoroalkyl, cycloalkyl, alkynyl, alkenyl, cyano, or COORa, wherein Ra is an alkyl;
- R2 is H, or alkyl and R2 is absent when W is N;
- or R1 and R2 are attached together with the aromatic ring atoms to form a carbocyclic ring;
- R3 is an optionally substituted phenyl, an optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl.
- 2. The method as defined in
embodiment 1, wherein said compound is a compound of formula Ia - 3. The method as defined in
embodiment 1, wherein said compound is a compound of formula Ib - 4. The method as defined in
embodiment 1, wherein said compound is a compound of formula Ic - 5. The method as defined in
embodiment 1, wherein said compound is a compound of formula Id - 6. The method as defined in
embodiment 1, wherein said compound is a compound of formula Ie - 7. The method of any one of
embodiments 1 to 6, wherein R1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl. - 8. The method of any one of
embodiments 1 to 7, wherein R2 is H. - 9. The method of any one of
embodiments 1 to 8, wherein R3 is an optionally mono or disubstituted phenyl at any ofpositions - 10. The method of any one of
embodiments 1 to 8, wherein R3 is an optionally monosubstituted 5- or 6-membered heteroaryl. - 11. The method of any one of
embodiments 1 to 10, comprising either i) contacting said starting cell population with a first compound for expanding stem cells and/or progenitor cells and expanding the cells for a first period of time, optionally substantially removing said first compound, adding said compound of formula I or a pharmaceutically acceptable salt thereof and expanding the cells further for a second period of time or ii) contacting said starting cell population with a compound for expanding stem cells and/or progenitor cells and said compound of formula I. - 12. A stem cells and/or progenitor cells population as expanded by a method as defined in any one of
embodiments 1 to 11. - 13. A method of treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease,comprising administering cell population as defined in
embodiment 12 or administering a compound as described in any one ofembodiments 1 to 10. - 14. A compound of formula I
- or a pharmaceutically acceptable salt thereof, wherein
- X is O or S;
- V1 is N or CH;
- V2 is N or CH;
- W is N or C;
- wherein not more than one of said V1, V2 andW is N;
- R1 is halo, alkyl, fluoroalkyl, cycloalkyl, alkynyl, alkenyl, cyano, or COORa, wherein Ra is an alkyl;
- R2 is H, alkyl or R2 is absent when W is N;
- or R1 and R2 are attached together with the aromatic ring atoms to form a carbocyclic ring;
- R3 is an optionally substituted phenyl, an optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl;
- provided that the compound is other than:
- 15. The compound as defined in embodiment 14, wherein said compound is a compound of formula Ia
- 16. The compound as defined in embodiment 14, wherein said compound is a compound of formula Ib
- 17. The compound as defined in embodiment 14, wherein said compound is a compound of formula Ic
- 18. The compound as defined in embodiment 14, wherein said compound is a compound of formula Id
- 19. The compound as defined in embodiment 14, wherein said compound is a compound of formula Ie
- 20. The compound as defined in any one of embodiments 14 to 19, wherein R1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
- 21. The compound as defined in any one of embodiments 14 to 20, wherein R2 is H.
- 22. The compound as defined in any one of embodiments 14 to 21, wherein R3 is an optionally mono or disubstituted phenyl at any of
positions - 23. The compound as defined in any one of embodiments 14 to 21, wherein R3 is an optionally monosubstituted 5- or 6-membered heteroaryl.
- 24. The compound as defined in embodiment 14, wherein said compound is selected from Tables 1 and 2 as described herein.
- 25. A pharmaceutical composition comprising a compound as defined in any one of
embodiments 1 to 24 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier. - 26. A pharmaceutical composition comprising stem cells and/or progenitor cells as defined in
embodiment 12 or as expanded by the method as defined in any one ofembodiments 1 to 13, and optionally a pharmaceutically acceptable carrier.
Claims (17)
1. A compound of formula I
or a pharmaceutically acceptable salt thereof, wherein
X is O or S;
V1 is N or CH;
V2 is N or CH;
W is N or C;
wherein not more than one of said V1, V2 and W is N;
R1 is halo, alkyl, fluoroalkyl, cycloalkyl, alkynyl, alkenyl, cyano, or COORa, wherein Ra is an alkyl;
R2 is H, alkyl or R2 is absent when W is N;
or R1 and R2 are attached together with the aromatic ring atoms to form a carbocyclic ring;
R3 is an optionally substituted phenyl, an optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted fused bicyclic heteroaryl;
7. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein R1 is halo, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C2-3alkynyl, C2-3alkenyl, cyano, or COORa wherein Ra is a C1-6alkyl.
8. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein R2 is H.
9. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein R3 is an optionally mono or disubstituted phenyl at any of positions 3, 4 and 5 of said phenyl.
10. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein R3 is an optionally monosubstituted 5- or 6-membered heteroaryl.
11. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein said compound is selected from Tables 1 and 2:
TABLE 1 V1
V2
W R1
R2
R3
N CH C (CH2)3
Ph
N CH C (CH2)3
4-F-Ph
N CH C Br H Ph
N CH C CI H Ph
N CH C CH3
CH3
Ph
N CH C (CH2)3
3-pyridinyl
N CH C (CH2)3
2-pyridinyl
N CH C CF3
H Ph
N CH C CH3
H Ph
N CH C F H Ph
N CH C CI H 4-pyridinyl
N CH C Br H 4-pyridinyl
N CH C CF3
H 4-pyridinyl
N CH C (CH2)3
4-pyridinyl
N CH C CF3
H 3-pyridinyl
N CH C CN H Ph
N CH C CF3
H 4-(CH2CH2OH)-Ph
N CH C CF3
H 4-(CH2OCH3)-Ph
N CH C CF3
H 4-(CH2OH)-Ph
N CH C CCH H 4-pyridinyl
N CH C Et H 4-pyridinyl
N CH C CF3
H 2-pyridinyl
N CH C CF3
H 5-CH3-2-thiazolyl
N CH C CF3
H 4-Et-Ph
CH CH N CF3
Ph
CH CH N CF3
4-pyridinyl
CH N C CF3
H Ph
CH N C CF3
H 4-pyridinyl
N CH C CF3
H 6-benzothiazolyl
N CH C CF3
H 4-Ph-Ph
N CH C CF3
H 4-BnO-Ph
N CH C CF3
H 4-(CH2CO2Et)-Ph
N CH C CF3
H (4-OCH3-3-Ph)-Ph
CH CH C CF3
H Ph
CH CH C CF3
H 4-pyridinyl
N CH C CF3
H 3-Br-Ph
N CH C CF3
H 4-Br-Ph
N CH C CF3
H 4-(CH2CN)-Ph
N CH C CF3
H 5-isoquinolinyl
N CH C CF3
H 5-quinolinyl
N CH C CF3
H 6-quinolinyl
N CH C CF3
H 3-quinolinyl
N CH C CF3
H 4-quinolinyl
N CH C CO2Et H Ph
N CH C CF3
H 4-Cl-Ph
N CH C CF3
H 4-(CH2CH2OMe)-Ph
N CH C CF3
H 4-CH3-Ph
N CH C CF3
H 4-OCH3-Ph
CH CH N CF3
4-Br-Ph
CH N C CF3
H 4-Br-Ph
CH CH N CF3
4-Cl-Ph
CH CH N CF3
4-CH3-Ph
CH N C CF3
H 4-Cl-Ph
CH N C CF3
H 4-CH3-Ph
N CH C CF3
H 4-(3-pyridinyl)-Ph
N CH C CF3
H 4-(4-pyridinyl)-Ph
N CH C CF3
H 3-(3-pyridinyl)-Ph
N CH C CF3
H 3-(4-pyridinyl)-Ph
N CH C CF3
H 3-Ph-Ph
N CH C CF3
H 4-F-Ph
N CH C CF3
H 4-CF3-Ph
N CH C CH3
H 4-Br-Ph
N CH C CH3
H 4-pyridinyl
CH CH C CF3
H 4-Br-Ph
CH CH C CF3
H 4-CH3-Ph
CH CH C CF3
H 4-Cl-Ph
CH CH C CF3
H 3-pyridinyl
N CH C CH3
H 4-Cl-Ph
N CH C CH3
H 4-CH3-Ph
N CH C CF3
H 6-CH3-3-pyridinyl
N CH C CF3
H 6-OCH3-3-pyridinyl
CH N C CH3
H Ph
CH N C CH3
H 4-Cl-Ph
N CH C CF3
H 3-Cl-4-F-Ph
N CH C CF3
H 3,4-diF-Ph
N CH C CF3
H 3-CH3-4-F-Ph
N CH C CF3
H 3-F-Ph
N CH C CF3
H 3-F-4-CH3-Ph
N CH C CF3
H 3,5-diF-Ph
CH CH N CF3
3-OCH3-Ph
N CH C (CH2)3
3-OCH3-Ph
N CH C (CH2)3
4-Cl-Ph
CH CH C CF3
H 4-OCH3-Ph
N CH C CF3
H 4-CF3O-Ph
N CH C CF3
H 3-OCH3-Ph
N CH C CF3
H 4-OCHF2-Ph
N CH C CF3
H 3-Cl-4-OCH3-Ph
CH CH N CF3
4-F-Ph
CH CH C CF3
H 4-F-Ph
N CH C CH2=CMe H Ph
N CH C c-Pr H Ph
N CH C CF3
H 4-OPh-Ph
N CH C CF3
H 3-Cl-Ph
N CH C CF3
H 3-CH3-Ph
N CH C CF3
H 3,4-diCl-Ph
N CH C CF3
H 3-CH3-4-Cl-Ph
N CH C CF3
H 3-OH-4-CI-Ph
N CH C CF3
H 3,4-(OCH2O)-Ph
N CH C CF3
H 3,4-(OCH2CH2O)-Ph
N CH C CF3
H 3-thienyl
N CH C CF3
H 2-CH3-5-benzothiazolyl
N CH C CF3
H 4-pyrimidinyl
N CH C i-Pr H Ph
N CH C (CH2)4
Ph
N CH C (CH2)4
4-OCH3-Ph
N CH C (CH2)4
4-F-Ph
N CH C CF3
H 2-pyrimidinyl
N CH C CF3
H 2-pyridazinyl
N CH C CF3
H 5-pyrimidinyl
N CH C CF3
H 5-indazolyl
N CH C Allyl H Ph
N CH C Et H Ph
N CH C (CH2)5
Ph
N CH C CH3
H 4-OCH3-Ph
N CH C CH3
H 4-F-Ph
CH N C CF3
H 4-OCH3-Ph
CH N C CF3
H 4-F-Ph
CH CH C CH3
H Ph
CH CH C CH3
H 4-OCH3-Ph
CH CH C CH3
H 4-F-Ph
N CH C CF3
H 3-OCH3-4-F-Ph
N CH C CF3
H 4-OEt-Ph
N CH C CF3
H 4-CONH2-Ph
N CH C CF3
H 4-(CONHCH3)-Ph
N CH C CF3
H 4-(CO2CH3)-Ph
N CH C CF3
H 4-(NMe2)-Ph
N CH C CF3
H 4-(SO2NH2)-Ph
N CH C CF3
H 5-F-2-pyridinyl
CH N C CH3
H 4-OCH3-Ph
CH CH C CH3
H 4-Cl-Ph
CH CH C CH3
H 4-CH3-Ph
CH CH C CH3
H 4-Br-Ph
N CH C CF3
H 4-SCH3-Ph
N CH C n-Pr H Ph
N CH C CH3
H 3-Cl-4-OCH3-Ph
CH CH C CF3
H 3-Cl-4-OCH3-Ph
N CH C CH3
H 4-CF3-Ph
CH CH C CF3
H 4-CF3-Ph
N CH C CH3
H 3-Cl-Ph
N CH C CH3
H 3-CH3-Ph
N CH C CH3
H 3,4-(OCH2CH2O)-Ph
N CH C CH3
H 4-OEt-Ph
N CH C CH3
H 4-SCH3-Ph
CH CH C CF3
H 3-Cl-Ph
CH CH C CF3
H 3-CH3-Ph
CH CH C CF3
H 3,4-(OCH2CH2O)-Ph
CH CH C CF3
H 4-OEt-Ph
CH CH C CF3
H 4-SCH3-Ph
N CH C CH3
H 4-OCF3-Ph
N CH C CH3
H 3-thienyl
CH CH C CH3
H 4-OCF3-Ph
CH CH C CF3
H 3-thienyl
TABLE 2 V1
V2
W R1
R2
R3
N CH C (CH2)3
Ph
N CH C CF3
H 4-F-Ph
or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/320,929 US20230338429A1 (en) | 2017-11-03 | 2023-05-19 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762581149P | 2017-11-03 | 2017-11-03 | |
PCT/IB2018/058593 WO2019087129A1 (en) | 2017-11-03 | 2018-11-01 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
US202016760780A | 2020-04-30 | 2020-04-30 | |
US18/320,929 US20230338429A1 (en) | 2017-11-03 | 2023-05-19 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/760,780 Division US11696928B2 (en) | 2017-11-03 | 2018-11-01 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
PCT/IB2018/058593 Division WO2019087129A1 (en) | 2017-11-03 | 2018-11-01 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230338429A1 true US20230338429A1 (en) | 2023-10-26 |
Family
ID=66332968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/760,780 Active 2040-02-17 US11696928B2 (en) | 2017-11-03 | 2018-11-01 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
US18/320,929 Pending US20230338429A1 (en) | 2017-11-03 | 2023-05-19 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/760,780 Active 2040-02-17 US11696928B2 (en) | 2017-11-03 | 2018-11-01 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
Country Status (12)
Country | Link |
---|---|
US (2) | US11696928B2 (en) |
EP (1) | EP3704126A4 (en) |
JP (1) | JP2021501582A (en) |
KR (1) | KR20200084873A (en) |
CN (1) | CN111417640B (en) |
AU (2) | AU2018361971A1 (en) |
BR (1) | BR112020008330A2 (en) |
CA (1) | CA3080695A1 (en) |
IL (1) | IL274291B2 (en) |
MX (1) | MX2020004414A (en) |
SG (1) | SG11202003807RA (en) |
WO (1) | WO2019087129A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111163766A (en) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | AHR inhibitors and uses thereof |
US20200063104A1 (en) * | 2018-08-22 | 2020-02-27 | Wisconsin Alumni Research Foundation | Expansion of hpsc-derived granulocytic and lymphoid progenitors with um171 |
AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
KR102426921B1 (en) * | 2019-09-24 | 2022-07-29 | 주식회사 이노보테라퓨틱스 | Heteroarylamidopyridinol derivatives and pharmaceutical composition for use in preventing or treating autoimmune diseases containing the same as an active ingredient |
CN116157397A (en) | 2020-06-04 | 2023-05-23 | 拜耳公司 | Heterocyclylpyridines as novel fungicides |
WO2023099445A1 (en) | 2021-11-30 | 2023-06-08 | Bayer Aktiengesellschaft | Bis(hetero)aryl thioether oxadiazines as fungicidal compounds |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022452A1 (en) | 1996-11-19 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives |
US20030225150A1 (en) | 1997-04-21 | 2003-12-04 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia |
EP1478639A1 (en) * | 2002-02-22 | 2004-11-24 | Bayer Pharmaceuticals Corporation | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders |
AU2002953533A0 (en) * | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
JP2005104838A (en) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | Condensed furan compound |
JP2005097199A (en) | 2003-09-26 | 2005-04-14 | Tanabe Seiyaku Co Ltd | Amine-type carboxamide derivative |
TW200524915A (en) | 2003-09-26 | 2005-08-01 | Tanabe Seiyaku Co | Carbamoyl-type benzofuran derivatives |
JP2008507518A (en) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス,インコーポレーテッド | Thienopyridine for treating hepatitis C |
KR20110136819A (en) | 2009-02-27 | 2011-12-21 | 시가 테크놀로지스, 인크. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
US20130129677A1 (en) | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
US8669256B2 (en) | 2010-05-28 | 2014-03-11 | Merck Sharp & Dohme B.V. | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity |
US9409906B2 (en) * | 2012-01-27 | 2016-08-09 | Universite De Montreal | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
WO2013126856A1 (en) * | 2012-02-23 | 2013-08-29 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
CA2893318A1 (en) | 2012-12-07 | 2014-06-12 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
CN105189474A (en) | 2013-01-23 | 2015-12-23 | 芝加哥大学 | Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs |
JP6053574B2 (en) | 2013-02-28 | 2016-12-27 | 国立大学法人 東京大学 | Visual field inspection support device |
-
2018
- 2018-11-01 BR BR112020008330-5A patent/BR112020008330A2/en unknown
- 2018-11-01 IL IL274291A patent/IL274291B2/en unknown
- 2018-11-01 WO PCT/IB2018/058593 patent/WO2019087129A1/en unknown
- 2018-11-01 SG SG11202003807RA patent/SG11202003807RA/en unknown
- 2018-11-01 MX MX2020004414A patent/MX2020004414A/en unknown
- 2018-11-01 KR KR1020207015361A patent/KR20200084873A/en not_active Application Discontinuation
- 2018-11-01 AU AU2018361971A patent/AU2018361971A1/en not_active Abandoned
- 2018-11-01 US US16/760,780 patent/US11696928B2/en active Active
- 2018-11-01 JP JP2020524269A patent/JP2021501582A/en active Pending
- 2018-11-01 CA CA3080695A patent/CA3080695A1/en active Pending
- 2018-11-01 CN CN201880074165.XA patent/CN111417640B/en active Active
- 2018-11-01 EP EP18872845.5A patent/EP3704126A4/en active Pending
-
2023
- 2023-05-19 US US18/320,929 patent/US20230338429A1/en active Pending
- 2023-10-06 AU AU2023241382A patent/AU2023241382A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200323923A1 (en) | 2020-10-15 |
EP3704126A1 (en) | 2020-09-09 |
JP2021501582A (en) | 2021-01-21 |
KR20200084873A (en) | 2020-07-13 |
IL274291B2 (en) | 2023-10-01 |
WO2019087129A1 (en) | 2019-05-09 |
MX2020004414A (en) | 2020-10-19 |
AU2023241382A1 (en) | 2023-10-26 |
IL274291B1 (en) | 2023-06-01 |
BR112020008330A2 (en) | 2020-10-06 |
EP3704126A4 (en) | 2020-12-09 |
CA3080695A1 (en) | 2019-05-09 |
CN111417640B (en) | 2024-04-05 |
US11696928B2 (en) | 2023-07-11 |
IL274291A (en) | 2020-06-30 |
CN111417640A (en) | 2020-07-14 |
AU2018361971A1 (en) | 2020-06-04 |
SG11202003807RA (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230338429A1 (en) | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | |
US10351572B2 (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
US10336747B2 (en) | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | |
US20230116062A1 (en) | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis | |
EP2765187B1 (en) | Method for producing megakaryocytes and/or platelets from pluripotent stem cells | |
US9212348B2 (en) | Method for producing hematopoietic stem cells using pyrazole compounds | |
US20220265712A1 (en) | Populations of natural killer cells for treating cancers | |
US20220378740A1 (en) | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | |
US20200155609A1 (en) | Compositions and methods of making expanded hematopoietic stem cells using pten inhibitors | |
IL262553A (en) | Technology for efficient activation of nkt cells | |
US20220273716A1 (en) | Populations of natural killer cells comprising a cd38 chimeric antigen receptor | |
EP3735412B1 (en) | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders | |
US20220251104A1 (en) | Aromatic compounds for use in activating hematopoietic stem and progenitor cells | |
JP2014003975A (en) | Method for producing hematopoietic stem cells using pyrazole compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITE DE MONTREAL, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMONEAU, BRUNO;CHANTIGNY, YVES;YEH, JONATHAN;AND OTHERS;SIGNING DATES FROM 20200213 TO 20200214;REEL/FRAME:063709/0302 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |